

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/26947 A2

- (51) International Patent Classification⁷: C12N 9/00 (72) Inventors: WEBSTER, Marion; Celera Genomics, 45 West Gude Drive C2-4#20, Rockville, MD 20850 (US). KETCHUM, Karen, A.; Celera Genomics, 45 West Gude Drive C2-4#20, Rockville, MD 20850 (US). DI FRANCESCO, Valentina; Celera Genomics, 45 West Gude Drive C2-4#20, Rockville, MD 20850 (US). BEASLEY, Ellen, M.; Celera Genomics, 45 West Gude Drive C2-4#20, Rockville, MD 20850 (US).
- (21) International Application Number: PCT/US01/29960
- (22) International Filing Date:
26 September 2001 (26.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/235,557 27 September 2000 (27.09.2000) US
09/734,675 13 December 2000 (13.12.2000) US
- (71) Applicant: PE CORPORATION (NY) [US/US]; 761 Main Avenue, Norwalk, CT 06859 (US).
- (74) Agent: MILLMAN, Robert, A.; Celera Genomics, Chief Intellectual Property Counsel, 45 West Gude Drive C2-4, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,

[Continued on next page]

(54) Title: ISOLATED HUMAN PROTEASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS, AND USES THEREOF

1 CCCCCTTATG CTGAAACCAT GGAATATTC CATTCTCATT GTTGTGTCG
51 TGACAGTGGT GGCAGTACAC ATGAGTCTCC TGGTCACTT CTTAGTATT
101 GACCAAAAGA AGGAGTACTA TGTGAGTCC TTAAATATT TAGATCCAC
151 AATCAATTTC AATTTCGAC AAAGGACAC ATATCAACTT AAGGACTTAC
201 GAGGAGGAC CAAAAATTC GTGAGTACA TTTTATAGA TTGAGCTGG
251 AAGAAATTT ATATCAAGA CCAATATTC AGACTGATC CAGAGGAGA
301 TGTGTGAAA GTAGATGCA TTATGTTT CAGTTTCCC TCTAGTAA
351 AAGGAGGCT AGGAGGAGG AAATCCAAA GCACTTAAA TCGAGAGTA
401 AGGATTTAA GAGCTTCCC AATAATGCC TCTATGTTT AATGATG
451 AATGAGTCA TCAACAGGG ATTAATCTT CCAAGCAGT TGTGTGAGC
501 GAGTTTCTC ATTAATCTT AAGGAGGCT CAGTATGAT CAGTATGAT
551 AAGGAGGCT GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
601 GAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
651 GAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
701 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
751 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
801 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
851 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
901 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
951 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
1001 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
1051 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
1101 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
1151 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT
1201 AAGTATGCA GAGTATGCA AGCTTCTCT CAGTATGAT CAGTATGAT

SEQUENCE:
5'UTR: 1-7
Start Codon: 8
Stop Codon: 1223
3'UTR: 1226

Homologous proteins:

gi 7441558 ref NP_054777.1	UBR1 protein [Homo sapiens]	gi 61...	371	e-102
gi 4734508 ref NP_004253.1	airway trypsin-like protease [Homo ...]		349	3e-95
gi 6467956 gb AA713253.1 AF198087.1	adrenal secretor...		277	1e-72

BLAST to dbEST:

gi 1679749 dbest-dbest/taxon=9606...	Score	E
	190	3e-46

EXPRESSION INFORMATION FOR REGULATORY USE:

Library source:
Expression information from BLAST dbEST hit:
Primary source

Expression information from PCR-based tissue screening panels:

Human Testis
Human placenta
Human fetal lung
Human fetal kidney
Human fetal heart
Human fetal brain
Human bone marrow

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.

WO 02/26947 A2



SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**ISOLATED HUMAN PROTEASE PROTEINS, NUCLEIC ACID MOLECULES
ENCODING HUMAN PROTEASE PROTEINS, AND USES THEREOF**

RELATED APPLICATIONS

5 The present application claims priority to provisional application U.S. Serial No. 60/235,557, filed September 27, 2000 (Atty. Docket CL000862-PROV) and U.S. Serial No. 09/734,675, filed December 13, 2000 (Atty. Docket CL000862).

FIELD OF THE INVENTION

10 The present invention is in the field of protease proteins that are related to the serine protease subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect protein cleavage/processing/turnover and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

15 **BACKGROUND OF THE INVENTION**

 The proteases may be categorized into families by the different amino acid sequences (generally between 2 and 10 residues) located on either side of the cleavage site of the protease.

20 The proper functioning of the cell requires careful control of the levels of important structural proteins, enzymes, and regulatory proteins. One of the ways that cells can reduce the steady state level of a particular protein is by proteolytic degradation. Further, one of the ways cells produce functioning proteins is to produce pre or pro-protein precursors that are processed by proteolytic degradation to produce an active moiety. Thus, complex and highly-regulated mechanisms have been evolved to accomplish this degradation.

25 Proteases regulate many different cell proliferation, differentiation, and signaling processes by regulating protein turnover and processing. Uncontrolled protease activity (either increased or decreased) has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and degenerative disorders.

30 An additional role of intracellular proteolysis is in the stress-response. Cells that are subject to stress such as starvation, heat-shock, chemical insult or mutation respond by increasing the rates of proteolysis. One function of this enhanced proteolysis is to salvage amino acids from non-essential proteins. These amino acids can then be re-utilized in the synthesis of

essential proteins or metabolized directly to provide energy. Another function is in the repair of damage caused by the stress. For example, oxidative stress has been shown to damage a variety of proteins and cause them to be rapidly degraded.

The International Union of Biochemistry and Molecular Biology (IUBMB) has recommended to use the term *peptidase* for the subset of peptide bond hydrolases (Subclass E.C 3.4.). The widely used term *protease* is synonymous with *peptidase*. *Peptidases* comprise two groups of enzymes: the endopeptidases and the exopeptidases, which cleave peptide bonds at points within the protein and remove amino acids sequentially from either N or C-terminus respectively. The term *proteinase* is also used as a synonym word for *endopeptidase* and four mechanistic classes of proteinases are recognized by the IUBMB: two of these are described below (also see: *Handbook of Proteolytic Enzymes* by Barrett, Rawlings, and Woessner AP Press, NY 1998). Also, for a review of the various uses of proteases as drug targets, see: Weber M, Emerging treatments for hypertension: potential role for vasopectidase inhibition; Am J Hypertens 1999 Nov;12(11 Pt 2):139S-147S; Kentsch M, Otter W, Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors, Drugs R D 1999 Apr;1(4):331-8; Scarborough RM, Coagulation factor Xa: the prothrombinase complex as an emerging therapeutic target for small molecule inhibitors, J Enzym Inhib 1998;14(1):15-25; Skotnicki JS, et al., Design and synthetic considerations of matrix metalloproteinase inhibitors, Ann N Y Acad Sci 1999 Jun 30;878:61-72; McKerrow JH, Engel JC, Caffrey CR, Cysteine protease inhibitors as chemotherapy for parasitic infections, Bioorg Med Chem 1999 Apr;7(4):639-44; Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR, Inhibitors of tryptase for the treatment of mast cell-mediated diseases, Curr Pharm Des 1998 Oct;4(5):381-96; Materson BJ, Will angiotensin converting enzyme genotype, receptor mutation identification, and other miracles of molecular biology permit reduction of NNT Am J Hypertens 1998 Aug;11(8 Pt 2):138S-142S

Serine Proteases

The serine proteases (SP) are a large family of proteolytic enzymes that include the digestive enzymes, trypsin and chymotrypsin, components of the complement cascade and of the blood-clotting cascade, and enzymes that control the degradation and turnover of macromolecules of the extracellular matrix. SP are so named because of the presence of a serine residue in the active catalytic site for protein cleavage. SP have a wide range of substrate specificities and can be subdivided into subfamilies on the basis of these specificities. The main

sub-families are trypases (cleavage after arginine or lysine), aspases (cleavage after aspartate), chymases (cleavage after phenylalanine or leucine), metases (cleavage after methionine), and serases (cleavage after serine).

A series of six SP have been identified in murine cytotoxic T-lymphocytes (CTL) and natural killer (NK) cells. These SP are involved with CTL and NK cells in the destruction of virally transformed cells and tumor cells and in organ and tissue transplant rejection (Zunino, S. J. et al. (1990) *J. Immunol.* 144:2001-9; Sayers, T. J. et al. (1994) *J. Immunol.* 152:2289-97). Human homologs of most of these enzymes have been identified (Trapani, J. A. et al. (1988) *Proc. Natl. Acad. Sci.* 85:6924-28; Caputo, A. et al. (1990) *J. Immunol.* 145:737-44). Like all SP, the CTL-SP share three distinguishing features: 1) the presence of a catalytic triad of histidine, serine, and aspartate residues which comprise the active site; 2) the sequence GDSGGP which contains the active site serine; and 3) an N-terminal IIGG sequence which characterizes the mature SP.

The SP are secretory proteins which contain N-terminal signal peptides that serve to export the immature protein across the endoplasmic reticulum and are then cleaved (von Heijne (1986) *Nuc. Acid. Res.* 14:5683-90). Differences in these signal sequences provide one means of distinguishing individual SP. Some SP, particularly the digestive enzymes, exist as inactive precursors or preproenzymes, and contain a leader or activation peptide sequence 3' of the signal peptide. This activation peptide may be 2-12 amino acids in length, and it extends from the cleavage site of the signal peptide to the N-terminal IIGG sequence of the active, mature protein. Cleavage of this sequence activates the enzyme. This sequence varies in different SP according to the biochemical pathway and/or its substrate (Zunino et al, supra; Sayers et al, supra). Other features that distinguish various SP are the presence or absence of N-linked glycosylation sites that provide membrane anchors, the number and distribution of cysteine residues that determine the secondary structure of the SP, and the sequence of a substrate binding sites such as S'. The S' substrate binding region is defined by residues extending from approximately +17 to +29 relative to the N-terminal I (+1). Differences in this region of the molecule are believed to determine SP substrate specificities (Zunino et al, supra).

Trypsin-like serine proteases have been isolated from patients with chronic airway diseases and may play a role in respiratory diseases and host defense systems on the mucous membranes of the respiratory system (see Yamaoka et al., *J. Biol. Chem.* 273: 11895-11901, 1998 and Yasuoka et al., *Am. J. Resp. Cell Molec. Biol.* 16: 300-308, 1997). Therefore, novel human serine protease proteins, and encoding genes, may be useful for screening for, diagnosing,

preventing, and/or treating disorders such as respiratory diseases. For example, serine protease genes/proteins may be useful in drug development, such as by serving as novel drug targets for respiratory disease, and SNPs in serine protease genes may be useful markers for diagnostic kits for respiratory diseases.

5

Trypsinogens

The trypsinogens are serine proteases secreted by exocrine cells of the pancreas (Travis J and Roberts R. Biochemistry 1969; 8: 2884-9; Mallory P and Travis J, Biochemistry 1973; 12: 2847-51). Two major types of trypsinogen isoenzymes have been characterized, trypsinogen-1, also called cationic trypsinogen, and trypsinogen-2 or anionic trypsinogen. The trypsinogen proenzymes are activated to trypsins in the intestine by enterokinase, which removes an activation peptide from the N-terminus of the trypsinogens. The trypsinogens show a high degree of sequence homology, but they can be separated on the basis of charge differences by using electrophoresis or ion exchange chromatography. The major form of trypsinogen in the pancreas and pancreatic juice is trypsinogen-1 (Guy CO et al., Biochem Biophys Res Commun 1984; 125: 516-23). In serum of healthy subjects, trypsinogen-1 is also the major form, whereas in patients with pancreatitis, trypsinogen-2 is more strongly elevated (Itkonen et al., J Lab Clin Med 1990; 115:712-8). Trypsinogens also occur in certain ovarian tumors, in which trypsinogen-2 is the major form (Koivunen et al., Cancer Res 1990; 50: 2375-8). Trypsin-1 in complex with alpha-1-antitrypsin, also called alpha-1-antiprotease, has been found to occur in serum of patients with pancreatitis (Borgstrom A and Ohlsson K, Scand J Clin Lab Invest 1984; 44: 381-6) but determination of this complex has not been found useful for differentiation between pancreatic and other gastrointestinal diseases (Borgstrom et al., Scand J Clin Lab Invest 1989; 49:757-62).

Trypsinogen-1 and -2 are closely related immunologically (Kimland et al., Clin Chim Acta 1989; 184: 31-46; Itkonen et al., 1990), but by using monoclonal antibodies (Itkonen et al., 1990) or by absorbing polyclonal antisera (Kimland et al., 1989) it is possible to obtain reagents enabling specific measurement of each form of trypsinogen.

When active trypsin reaches the blood stream, it is inactivated by the major trypsin inhibitors alpha-2-macroglobulin and alpha-1-antitrypsin (AAT). AAT is a 58 kilodalton serine protease inhibitor synthesized in the liver and is one of the main protease inhibitors in blood. Whereas complexes between trypsin-1 and AAT are detectable in serum (Borgstrom and Ohlsson, 1984) the complexes with alpha -2-macroglobulin are not measurable with antibody-based assays (Ohlsson K, Acta Gastroenterol Belg 1988; 51: 3-12).

Inflammation of the pancreas or pancreatitis may be classified as either acute or chronic by clinical criteria. With treatment, acute pancreatitis can often be cured and normal function restored. Chronic pancreatitis often results in permanent damage. The precise mechanisms which trigger acute inflammation are not understood. However, some causes in the order of their importance are alcohol ingestion, biliary tract disease, post-operative trauma, and hereditary pancreatitis. One theory provides that autodigestion, the premature activation of proteolytic enzymes in the pancreas rather than in the duodenum, causes acute pancreatitis. Any number of other factors including endotoxins, exotoxins, viral infections, ischemia, anoxia, and direct trauma may activate the proenzymes. In addition, any internal or external blockage of pancreatic ducts can also cause an accumulation of pancreatic juices in the pancreas resulting cellular damage.

Anatomy, physiology, and diseases of the pancreas are reviewed, inter alia, in Guyton AC (1991) Textbook of Medical Physiology, W B Saunders Co, Philadelphia Pa.; Isselbacher K J et al (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York City; Johnson K E (1991) Histology and Cell Biology, Harwal Publishing, Media Pa.; and The Merck Manual of Diagnosis and Therapy (1992) Merck Research Laboratories, Rahway N.J.

Metalloprotease

The metalloproteases may be one of the older classes of proteinases and are found in bacteria, fungi as well as in higher organisms. They differ widely in their sequences and their structures but the great majority of enzymes contain a zinc atom which is catalytically active. In some cases, zinc may be replaced by another metal such as cobalt or nickel without loss of the activity. Bacterial thermolysin has been well characterized and its crystallographic structure indicates that zinc is bound by two histidines and one glutamic acid. Many enzymes contain the sequence HEXXH, which provides two histidine ligands for the zinc whereas the third ligand is either a glutamic acid (thermolysin, neprilysin, alanyl aminopeptidase) or a histidine (astacin). Other families exhibit a distinct mode of binding of the Zn atom. The catalytic mechanism leads to the formation of a non covalent tetrahedral intermediate after the attack of a zinc-bound water molecule on the carbonyl group of the scissile bond. This intermediate is further decomposed by transfer of the glutamic acid proton to the leaving group.

Metalloproteases contain a catalytic zinc metal center which participates in the hydrolysis of the peptide backbone (reviewed in Power and Harper, in Protease Inhibitors, A. J. Barrett and G. Salversen (eds.) Elsevier, Amsterdam, 1986, p. 219). The active zinc center differentiates

some of these proteases from calpains and trypsins whose activities are dependent upon the presence of calcium. Examples of metalloproteases include carboxypeptidase A, carboxypeptidase B, and thermolysin.

5 Metalloproteases have been isolated from a number of procaryotic and eucaryotic sources, e.g. *Bacillus subtilis* (McConn et al., 1964, J. Biol. Chem. 239:3706); *Bacillus megaterium*; *Serratia* (Miyata et al., 1971, Agr. Biol. Chem. 35:460); *Clostridium bifermentans* (MacFarlane et al., 1992, App. Environ. Microbiol. 58:1195-1200), *Legionella pneumophila* (Moffat et al., 1994, Infection and Immunity 62:751-3). In particular, acidic metalloproteases have been isolated from broad-banded copperhead venoms (Johnson and Ownby, 1993, Int. J. Biochem. 25:267-278), rattlesnake venoms (Chlou et al., 1992, Biochem. Biophys. Res. Commun. 187:389-396) and articular cartilage (Treadwell et al., 1986, Arch. Biochem. Biophys. 251:715-723). Neutral metalloproteases, specifically those having optimal activity at neutral pH have, for example, been isolated from *Aspergillus sojae* (Sekine, 1973, Agric. Biol. Chem. 37:1945-1952). Neutral metalloproteases obtained from *Aspergillus* have been classified into 15 two groups, npI and npII (Sekine, 1972, Agric. Biol. Chem. 36:207-216). So far, success in obtaining amino acid sequence information from these fungal neutral metalloproteases has been limited. An npII metalloprotease isolated from *Aspergillus oryzae* has been cloned based on amino acid sequence presented in the literature (Tatsumi et al., 1991, Mol. Gen. Genet. 228:97-103). However, to date, no npI fungal metalloprotease has been cloned or sequenced. Alkaline 20 metalloproteases, for example, have been isolated from *Pseudomonas aeruginosa* (Baumann et al., 1993, EMBO J 12:3357-3364) and the insect pathogen *Xenorhabdus luminescens* (Schmidt et al., 1998, Appl. Environ. Microbiol. 54:2793-2797).

Metalloproteases have been divided into several distinct families based primarily on activity and structure: 1) water nucleophile; water bound by single zinc ion ligated to two His 25 (within the motif HEXXH) and Glu, His or Asp; 2) water nucleophile; water bound by single zinc ion ligated to His, Glu (within the motif HXXE) and His; 3) water nucleophile; water bound by single zinc ion ligated to His, Asp and His; 4) Water nucleophile; water bound by single zinc ion ligated to two His (within the motif HXXEH) and Glu and 5) water nucleophile; water bound by two zinc ions ligated by Lys, Asp, Asp, Asp, Glu.

30 Examples of members of the metalloproteinase family include, but are not limited to, membrane alanyl aminopeptidase (*Homo sapiens*), germinal peptidyl-dipeptidase A (*Homo sapiens*), thimet oligopeptidase (*Rattus norvegicus*), oligopeptidase F (*Lactococcus lactis*), mycolysin (*Streptomyces cacaoi*), immune inhibitor A (*Bacillus thuringiensis*), snapalysin

(*Streptomyces lividans*), leishmanolysin (*Leishmania major*), microbial collagenase (*Vibrio alginolyticus*), microbial collagenase, class I (*Clostridium perfringens*), collagenase 1 (*Homo sapiens*), serralysin (*Serratia marcescens*), fragilysin (*Bacteroides fragilis*), gametolysin (*Chlamydomonas reinhardtii*), astacin (*Astacus fluviatilis*), adamalysin (*Crotalus adamanteus*),
 5 ADAM 10 (*Bos taurus*), neprilysin (*Homo sapiens*), carboxypeptidase A (*Homo sapiens*), carboxypeptidase E (*Bos taurus*), gamma-D-glutamyl-(L)-meso-diaminopimelate peptidase I (*Bacillus sphaericus*), vanY D-Ala-D-Ala carboxypeptidase (*Enterococcus faecium*), endolysin (bacteriophage A118), pitrilysin (*Escherichia coli*), mitochondrial processing peptidase (*Saccharomyces cerevisiae*), leucyl aminopeptidase (*Bos taurus*), aminopeptidase I
 10 (*Saccharomyces cerevisiae*), membrane dipeptidase (*Homo sapiens*), glutamate carboxypeptidase (*Pseudomonas* sp.), Gly-X carboxypeptidase (*Saccharomyces cerevisiae*), O-sialoglycoprotein endopeptidase (*Pasteurella haemolytica*), beta-lytic metalloendopeptidase (*Achromobacter lyticus*), methionyl aminopeptidase I (*Escherichia coli*), X-Pro aminopeptidase (*Escherichia coli*), X-His dipeptidase (*Escherichia coli*), IgA1-specific metalloendopeptidase (*Streptococcus sanguis*), tentoxilysin (*Clostridium tetani*), leucyl aminopeptidase (*Vibrio proteolyticus*),
 15 aminopeptidase (*Streptomyces griseus*), IAP aminopeptidase (*Escherichia coli*), aminopeptidase T (*Thermus aquaticus*), hyicolysin (*Staphylococcus hyicus*), carboxypeptidase Taq (*Thermus aquaticus*), anthrax lethal factor (*Bacillus anthracis*), penicillolysin (*Penicillium citrinum*), fungilysin (*Aspergillus fumigatus*), lysostaphin (*Staphylococcus simulans*), beta-aspartyl dipeptidase (*Escherichia coli*), carboxypeptidase Ss1 (*Sulfolobus solfataricus*), FtsH
 20 endopeptidase (*Escherichia coli*), glutamyl aminopeptidase (*Lactococcus lactis*), cytophagalysin (*Cytophaga* sp.), metalloendopeptidase (vaccinia virus), VanX D-Ala-D-Ala dipeptidase (*Enterococcus faecium*), Ste24p endopeptidase (*Saccharomyces cerevisiae*), dipeptidyl-peptidase III (*Rattus norvegicus*), S2P protease (*Homo sapiens*), sporulation factor SpoIVFB (*Bacillus subtilis*), and HYBD endopeptidase (*Escherichia coli*).
 25

30 Metalloproteases have been found to have a number of uses. For example, there is strong evidence that a metalloprotease is involved in the in vivo proteolytic processing of the vasoconstrictor, endothelin-1. Rat metalloprotease has been found to be involved in peptide hormone processing. One important subfamily of the metalloproteases are the matrix metalloproteases.

A number of diseases are thought to be mediated by excess or undesired metalloprotease activity or by an imbalance in the ratio of the various members of the protease family of proteins. These include: a) osteoarthritis (Woessner, et al., J. Biol.Chem. 259(6), 3633, 1984; Phadke, et

al., J. Rheumatol. 10, 852, 1983), b) rheumatoid arthritis (Mullins, et al., Biochim. Biophys. Acta 695, 117, 1983; Woolley, et al., Arthritis Rheum. 20, 1231, 1977; Gravallesse, et al., Arthritis Rheum. 34, 1076, 1991), c) septic arthritis (Williams, et al., Arthritis Rheum. 33, 533, 1990), d) tumor metastasis (Reich, et al., Cancer Res. 48, 3307, 1988, and Matrisian, et al., Proc. Nat'l. Acad. Sci., USA 83, 9413, 1986), e) periodontal diseases (Overall, et al., J. Periodontal Res. 22, 81, 1987), f) corneal ulceration (Burns, et al., Invest. Ophthalmol. Vis. Sci. 30, 1569, 1989), g) proteinuria (Baricos, et al., Biochem. J. 254, 609, 1988), h) coronary thrombosis from atherosclerotic plaque rupture (Henney, et al., Proc. Nat'l. Acad. Sci., USA 88, 8154-8158, 1991), i) aneurysmal aortic disease (Vine, et al., Clin. Sci. 81, 233, 1991), j) birth control (Woessner, et al., Steroids 54, 491, 1989), k) dystrophic epidermolysis bullosa (Kronberger, et al., J. Invest. Dermatol. 79, 208, 1982), and l) degenerative cartilage loss following traumatic joint injury, m) conditions leading to inflammatory responses, osteopenias mediated by MMP activity, n) temporomandibular joint disease, o) demyelinating diseases of the nervous system (Chantry, et al., J. Neurochem. 50, 688, 1988).

15

Aspartic protease

Aspartic proteases have been divided into several distinct families based primarily on activity and structure. These include 1) water nucleophile; water bound by two Asp from monomer or dimer; all endopeptidases, from eukaryote organisms, viruses or virus-like organisms and 2) endopeptidases that are water nucleophile and are water bound by Asp and Asn.

Most of aspartic proteases belong to the pepsin family. The pepsin family includes digestive enzymes such as pepsin and chymosin as well as lysosomal cathepsins D and processing enzymes such as renin, and certain fungal proteases (penicillopepsin, rhizopuspepsin, endothiapepsin). A second family comprises viral proteases such as the protease from the AIDS virus (HIV) also called retropepsin. Crystallographic studies have shown that these enzymes are bilobed molecules with the active site located between two homologous lobes. Each lobe contributes one aspartate residue of the catalytically active diad of aspartates. These two aspartyl residues are in close geometric proximity in the active molecule and one aspartate is ionized whereas the second one is unionized at the optimum pH range of 2-3. Retropepsins, are monomeric, i.e. carry only one catalytic aspartate and then dimerization is required to form an active enzyme.

In contrast to serine and cysteine proteases, catalysis by aspartic protease do not involve a covalent intermediate though a tetrahedral intermediate exists. The nucleophilic attack is achieved by two simultaneous proton transfer: one from a water molecule to the diad of the two carboxyl groups and a second one from the diad to the carbonyl oxygen of the substrate with the concurrent CO-NH bond cleavage. This general acid-base catalysis, which may be called a "push-pull" mechanism leads to the formation of a non covalent neutral tetrahedral intermediate.

Examples of the aspartic protease family of proteins include, but are not limited to, pepsin A (*Homo sapiens*), HIV1 retropepsin (human immunodeficiency virus type 1), endopeptidase (cauliflower mosaic virus), bacilliform virus putative protease (rice tungro bacilliform virus), aspergillopepsin II (*Aspergillus niger*), thermopsin (*Sulfolobus acidocaldarius*), nodavirus endopeptidase (flock house virus), pseudomonapepsin (*Pseudomonas* sp. 101), signal peptidase II (*Escherichia coli*), polyprotein peptidase (human spumaretrovirus), copia transposon (*Drosophila melanogaster*), SIRE-1 peptidase (*Glycine max*), retrotransposon bs1 endopeptidase (*Zea mays*), retrotransposon peptidase (*Drosophila buzzatii*), Tas retrotransposon peptidase (*Ascaris lumbricoides*), Pao retrotransposon peptidase (*Bombyx mori*), putative proteinase of Skippy retrotransposon (*Fusarium oxysporum*), tetravirus endopeptidase (*Nudaurelia capensis* omega virus), presenilin 1 (*Homo sapiens*).

Proteases and Cancer

Proteases are critical elements at several stages in the progression of metastatic cancer. In this process, the proteolytic degradation of structural protein in the basal membrane allows for expansion of a tumor in the primary site, evasion from this site as well as homing and invasion in distant, secondary sites. Also, tumor induced angiogenesis is required for tumor growth and is dependent on proteolytic tissue remodeling. Transfection experiments with various types of proteases have shown that the matrix metalloproteases play a dominant role in these processes in particular gelatinases A and B (MMP-2 and MMP-9, respectively). For an overview of this field see Mullins, et al., *Biochim. Biophys. Acta* 695, 177, 1983; Ray, et al., *Eur. Respir. J.* 7, 2062, 1994; Birkedal-Hansen, et al., *Crit. Rev. Oral Biol. Med.* 4, 197, 1993.

Furthermore, it was demonstrated that inhibition of degradation of extracellular matrix by the native matrix metalloprotease inhibitor TIMP-2 (a protein) arrests cancer growth (DeClerck, et al., *Cancer Res.* 52, 701, 1992) and that TIMP-2 inhibits tumor-induced angiogenesis in experimental systems (Moses, et al. *Science* 248, 1408, 1990). For a review, see DeClerck, et al., *Ann. N. Y. Acad. Sci.* 732, 222, 1994. It was further demonstrated that the synthetic matrix

metalloprotease inhibitor batimastat when given intraperitoneally inhibits human colon tumor growth and spread in an orthotopic model in nude mice (Wang, et al. Cancer Res. 54, 4726, 1994) and prolongs the survival of mice bearing human ovarian carcinoma xenografts (Davies, et al., Cancer Res. 53, 2087, 1993). The use of this and related compounds has been described in

5 Brown, et al., WO-9321942 A2.

There are several patents and patent applications claiming the use of metalloproteinase inhibitors for the retardation of metastatic cancer, promoting tumor regression, inhibiting cancer cell proliferation, slowing or preventing cartilage loss associated with osteoarthritis or for treatment of other diseases as noted above (e.g. Levy, et al., WO-9519965 A1; Beckett, et al.,

10 WO-9519956 A1; Beckett, et al., WO-9519957 A1; Beckett, et al., WO-9519961 A1; Brown, et al., WO-9321942 A2; Crimmin, et al., WO-9421625 A1; Dickens, et al., U.S. Pat. No. 4,599,361; Hughes, et al., U.S. Pat. No. 5,190,937; Broadhurst, et al., EP 574758 A1; Broadhurst, et al., EP 276436; and Myers, et al., EP 520573 A1.

15 Protease proteins, particularly members of the serine subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of protease proteins. The present invention advances the state of the art by providing a previously unidentified human protease proteins that have homology to members of the serine subfamily.

20

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human protease peptides and proteins that are related to the serine protease subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and

25 nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate protease activity in cells and tissues that express the protease. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in

30 cancers.

DESCRIPTION OF THE FIGURE SHEETS

FIGURE 1 provides the nucleotide sequence of a cDNA molecule that encodes the protease protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that
5 allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers.

FIGURE 2 provides the predicted amino acid sequence of the protease of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein
10 family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIGURE 3 provides genomic sequences that span the gene encoding the protease protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to
15 readily determine specific uses of inventions based on this molecular sequence. As indicated in Figure 3, SNPs, including insertion/deletion polymorphisms ("indels"), were identified at 69 different nucleotide positions in and around the gene encoding the serine protease protein of the present invention.

20 DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share
25 structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a protease protein or part of a protease protein and are related to the serine protease subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human protease peptides and proteins
30 that are related to the serine protease subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these protease peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and

information about the closest art known protein/peptide/domain that has structural or sequence homology to the protease of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known protease proteins of the serine protease subfamily and the expression pattern observed. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known serine family or subfamily of protease proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the protease family of proteins and are related to the serine protease subfamily (protein sequences are provided in Figure 2, transcript/cDNA sequences are provided in Figure 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in Figure 3, will be referred herein as the protease peptides of the present invention, protease peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the protease peptides disclosed in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1, transcript/cDNA or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present

invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

5 In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

10 The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the protease peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical
15 precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

 The isolated protease peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in Figure 1 indicates expression in humans in
20 testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. For example, a nucleic acid molecule encoding the protease peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

25 Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in Figure 2. A protein consists of an amino acid sequence when the amino acid sequence
30 is the final amino acid sequence of the protein.

 The present invention further provides proteins that consist essentially of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic

sequences provided in Figure 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

5 The present invention further provides proteins that comprise the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only
10 the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the protease peptides of the present invention are the naturally occurring mature proteins. A brief
15 description of how various types of these proteins can be made/isolated is provided below.

 The protease peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a protease peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the protease peptide. "Operatively linked" indicates that the protease peptide and the
20 heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the protease peptide.

 In some uses, the fusion protein does not affect the activity of the protease peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged,
25 HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant protease peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

 A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-
30 frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be

annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A protease peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-
5 frame to the protease peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralog of the peptides. Such
10 variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other
15 peptides based on sequence and/or structural homology to the protease peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid
20 sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or
25 nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the
30 number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the protease peptides of the present invention as well as being encoded by the same genetic locus as the protease peptide provided herein. The gene provided by the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a protease peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the protease peptide as well as being encoded by the same genetic locus as the protease peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human. The gene provided by the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a protease peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides information on SNPs that have been identified in the gene encoding the protease protein of the present invention. SNPs, including indels (indicated by a "-"), were identified at 69 different nucleotide positions. Non-synonymous cSNPs were identified at position 30496. The changes in the amino acid sequence caused by these SNPs is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

Paralogs of a protease peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the protease peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a protease peptide

encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a protease peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the protease peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a protease peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins. The gene provided by the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Figure 3 provides information on SNPs that have been identified in the gene encoding the protease protein of the present invention. SNPs, including indels (indicated by a "-"), were identified at 69 different nucleotide positions. Non-synonymous cSNPs were identified at position 30496. The changes in the amino acid sequence caused by these SNPs is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

Non-naturally occurring variants of the protease peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the protease peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a protease peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant protease peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to cleave substrate, ability to participate in a signaling pathway, etc. Fully functional variants typically contain only conservative variation or variation in

non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

5 Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 10 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as protease activity or in assays such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or 15 photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the protease peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to 20 be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a protease peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the protease peptide or could be chosen for the ability to 25 perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the protease peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, 30 and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common
5 modifications that occur naturally in protease peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-
ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety,
10 covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing,
15 phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and
20 ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

25 Accordingly, the protease peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature protease peptide is fused with another compound, such as a compound to increase the half-life of the protease peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature protease
30 peptide, such as a leader or secretory sequence or a sequence for purification of the mature protease peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a protease-effector protein interaction or protease-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, proteases isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the protease. Experimental data as provided in Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow. A large percentage of pharmaceutical agents are being developed that modulate the activity of protease proteins, particularly members of the serine subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in Figure 1. Experimental data as provided in Figure 1 indicates expression in humans

in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

5 The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to proteases that are related to members of the serine subfamily. Such assays involve any of the known protease functions or activities or properties useful for diagnosis and treatment of protease-related conditions that are specific for the subfamily of proteases that the one of the present invention belongs to, particularly in cells and tissues that express the protease. Experimental data as provided in Figure 1
10 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow.

The proteins of the present invention are also useful in drug screening assays, in cell-based
15 or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the protease, as a biopsy or expanded in cell culture. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the protease protein.

20 The polypeptides can be used to identify compounds that modulate protease activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the protease. Both the proteases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the protease. These compounds can be further screened against a functional protease to
25 determine the effect of the compound on the protease activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the protease to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the protease protein and a molecule that normally
30 interacts with the protease protein, e.g. a substrate or a component of the signal pathway that the protease protein normally interacts (for example, a protease). Such assays typically include the steps of combining the protease protein with a candidate compound under conditions that allow the protease protein, or fragment, to interact with the target molecule, and to detect the formation of a

complex between the protein and the target or to detect the biochemical consequence of the interaction with the protease protein and the target, such as any of the associated effects of signal transduction such as protein cleavage, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including
5 Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-
10 idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant proteases or appropriate fragments containing
15 mutations that affect protease function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) protease activity. The assays typically involve an assay of events in the signal
20 transduction pathway that indicate protease activity. Thus, the cleavage of a substrate, inactivation/activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the protease protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the protease can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described
25 herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the protease can be assayed. Experimental data as provided in Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta,
30 fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow.

Binding and/or activating compounds can also be screened by using chimeric protease proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized by the native protease. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the protease is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the protease (e.g. binding partners and/or ligands). Thus, a compound is exposed to a protease polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble protease polypeptide is also added to the mixture. If the test compound interacts with the soluble protease polypeptide, it decreases the amount of complex formed or activity from the protease target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the protease. Thus, the soluble polypeptide that competes with the target protease region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the protease protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of protease-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example,

either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation.

- 5 Preparations of a protease-binding protein and a candidate compound are incubated in the protease protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the protease protein target molecule, or which are reactive with protease protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

- 15 Agents that modulate one of the proteases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

- 20 Modulators of protease protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the protease pathway, by treating cells or tissues that express the protease. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. These methods of treatment include the steps of administering a modulator of protease activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

- 25 In yet another aspect of the invention, the protease proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the protease and are involved in protease activity. Such protease-binding proteins are also likely to be involved in the propagation of signals by the protease proteins or protease targets as, for example, downstream elements of a protease-mediated signaling pathway. Alternatively, such protease-binding proteins are likely to be protease inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two

different DNA constructs. In one construct, the gene that codes for a protease protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a protease-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the protease protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a protease-modulating agent, an antisense protease nucleic acid molecule, a protease-specific antibody, or a protease-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The protease proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. The method involves contacting a biological sample with a compound capable of interacting with the protease protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered protease activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from

standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the protease protein in which one or more of the protease functions in one population is different from those in another population. The peptides thus allow a target to
5 ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and protease activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific
10 polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Accordingly, methods for treatment include the use of the protease
15 protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof.
20 As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still
25 selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab)₂, and
30 Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the protease proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or protease/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the

present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in
5 cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during
10 development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental
15 expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

20 The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting
25 expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment
30 modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

5 The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the protease peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites
10 required for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

 The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount
15 of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

20

Nucleic Acid Molecules

 The present invention further provides isolated nucleic acid molecules that encode a protease peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide
25 sequence that encodes one of the protease peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

 As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3'
30 ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide

encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

5 Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

10 For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include
15 such molecules produced synthetically.

 Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide
20 sequence is the complete nucleotide sequence of the nucleic acid molecule.

 The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a
25 nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

 The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID
30 NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide

sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

5 In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

15 The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

20 As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the protease peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

30 Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded

or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the protease proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or

more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2. As indicated in Figure 3, SNPs, including insertion/deletion polymorphisms ("indels"), were identified at 69 different nucleotide positions in and around the gene encoding the transporter protein of the present invention.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product.

5 For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. The gene

10 provided by the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

15 The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or

20 all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in

25 Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a

30 specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or

organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in protease protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a protease protein, such as by measuring a level of a protease-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a protease gene has been mutated. Experimental data as provided in Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate protease nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the protease gene, particularly biological and pathological processes that are mediated by the protease in cells and tissues that express it. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. The method typically includes assaying the ability of the compound to modulate the expression of the protease nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired protease nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the protease nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for protease nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the protease protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of protease gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of protease mRNA in the presence of the candidate compound is compared to the level

of expression of protease mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate protease nucleic acid expression in cells and tissues that express the protease. Experimental data as provided in Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, and bone marrow. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) of nucleic acid expression.

Alternatively, a modulator for protease nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the protease nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in Figure 1 indicates expression in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the protease gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in protease nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in protease genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the protease gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the protease gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a protease protein.

Individuals carrying mutations in the protease gene can be detected at the nucleic acid level by a variety of techniques. Figure 3 provides information on SNPs that have been identified in the gene encoding the protease protein of the present invention. SNPs, including indels (indicated by a "-"), were identified at 69 different nucleotide positions. Non-synonymous cSNPs were identified at position 30496. The changes in the amino acid sequence caused by these SNPs is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements. The gene provided by the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the

size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

5 Alternatively, mutations in a protease gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

 Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage
10 digestion assays or by differences in melting temperature.

 Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant protease gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the
15 diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

 Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes
20 (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing
25 gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

 The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic
30 acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content

of the protease gene in an individual in order to select an appropriate compound or dosage regimen for treatment.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control protease gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of protease protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into protease protein. Figure 3 provides information on SNPs that have been identified in the gene encoding the protease protein of the present invention. SNPs, including indels (indicated by a "-"), were identified at 69 different nucleotide positions. Non-synonymous cSNPs were identified at position 30496. The changes in the amino acid sequence caused by these SNPs is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of protease nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired protease nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the protease protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in protease gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired protease protein to treat the individual.

The invention also encompasses kits for detecting the presence of a protease nucleic acid in a biological sample. Experimental data as provided in Figure 1 indicates that protease proteins of the present invention are expressed in humans in testis, placenta, fetal lung, fetal kidney, fetal heart, fetal brain, bone marrow, and in cancers. Specifically, a virtual northern blot shows expression in cancers. In addition, PCR-based tissue screening panels indicate expression in testis, placenta, fetal

lung, fetal kidney, fetal heart, fetal brain, and bone marrow. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting protease nucleic acid in a biological sample; means for determining the amount of protease nucleic acid in the sample; and means for comparing the amount of protease nucleic acid in the sample with a standard.

- 5 The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect protease protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or
10 microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is
15 prepared and used according to the methods described in US Patent 5,837,832, Chee *et al.*, PCT application W095/11995 (Chee *et al.*), Lockhart, D. J. *et al.* (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. *et al.* (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown *et al.*, US Patent No. 5,807,522.

20 The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to
25 use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

30 In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are

unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence.

5 The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

10 In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a
15 vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially
20 available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or
25 detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative
30 abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct

sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the protease proteins/peptides of the present invention. In detail, such methods comprise
5 incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the protease gene of the present invention. Figure 3 provides information on SNPs that have been identified in the gene encoding the protease protein of the present
10 invention. SNPs, including indels (indicated by a "-"), were identified at 69 different nucleotide positions. Non-synonymous cSNPs were identified at position 30496. The changes in the amino acid sequence caused by these SNPs is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

15 Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed
20 herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular*
25 *Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be
30 readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents,
5 reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the
10 samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in
15 the art will readily recognize that the previously unidentified protease gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

20 Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a
25 plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules
30 when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule
5 may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

10 The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

15 In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can
20 also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A
25 Laboratory Manual. 2nd. ed.*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal
30 elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate

cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

5 The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

10 The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

15 The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

20 As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic
25 enzymes include, but are not limited to, factor Xa, thrombin, and enteroprotease. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann
30 *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant

protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

5 The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

10 The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

15 In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

20 The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

25 The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or
30 inducible expression, tissue-specific expression).

 The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989*).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as proteases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with proteases, the protein can be isolated from the host cell by standard disruption procedures, including

freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a protease protein or peptide that can be further purified to produce desired amounts of protease protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the protease protein or protease protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native protease protein is useful for assaying compounds that stimulate or inhibit protease protein function.

Host cells are also useful for identifying protease protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant protease protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native protease protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a protease protein and identifying and evaluating modulators of protease protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the protease protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

5 Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the protease protein to particular cells.

10 Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon
15 the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously
20 recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al. PNAS* 89:6232-6236 (1992). Another example of a
25 recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al. Science* 251:1351-1355 (1991). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and
30 the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al. Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell,

from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then
5 transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect substrate binding, protease protein
10 activity/activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* protease protein function, including substrate interaction, the effect of specific mutant protease proteins on protease protein function and substrate interaction, and the effect of chimeric protease proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely
15 eliminate one or more protease protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific
20 preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.

8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.

16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.
17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.
18. A method for treating a disease or condition mediated by a human protease protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.
19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.
20. An isolated human protease peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.
21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.
22. An isolated nucleic acid molecule encoding a human protease peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.
23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

```
1 CGCCCTTATG CTGAAGCCAT GGATGATTGC CGTTCTCATT GTGTTGTCCC
51 TGACAGTGGT GGCAGTGACC ATAGGTCTCC TGGTTCACCT CCTAGTATTT
101 GACCAAAAAA AGGAGTACTA TCATGGCTCC TTTAAAAATT TAGATCCACA
151 AATCAATTTT AATTTGGGAC AAAGCAACAC ATATCAACTT AAGGACTTAC
201 GAGAGACGAC CGAAAATTTG GTGGATGAGA TATTTATAGA TTCAGCCTGG
251 AAGAAAAATT ATATCAAGAA CCAAGTAGTC AGACTGACTC CAGAGGAAGA
301 TGGTGTGAAA GTAGATGTCA TTATGGTGTT CCAGTTCCCC TCTACTGAAC
351 AAAGGGCAGT AAGAGAGAAG AAAATCCAAA GCATCTTAAA TCAGAAGATA
401 AGGAATTTAA GAGCCTTGCC AATAAATGCC TCATCAGTTC AAGTTAATGC
451 AATGAGCTCA TCAACAGGGG AGTTAACTGT CCAAGCAAGT TGTGGTAAAC
501 GAGTTGTTCC ATTAAACGTC AACAGAATAG CATCTGGAGT CATTGCACCC
551 AAGGCGGCCT GGCCTTGCCA AGCTTCCCTT CAGTATGATA ACATCCATCA
601 GTGTGGGGCC ACCTTGATTA GTAACACATG GCTTGTCAC TGCAGCAGCT
651 GCTTCCAGAA GTATAAAAAT CCACATCAAT GGACTGTTAG TTTTGGGAACA
701 AAAATCAACC CTCCCTTAAT GAAAAGAAAT GTCAGAAGAT TTATTATCCA
751 TGAGAAAGTAC CGCTCTGCAG CAAGAGAGTA CGACATTGCT GTTGTGCAGG
801 TCTCTTCCAG AGTCACCTTT TCGGATGACA TACGCCGGAT TTGTTTGCCA
851 GAAGCCTCTG CATCCTTCCA ACCAAATTTG ACTGTCCACA TCACAGGATT
901 TGGAGCACTT TACTATGGTG GGGAAATCCA AAATGATCTC CGAGAAGCCA
951 GAGTGAAAAT CATAAGTGAC GATGTCTGCA AGCAACCACA GGTGTATGGC
1001 AATGATATAA AACCTGGAAT GTTCTGTGCC GGATATATGG AAGGAATTTA
1051 TGATGCCTGC AGGGGTGATT CTGGGGGACC TTTAGTCACA AGGGATCTGA
1101 AAGATACGTG GTATCTCATT GGAATTGTAA GCTGGGGAGA TAACTGTGGT
1151 CAAAAGGACA AGCCTGGAGT CTACACACAA GTGACTTATT ACCGAAACTG
1201 GATTGCTTCA AAAACAGGCA TCTAA (SEQ ID NO:1)
```

FEATURES:

5'UTR: 1-7
Start Codon: 8
Stop Codon: 1223
3'UTR: 1226

Homologous proteins:

	Score	E
gi 7661558 ref NP_054777.1 DESC1 protein [Homo sapiens] >gi 61...	371	e-102
gi 4758508 ref NP_004253.1 airway trypsin-like protease [Homo ...	349	3e-95
gi 6467958 gb AAF13253.1 AF198087_1 (AF198087) adrenal secretor...	277	1e-73

BLAST to dbEST:

	Score	E
gi 1679749 /dataset=dbest /taxon=9606 ...	190	3e-46

EXPRESSION INFORMATION FOR MODULATORY USE:

library source:

Expression information from BLAST dbEST hit:

Primary cancers

Expression information from PCR-based tissue screening panels:

- Human Testis
- Human placenta
- Human fetal lung
- Human fetal kidney
- Human fetal heart
- Human fetal brain
- Human bone marrow

FIGURE 1

1 MLKPWMI AVL IVLSLT VVAV TIGLLVHFLV FDQKK EYYHG SFKILD PQIN
51 FNFGQ SNTYQ LKDLRETTEN LVDEIFIDSA WKKNYIKNQV VRLTPSEDGV
101 KVDVIMV FQF PSTEQRAVRE KKIQSILNQK IRNLRALPIN ASSVQVNAMS
151 SSTGELTVQA SCGKR VVPLN VNRIASGVIA PKAAWPWQAS LOYDNIHQCG
201 ATLLISNTWL V TAAHCFQKYK NPHQWTVSFG TKINPPLMKR NVRRFIIHEK
251 YRSAAREYDI AVVQVSSRVT PSDDIRRICL PEASASFQPN LTVHITGFPA
301 LYYGGESQND LREARVKIIS DDVCKQPQVY GNDIKPGMFC AGYMEGIYDA
351 CRGDSGGPLV TRDLKDTWYL IGIVSWGDNC GQKDKPGVYT QVTTYRNWLA
401 SKTGI (SEQ ID NO:2)

FEATURES:**Functional domains and key regions:****Prosite results:**

[1] PDOC00001 PS00001 ASN_GLYCOSYLATION
N-glycosylation site

Number of matches: 2

1 140-143 NASS
2 290-293 NLTV

[2] PDOC00005 PS00005 PKC_PHOSPHO_SITE
Protein kinase C phosphorylation site

Number of matches: 2

1 41-43 SFK
2 266-268 SSR

[3] PDOC00006 PS00006 CK2_PHOSPHO_SITE
Casein kinase II phosphorylation site

Number of matches: 5

1 94-97 TPEK
2 152-155 STGE
3 270-273 TFSD
4 307-310 SQND
5 375-378 SWGD

[4] PDOC00007 PS00007 TYR_PHOSPHO_SITE
Tyrosine kinase phosphorylation site

362-369 RDLKDTWY

[5] PDOC00008 PS00008 MYRISTYL
N-myristoylation site

Number of matches: 3

1 54-59 GQSNY
2 337-342 GMFCAG
3 346-351 GIYDAC

[6] PDOC00009 PS00009 AMIDATION
Amidation site

162-165 CGKR

FIGURE 2

[7] PDOC00016 PS00016 RGD
Cell attachment sequence

352-354 RGD

[8] PDOC00124 PS00134 TRYPSIN_HIS
Serine proteases, trypsin family, histidine active site

210-215 VTAAHC

[9] PDOC00124 PS00135 TRYPSIN_SER
Serine proteases, trypsin family, serine active site

349-360 DACRGDSGGPLV

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	11	31	2.281	Certain
2	203	223	1.014	Certain
3	291	311	0.791	Putative

FIGURE 2:

BLAST Alignment to Top Hit:

Alignment to top blast hit:

>gi|7661558|ref|NP_054777.1| DESC1 protein [Homo sapiens]
 >gi|6137097|gb|AAF04328.1|AF064819_1 (AF064819) serine
 protease DESC1 [Homo sapiens]
 Length = 422

Score = 371 bits (943), Expect = e-102

Identities = 176/403 (43%), Positives = 267/403 (65%), Gaps = 4/403 (0%)

Frame = +2

Query: 14 KPWMIAVLIVLSLTVAVTIGLLVHFLVFDQKKEY-YHGSFKILDPOINFNFGQSNTYQL 190
 +PW+I ++I +SL V+AV IGL VH++ ++QKK Y Y+ + ++ FG+ +
 Sbjct: 16 EPWVIGLVIFISLIVLAVCIGLTVHYVRYNQKKTYNYSTLSFTTDKLYAEFGREASNNF 75

Query: 191 KDLRETTENLVDEIPIDSAWKKNYIKNQVRLTPEEDGVKVDVIMVFPFPSTEQRVREK 370
 ++ + E++V P S ++ ++K+QV++ + ++ GV ++++ +F STE +K
 Sbjct: 76 TEMSQRLSEMVKNAPYKSPLEEFVKSQVIKFSQKKGVLAHMLLICRPHSTEDPETVDK 135

Query: 371 KIQSILNQKIRNLRALP-INASSVQVNAMESSSTGELTVQASCG-KRVVPLNVN-RIASGV 541
 +Q +L++K+++ P ++ SV++ ++ + + + CG +R L + RI G
 Sbjct: 136 IVQLVLHEKLDQAVGPPKVDPHSVKIKRKINKTETDSYLNHCCGTRRSKTLGQSLRIVGGT 195

Query: 542 IAPKAANPWQASLQYDNIHQCGATLISNTWLVTAAHCFQKYKNPHQWTVSFGTKINPPLM 721
 + WPWQASLQ+D H+CGATLI+ TWLV+AAHCF YKNP +WT SFG I P M
 Sbjct: 196 EVEEGEWPWQASLQWDGSHRCGATLINATWLVSAAHCFTTYKNPARWTASFGVTIKPSKM 255

Query: 722 KRNVRRFIIHEKYRSAAREFYDIAVVQVSSRVTPSDDIRRICLPRASASFQPNLTVHITGF 901
 KR +RR I+HEKY+ + +YDI++ ++SS V +++ + R+CLP+AS FQP + +TGF
 Sbjct: 256 KRGLRRIIVHEKYKHPSHDYDISLAELSSFPVPTNAVHRVCLPDASYEFQPGDVMFVTGF 315

Query: 902 GALYYGGESQNDLREARVKIISDDVCKQPQVYGNDIKPGMFCAGYMEGIYDACRGDSGGP 1081
 GAL G SQN LR+A+V +I C +PQ Y + I P M CAG +EG DAC+GDSGGP
 Sbjct: 316 GALKNDGYSONHLRQAQVTLIDATTCNEPQAYNDAITPRMLCAGSLEGKTDACQGDSSGP 375

Query: 1082 LVTRDLKDTWYLIGIVSWGDNCGQKDKPGVYTQVTTYRNWIASKTGI 1222
 LV+ D +D WYL GIVSWG D C + +KPGVYT+VT R+WI SKTGI
 Sbjct: 376 LVSSDARDIWYLAGIVSWGDECAKPNKPGVYTRVTALRDWITSKTGI 422 (SEQ ID NO:4)

Hmmer search results (Pfam):

Scores for sequence family classification (score includes all domains):

Model	Description	Score	E-value	N
PF00089	Trypsin	274.8	1.9e-86	1

Parsed for domains:

Model	Domain	seq-f	seq-t	hmm-f	hmm-t	score	E-value
PF00089	1/1	174	399 ..	1	259 []	274.8	1.9e-86

FIGURE 2

1 TTATATTCAT AAAAGTAGGC AGTAAGTTGA AGATTTATTC ATATAGGATT
51 TAGTAGCTGC AGCTTTAACC TGTGGCTTCT GTAGCTTTTG TAATCTGGCA
101 GTGCGCATCT GCTATATTAT CTAAATGTTT CCTCAAAGG AGAAACACTC
151 TAACAACTTA TCACCCTAGT CTGCTGGCCA CCAITTTCCC TCAGATGCTC
201 ACAGCTTCTT CCGTGGGATT TGAAGATATG ACTTCCATGA CACTTGATCA
251 GTATGTCAAT GGGTATTGAA CCACTCTTCA GCTCTGATCC CACGGTTCAG
301 TTCCTTTTCAG TGTGACTATG TGTCTTGGTG GTGGGAGATG TGATTCTTTT
351 ATCTACTTTC TCCATTTATC TTACTCAGAG GAACTGTGCT CTAATAGGGA
401 AATAGATTGA AAGCTTATAA ATTTCTTGA GTTTTAACCT TTCTCCTTTG
451 GTCTTTTTTT CTTTTCAAAT GACTTGAAGA CACATTGATA AGATTCTATG
501 AGAAAATGAA GAGTTGAACA AATTGAATAT GTATGAGTGA ATGAATAGAT
551 TAATACATAA ATGATAAATT TATTAAATAA TTTGAACGAA ATCAATCGAG
601 AGGCACCGAG AATAAATTG TGTCTAGAA GTAAGAAGAC CTGAGTTTGA
651 GATAACTAGT AGTTCTATTA TACTGGAGAA ATTACTTAAT CATCACTGGA
701 CTTCAATTTT CTCATATGGA AAGTAATTCA ATCACACTAA ACAATCTTTA
751 AGGTCTCCTT CACTTATAAA TGTATGTTT AAGCCATTTA GGAGGTTAAA
801 TAATGTCATG TCCCATGGGA CTTCTGTTTG TTGTTCTATT CAAGCATGTT
851 AGCTTGTTC TATCACAGGA CCGCTGCCT TTCCGCAGCC AGTTCTCTAG
901 ATTATTTTAA ATCAGTCGGT GCACACATGG TCAATATTTA CTCAATAGAA
951 TTCAGGTTTC CCAAATCCA TGAGGATTCT TGATTAATTT TATTACTTAT
1001 GCCAAAATA TTATCTTCTT AACTATTTTA GGTCCAAACA GTTTTAACCT
1051 TTATCCTGGC ATTTATATAT AAAAATCTT TGTAAGACCG GGTGCAGTGG
1101 CTCATGCCCT TAATCCGAG ACTTTGGGAG GCCGAGGTGG GTGGATCACC
1151 AGGTCAGGAG ATGGAGACCA TCCTGGCTAA CACCATGAAA CCCTGTTTCT
1201 ACTAAAAATA CAAAAATTA GCGGGCGTG GTGGTGGACG CCTTTAGTCC
1251 CAGCTATTCA GGAGGCTGAG GCAGGAGAAT GCGGTGAACC TGGGAGGCAG
1301 AGCTTGCAGT GAGCAGAGAT CACACCACTG CACTCCAGCC TGGCAGCCTG
1351 GATGACACAG CGAGACTCCG TCTCAAAAAA AAAAAAATAA AAAAGAAAAA
1401 AACTGTTTTA TAGTCAAAG AAAAATCTT TATAAATCAA CCAATCCTGT
1451 GAAGAAAATA TGAAAAATAT CCTCTGTTTC CAAAAAAT TAGGCTATCA
1501 ATATATACAC ATAAAGAGAT AAATCTGAT AAATTGGATA AATAAAATTC
1551 ACTATAATAG CAAGTTTTAG AGAACAAGCA CGGGAGTTAG TCGACCTGGG
1601 CCCTTAAACA GATATCCTCT CTCTCATCCT GTGTTATTTT CTGTGTAATG
1651 TTGGTATCAT TCCTGCCTGA CTCTCATAGA TTTATATGAT TCCTACTCTG
1701 TCCAGGTGCC TTATTGGGTC TTAGCGGTAA AAAGATGAAC AAGGCTAATG
1751 CAGCCCATTG AGAAGCTATC TGTAAGTGAA CATACATGCA AACTAATACT
1801 TGATTCAATG TGAGAAGCAC TGTGCTGAT CATAGGTGCC AGAAGAACAG
1851 CAAAGAGTTA TTTTTCTC CAAAATGTG GAAAAATTTT TATCCCGGT
1901 GTGATGCAAT ATAAATACA CAGCACCACC TTTGAAGTAT TCTTGCCAAA
1951 TGAATTTAAC CAAAATCTAA TCAAGACTTC AGAGCTAAAG AAAATCTAAA
2001 GGTAAATCAA TTTATAGGAA ATGAGGGATA TAAAAGAACA AGTTAAATAA
2051 TACCACAGGA AAGCATTGAG ACAAGTCCAG AAAGTAAGAT ATTCTAAAGG
2101 ATGTTTAGCT TGATCTCTTC AACAGTCAAT GTCATTAAAA ACTAAAAAAG
2151 AAGCAGGACT CTTTTAGATT AAAAGAGATT AAAAAGGCAT AACAAACAAG
2201 TGCATGCAAT GGTCTCTGAT TATGCTTGG CTTTTACAAA TCATGTGTAA
2251 TTATAATGAA ACCATGGAGG GAACTTGAAG ATGGACTGGG TATTAGATGA
2301 TATGGCAGAA ATATCATTAA TTTTTAGGA GTGTTAAGAG TATCATGGTT
2351 ATGTTGGATA TATCCTAATT GTCTATAATA ATGATTGGGT AAAAAGTCAC
2401 GATGTTTTAT TTCACATTAA AATATAGCAG CAGAAAAAAT AAATGAGCCA
2451 AATACAGTAA AATTTTCAAC AATTGATATA ATAATGTGAT ATATATATGG
2501 ATGTTCAATT ATACTATTCT TAGTAATTTT TTATGTCTGA ACATTTTCAT
2551 AATACTTAAA AATAAAGAT AAAAGATAAA AATAAATGAG ATAATAGATT
2601 TAAAATCACT TTGTAACTC TAAAAGGATA GACAGATAAA AGAGATAACA
2651 AAGTGCTGGA GAAAGGAGGA ATGGTCCCTT TTCAAGCATG TATGCCACCT
2701 TGGACCATGC TGCTAAGAGA AACCATTCTT GACCACCACA AAGAGGCCAC
2751 CAAATGCCTC TAAAATAGAA AGCAGGAGCA ACATTAGGAT TCCCAGATCC
2801 TGATATTTTT TTTTAAACAC ATCTTCTCAG ACCAAGATGA CATTGAACAA
2851 AATTAAAGAC CTTTTTGCAG GGAAAGGTAG GCTACAGCAA CTTGAACTTG
2901 TCTAAGGAGA GCTGGAAAAC CTGCAAGCAT TGCTATCTGA GAGTAACCAG
2951 TGGGCCCTTC CTTTTCTCAG GACAGTGGGA TTTGGCACCC GAAGCAGAAA
3001 TGCTGAAGCC ATGGATGATT GCGTTCTCA TTGTTGTGTC CCTGACAGTG
3051 GTGGCAGTGA CCATAGGTCT CCTGGTTTCA TTCTAGTAT TTGGTAGGTA
3101 AAATTAAAGA TTTCACTCTA TTTGATTTTA TTTTCTGCA AAGCTCCATT
3151 TACATATATG TAAATGTAA TTTATCTAAA AAATTGCACA TTTACCTTCA
3201 AATTTCCACA GAGTATATTT AACTGTTTCA GTCATTTTCA CAACAAACAA
3251 GACTAAATT CTTATTATAT GTGAGTACTT TTCTGGATAT TCAAGATACA

FIGURE 3

3301 GCTTTAAGCA AAGTAGACAG ATTTCTAATT TCCTTAGAGC TCTCAACCCA
3351 GAATTCCTTT GAGAATCTAC AAAAAAGAT CAAAAATTGT AATTGTCTGA
3401 AACTTACTAG TAATTATAAT AAACAACCTCA TCACCTATTA TATATTAAAA
3451 TGAAAAGCTA TGATAAATTA GTTATTAAAA TTGGCTCTTT TACTCATGAA
3501 CCATCATTCT CTGTCCAACA TTTCTAAGGC AAAAGAAAAA CACTTGTCTA
3551 ATAAAATAAG GAATTTCAAA ATGATTGAAA ACCTATACGT ATGACACAAT
3601 ATTATCATT ATTTTCTAGAG AAAAAAATT TTAATCTTTC CAAAAAATA
3651 TTCAGGGATT ATATTTTAT CAACTAATAT ATTTGTAATT ACACAAATA
3701 TGCACTTCAA GATTCTCTTT TTACATTCAG TCTCTTCTG GGGAGAATGC
3751 AAGCCATTTA CATTTTCTCA CAAATCTCTA CAATGTGACT CTCACATGGA
3801 TGTATGTGAT AAAACAAATA ACTCAGGCTG CTCACCTTAA CGCTCTTATC
3851 TGCTGTCACC TTCACAGAGT CAATGGGGGA GCAAAGACTC TACTTGGAGC
3901 CTTAAAGGGC TTAAGATCAT AGTCCTAGGC CTTATATGAT AACCCAGCT
3951 GTAGTTTATA CCATTGGCAA AAGATTCTCA GGTCACCTTA TTTGGTTGCA
4001 TAAAAGTCTC TTTACAATGA GAGTAAGGTT TGTTAACAGT ATGGATTATA
4051 TGGGTAAGTA ATCAGGATGT CCAAAAATGT ATTACAAGGT CCAGAGATTT
4101 CCCACTTAAG ACATATGCCT TCCTGATATC CCTGTTTCTT TCCTTGGTTT
4151 GTAGTCTCGA AACCCTCTCC CTCTTCCCTG AGCCAGGCTT CTCAAGGATT
4201 GAGGTGTTT TGTATTTTTC CCATCTCTTA TCTTTAACTC TGTATCTTTC
4251 TTAATCCCTC TGGGCTTAC TCCTCAGATT ACCAAATTC TTAGGAGTCT
4301 CAACTGCTTT CCTTCTTAC ATTTCTTAAT AGATTATACC CTGTTTCATG
4351 CTCGTCTTGT CTTCAATCTC AGACAGCTCT TCTCTACACT TTCTTTTCAG
4401 GTTTTCTTA GTGTGCTGG CTCTCTTGT AAAAATCAAA ATTCACAAGG
4451 ACATTCACCT ATCTCTACT CCACTAGAGT GTATGATGGT ACACATTTCA
4501 ACTCAGCAAG GAGCAATGTA GCAATGAAAT GTTCAAGCTC TACAGCTAGA
4551 CTGGATTAA AACTTGGACA GGCCACCTAC TAGTTACAGA ACAATTTACT
4601 TAATGCCTCT GTGCCTTAAT TTCCTTATCT GTAAAATGAA GGTGATACCA
4651 ATCTTAGAGA GCTGGTGTGG GGATTAAATG GGCTAATACA TAAAAGTGC
4701 ACAGGACAGT GCCTGCCATA TTGTAGAAAC TCAATAAATG GCAGCTATTA
4751 TAATTGATAT AAAACATTAA CTGTTATTTT TTAATAAAA CTCAATTATG
4801 AAGAGGCTCA GGGACATATT CAAGATTTAT ATTGGCCCCA TTGTAATTGA
4851 GTTCTGAAAT CTTTGTCCAA ACCATTTAGT TTCCTATTTT TCATTTCCAT
4901 TGCAGACCAA AAAAAGGAGT ACTATCATGG CTCCTTTAAA ATTTTAGATC
4951 CACAAATCAA TAACAATTTT GGACAAAGCA ACACATATCA ACTTAAGGAC
5001 TTACGAGAGA CGACCGAAAA TTTGGTGAGT CAGGTAAACT TCTTTTATC
5051 ATAGAATAAT GCAAGTGGAA GGGATTTTGT GGATCATTTT TCCATTTCTA
5101 AAAACATGAT TTTCAGACCG CCAACATTAG AATCATCTTG CAGATTGCTA
5151 GGCCCCATCC CAGACCTGCT TAATCAGAGT ATGATGAGAT GGGTAGGTGG
5201 GGAGAGGAGA GTAAGGGAAT CTGCATGTCT AACAATGGG TGATTCTAAT
5251 AAGCCTCTCT TTCTAACTCA GCTACCTTAT TTAAAGGTAA GAGAATTGAG
5301 GCCAAGATAT CCTAGCCCGT TTCTTCCCCA ATTCACCAC GTTCCCCTG
5351 TAGAAAAGCC TAATCATACC AAAACTAGTT TTTATAAGTC CACACACTTG
5401 TTTGTAAGAC CACATTTTAA GATTTTGAGT ATTTTCAGAA TTTACGTTCA
5451 TCTTGTAAGT ATATTGATAA AGACAAAAA CCAGACTTAT TTTGTAGTAA
5501 TCAAGTCAAA TGCTAATAAT TTTGTTAAAG CTAAAGTGCA AGACTGCTCC
5551 CAAAAGAAA AAAAGCACAC TCAGTTGTAT AATCATTTCA CTCAGAATGC
5601 CCATGAATCT TCACTCAAAA ACTAGTTTCA AATTAATTTT TCTAACAAGG
5651 AAGCACAGAA GCAGAGACTT ATTTTAAAA GAAAGAAATG ACAAATGTAT
5701 TGGTTTGTCT TAATCAAAGA ACCATTTTAA AGACACTTTC TTTCCCAAAT
5751 CATCTACCAT TTTTCTCTGT CATCATTTGC TCTTGTCCA TAGTATACCT
5801 AATGGCATCA TATTTACAAT AATATTGTAG AGTTTATAAT CTCTATTTTC
5851 AGTTAACATT AAATCATTTA CAATTTCTTA ATTTTGTGGT TTCATCTTTC
5901 CCAACCAATA ATTAATGTCT ACAGATTGAT ATAGATTCTG CATTCTTTCA
5951 CATGCAGAGC ATCTTATAAA AGAGCATTTG CAATCAGTTC TTAAGTTATG
6001 CTAGGATGAA CGGGGAGCCT GCACCAATAC ACCCAAATAC CTTCTCTACT
6051 CCTCCAGTCC TAAGTGAATC CACATAACCT CCTCGATGCA AAAAGAGAAA
6101 ACTCTTAAT TGCCCTAGTT AAAAAGATAA ACACACCTTT GAATGATGGA
6151 AAATGTTACA ATTTACTGGG AAATTTTGAA ATTTGTTTCA TTTATATTTT
6201 ATGGCCAACA TTAATGCTAC TGTGTGTTT GTAAGTTAAC TAGGCAATTC
6251 TGTCTTTACT GAAGTAAACG GACAAGATG CAATAGGTCT TAAAAGAGT
6301 GAGAGAAATG CAGAGGTGCA TGTGGAACAG AAATCTATT TAAAAGTGA
6351 GTTTTAAGTT TCACCTAAGC ATGTGTTTCT TCAAAGGCTA AGGCTAAGTT
6401 AAGTAAGGAC ACATTATCAT CATGGGTACC TGCAAGGCCC TTCTCTGGTT
6451 GTCATTATTT ATTTATCCTC CTTTATCACC ATAGCATAAG CCCTTACCCT
6501 CCCCCCTGCG AGGAAATCAT TCTATGTTTC ATGTGGTATT CTTTGTGTTG
6551 TATTCATTCT TACAAAAATA TGTTTTGCTA TTTTGCCTAC ACTTGCTTTT

FIGURE 3

6601 AACTTACATT TTGTGTTATA AATCACTTTT GTTTCATCTC TTTTACTGA
6651 GAACTTTTTA AAAGATATAT GTTACTAAAT ATACCTTTAG TTTATTGCTG
6701 TTAGCTGCTA ATTCATAGTG TGTATCTTCC ATATTTACCT GCCTGTCATG
6751 CCAAGAAATG CCACACTAAA CAGACTCCTA CTTACCCCTT TATAGACCTA
6801 TGCAAGTACT TCTGGAAGCA GAATTACTAG GTCATTGAAT GTACATATAC
6851 TTAACCTGAC CAATTGGTGC AGGTTTGCTC TTCAAAATGG CTGACTCAGT
6901 GTGCACGCC ATCTACAATG CATGAGGATT TCTATGTCCC CACATCTAAC
6951 CAACACTTAG TGTCTTAGTA TGTTTAGGCT ACTACAACAA AAAATACCAT
7001 AGGCTGGGTA TCTTAAACAA CAAACAATTA TTTCTCATAG TTCTGGAGGC
7051 TGAAGATTCC AAGATGAAGA TGATCAAGGC TCTAGCAGAT GTCTGGTGAG
7101 AGCCTGCTTC CTGGTTCATA GAATACCATC TTGCTGTGTC CCTCATGGCA
7151 GAAGCCATAA GAGAACCTTC TTTTGTAAGG AACTAATGA CTTTCATGAG
7201 AACTCCACCC TCATGACCCTA ACTATCCTCC AAAGGCCCCA TCTCCTCTAT
7251 CATCGGTTTG GGAGTTAAGG TCTCAAAATA TAAATTTTCTAG GGGAACACAA
7301 ACATTGAGTC CACAGCACTT GGTATTATTT GGCTTTCTAA ATTTGCCACC
7351 CTAATATGTA TAAAGTAGTA TTTTATTTGT GATTAAATTT GCATGTTTCT
7401 AATTACTAAT GAGTTTGTGC ATTGTTACGT ATAATTATTA ACTTTTTGGA
7451 CTTTCATTTT TATAAATTGC CTGTACATAT TATTTGCCTA TTTTCTGTT
7501 AAACCTGCTT TTTACCTTA TTTGTATTGC TTTGCAGAAG TTCTTTACAT
7551 TTTCTGGATA TTGATAGTGT GTTGGTTGTG GACACTGCGC TTATCCATT
7601 TGTCTTCTAC TAATATGGAC CGTGTGTTTC TTTATGAAAC CGAAATCTGT
7651 AACTGAAGTA ATCATTTTTT CACTGTTTTG CCTTATGATT GTATTTTGAA
7701 GCTTTTCTTT AAGAAGTCCT TCTTCCCTTC TAAGACATAA AAATATTTTA
7751 CTATGTTACT TATTAACCTT ATAGTTTTAT CTTTACATT AGGTCTCCAA
7801 TACATGTGGA ATCCACCTTT GGATGTGTTA GGTAGATTCA GTTTTTAAT
7851 TCATATAGTG AGCCAGTTT TGAATATAAC TAGTTAAAT ATCTTGGCTT
7901 TTCTTAATAT ATGGTATTAT TATTGAGTTC ATTGCATGCA TTTCTTGGCA
7951 CCTGGGTCTT GCAGAAAAGG AAACATGAAT CTGTCTCCTC AAATTGCTTC
8001 CAATCTTTTT GGAAAGATGT GAGTAACACA CATGGAATTG AATATCATGA
8051 CATGATATAA TTAAGGGCTA AATTACATGT TGAGGACAGT AAGTACAGAA
8101 AAACCTCAA ACCAAACAAG GGTCCCCTG GTCAGAAAAG GCTTTATATT
8151 ATTTTACCTT TGTTTAAATG AGACAGGTGT TTTTCTCCTC CCATCCCGCA
8201 CCAGGTTAGC TTTAGAAGAA TTACAGGAAG AGTTTATGCC TCATCCTGAG
8251 CCACACCTGT TTGTTGTTGC TAAATCCCAA TGAATACAAC CAGATTCTTC
8301 TCTCTGTCCT ATATGGGTGC TAATTAGACA ACCAAGGAAG AACAGGTTGC
8351 ACGTCTGTT CTTCTCACA TTGGGCTTTA CTGATTTGAA TGCAAATTGA
8401 GATGCAAAAG TAAAATGAG TTCATATTTA GATATTGCTA TAATCCGCCC
8451 CTGTTCCCTG AGATAGTGGA GCAGACATAT CTCATCTCTC ATATCATTCT
8501 TCAGAGAAGG GTCCATTAAAT CAGACATTAC TGATGTCTGA TTAGTGCCGG
8551 CTGGCCATCC TGCAGGTGGA GAAGCATGGC ATCCAGCAGA AACTGACAGC
8601 ATGCACCTTG AGGGAGGGAA GGATAAGCCA GGAATTTATG CTGAATAAGC
8651 TGCCTAAGTA TACATGTTCA ATAAGTTCTA GGGGAAGTCA CAAATACTTA
8701 TGAAAGGAGA AACATAACTA TGTGCAATTG AGCTTTATGT CTCTTCATGT
8751 GTTGCAATGT CAAAAATGG TGGCATTAGC ATGATCCAAG GGTGGAGTTT
8801 TCAGCCATTT GATGTTCAA GGTGAAGCAG AGGACACAAA ACCCTTACTA
8851 TGCATCCTCT GTGAGTCAGC CAAAACCAGT CTGGACTGCT AGCTAGATTA
8901 ACAAAGAAAA AAAGAGAAAG AAGATACAAA TAAGCACGAT CAGAAATGAT
8951 AGAGGTAACA TTACAACCAA TCCCACAGAA ATACAAAAGA TCGTCTGAGA
9001 CTCTTATGAA CACTTCTATG TAGATAAACT AGAAAATCTA GAGGAAATGG
9051 GTAAATTCCT GGAAAAACAC AATCTTCCAA GATTGAATCA GAAAGAAATT
9101 GAAACCTGTA ACAGACCAAT ATTGAGTTCA TACTTAAATC AGTAATTTAA
9151 AAAACTTACC AGCCAAAAGG AAAAAAAAAG GCCCAAATA GATGGATTCA
9201 CAGCCAAATT CTACCAGACG TACAAGAAAT AGCTAGGACC AATTCTAGTG
9251 AAACATTTCC AAAGAATTGA GAAGAGACTT CTTCTTAAAT CATTCTATGA
9301 AGTCAGCATT ACCCTAACGC CAAAACCTCA CAAAGACAGA ATGAAAAAAG
9351 AAAATTACAG GCCAATATCC CTGATGAACA TAGATATAAA AATCCTCAAC
9401 CAAATACCAG CAAACCAAT CCAGCAGCAC ATCAAAAAGT TAATTTTCCA
9451 AAATCAAGTA GGCTTTATTT CTGTGATGCA AGACTGGTTC AACATATGTA
9501 AATCAATAAA TGCGATTTAC CACATAAACC GAATTAATAA CAAAAATCAT
9551 ACAATTAGCC AGGCATGGTG GCTCACACTT GTAATCCCAG CACTTTGGGA
9601 GACCATGGTG GGCAAAATAC CTGAGGTCAG AAGTTCGAGA CCAACCTGGC
9651 CAACATGGTG AAACCCCATC TGTATTAAAA ATACGAAAAT TAGCCGGGCA
9701 TGGTGGCAGG TGCCTGTAAT CCCAGCTACT CGGAGGGCTG AGGCAGGAGA
9751 ATCACTTGAA CCCAGGAGGC AGAGGTTGCA GTGAGCCGAG ATCGTGCCAT
9801 TGCATCCAG CCTGGGTGAC AGAGCAAAAA TCCATCTCAA AAAAAATTA
9851 AATTTAAGAA AATTAAATC ATACAATCAT CTCAATATAT GTAGAAAAAG

FIGURE 3

9901 CTTTTGATAA AATTAAACAT CCCTTCATAA TAAAAACACT TAGACTAGGC
9951 ATCGAAGAAA CATACTTCAA AATAATAAGA GCCATCTGTG ACAAACCCAC
10001 AGCCATCATC ACACTGAATG GGCAAAAGCT GGAGGCACTA TCCTTAAGAA
10051 CAGGGAAAAA GACAAGAATG TTCACTCTCA CTACTCCTAT TCAACATAGT
10101 ACTAGAAGTT CTAGAAAGAG CAATCGAGCA GGAGAAAGAA GGAAAATGCA
10151 TCCAAATACG AAAAGAGGAA GTCAAATTAT CTCTCTTTAC TGACAATATG
10201 ATTATATGCC TAGAAAACCC TAAAGACTTT ACAAAGGTT TCCAAAACCTG
10251 ATAAACAACT TCAGTAAAGT TTCAGGATAC AAAATCAATG TACAAAATTC
10301 AGTAGCATT CTAAACAATA ATGTCCAAGC TGAGAACCAA ATCAAGAACA
10351 CAATCCCAT TTTCAATAGCG ACACACACAC ACAAATGAAA TACCTAGGAA
10401 TACATCTAAC CAAGGAGGTA AAAGATCTCT ATAAGGAGAA TAAAAAACA
10451 CTATTGAAAG AAATCGGAGA TGACACAAAT GAATGCAAAA ACATTCCATG
10501 CTCATGGATT GGAAGAATCA ATATTGTTAA AATGTCCCTA CTGCCCAGAG
10551 CAATCTACAG ATTCAATGCT ATTCCTATCA AACTACCAAC ATAATTTTCC
10601 ACACAAAGTT AGAAAAAGCT TTTGTAATTT TCATATGGTA CAAAAAATA
10651 AAGCCCCAAT AGCCAAAGGA CTCCTAATAA AAAAGAACAG AGCCAGAGGC
10701 CTCACATTAT CTGACTTCAA ACTATACTTT AAGGCTACAG TAATCAAAAC
10751 AGAATGGCAT TGGTCAAAAA CAGACATATA AACCAATAGA ACAGAATAGA
10801 GAACCCAGAA ATAAAGCCAC ACATCTACAG CCATCAGATA TTCAATAAAA
10851 TTAACAAAAA TAAGCAATGG GGAGAGAAGT TTCTATTCAA TAAATGGTGC
10901 TGGAATAGCT AGCTAGTCAG AAGCAGAAAA ATGAAATTGG ACTCCTATCA
10951 CTAAATACAA AACTAACTC AAGATGCAGT AAAGAATTAA ATGTAAGACC
11001 ACAAACAATT AATACAAGAA CCCTAGAAGA AAACCTAGGA AATACTGTTG
11051 TAGACATCAG TCTTGGCACA GAATTTAGGA CTAAGTCCTC AAAAGCAACT
11101 GCAACAAAAA CAAAATTGA TAAGTTGGAC CTAATTAAAC TAAAGAACTT
11151 CTGCACAATA AAAGAACTA TCAACAGAGT AAACAAACAA CCTACAGACT
11201 GGGAGAAAAT ATTTGCAAACTATGCACTCTG AAAAGGTCTA ATGTCCAGAA
11251 TCTGTAAAGA ACTTAAACAA CTCAACAAGC AAAAGAAACC AAGTAACGCC
11301 ATTAAAAAGT AGGCAAAGAA CATGAACAGA TGCTTCACAA AAGAAGACAT
11351 ACAACGCAGT CAAGAAACAT ATGAACAAAT GCTCCACATC ACTAATTATC
11401 CAAGTAATGC AAATCAAAAC TACAGTGAGA TAATATCTCA TACCAGTTAC
11451 AATGGCTATT ATTAAAGATT AAAAAAATAA CATGCTGATG AGACTGCGGA
11501 GGAAAGAGAA TGCTTAAATA CTGTGGGAAA CGTAAATGGG TTCAGCCACT
11551 GTGGAAAGCA GTTTGGAGAC TTCTCAAAGT ACTTAAATG GAACTACTAT
11601 TCAACCTAGC AATCCTACTT ACTGGGTGTA TACCCAAAGG AGTATAAACT
11651 TTTTCCCAG AAAGACAGCT GCACTCTCAC ATTAATTACC ACAGTATTCA
11701 CAATAGCAAA GATGTGGAAT CAACCTAGAT ATCCATCAAT GGTGGATTGG
11751 ACAAAGAAAC TGTGAGATAT ATATGTATAT ATATCTATAT ATACCATGGA
11801 ATACTATGTA GCCATAAAAA AGGATGAAAT CATGTCCTTT GCAGCAACAT
11851 GGATGTAACA CCACAAGGAA GGCACITTTA TCTCCTCTTT ACAGGTAAGA
11901 GAACCAAGCT TCTGAAATTA AGGTCCATAG CTGGAAAATG ATGGAGGGGA
11951 GATTGGAAGT CATCTAGGCA ACTCCACACA TGTGCTCTTT CCACTAAATT
12001 GTTCTACTGT CAGGAAGGGA CTCAGCTAAG ACAGAAGATA AAATTATTAA
12051 AATCTAAATC AATCTTTCTC TCATTTTATT TTTTAAATCC ATGAAGATTA
12101 TAAATCCTCT ATGCTGTGCT AGCTAACTTT TTCTTGACAG ATACATTAGG
12151 TATACTTATT AGAGAAAAAT ATTCTCTTTC TCATTTCCCT GTATCAGTTT
12201 TTGGTGAGGA AGGCAAAGGT AGGAGGAACT GTAATAGAGA AAGATGAAGG
12251 AAGCTGATGG ATATATTGAC ATGTGTATGT ACATCTAGTG TGAACAATCT
12301 ATAGTTGGAA GAAAGGTGTG GATGGGTATG CTTTTTGAGG GAAGTTTTTG
12351 AGAAAAGAAG TAATATGAAC TATTTCTAAA TTTCTGATA AAGTTGTAAA
12401 TACAGCATAG TCTTCACAGG AGAATCTATT TAGTTTATCA TCATCATTCA
12451 GCAATACAG CATGATGTTA GGCACATAA AAGGCTAAGA AAAATGATTC
12501 TCTCTCTCTC ATAAACTAAT CCAATTTAGA GATTTAGAAG ACAACAAATC
12551 TGGAGAGGAC ATGAACCTTC TAAATAATGA CCTTCCCTTG CTTTGGGTAT
12601 CCTGGTTTTA AATATTTTTA GTACAGCTTT AAATAGATCC AAATGAGATA
12651 TTTTCTCTTT TTACAAAAGC AATTCAAAGA TCTAGGTTTT TGTGTACAC
12701 TGAGAAATTAA TACTTTTTTC TTTAAATCC TTAATTGCAA ATCTTTAAAT
12751 TCTATAAATA TTTTGCCCTG TGATCTCAGA AATATAAGCC AATTGGGGAT
12801 ATGGATATCT AATATATTGC TACTTGTTAC ACGTGAGTAG TGACAGATGT
12851 CTGTCCATTT CTTTCTGACA TTCCACAAAG AAACACTGAA GAAGGACCAG
12901 TGCAATCAAA GAAATGACTG ATGGCATCAC AAAATATCAC ATCCCATTTG
12951 ATGATCTGAT TACCTTTTTG TTTAGGGTGA TCAGAAAGTC ACAGTTTCAT
13001 GGCACCTTCC ACACCCACAC ACCTTGATG ACACTGGATC CAACTGCTTT
13051 CTCCAATAGA CACAGCACTT AAAGATGTGG CAGTTAGGCT TGACCCCAAG
13101 AAGGCCAAAA AGCCTTCTGT GAGCATCACT CAGTGCTCAG GTTGACTAAG
13151 CTCTATCCAG GCTTGAGAGA ATGGTTTATA GCTGACTTCT TGGATCCAAA

FIGURE 3

13201 AAAAAAAAAA AAACACCTAG AGTTTTATAC AGATATGATA CGAACTTAAA
13251 AGGACTGCAC TAAAACTAC CAAGATTATG ATTCTTATTT TTGGAGAGTA
13301 AAGAAAATAG GCTGCCCTTG GAGAGGGGTG CAACAGTTTC TGATCCTCTT
13351 ACAAACCTGCT TGCTGCCCAT CAGTGGGTAG GAGGTCTTAG TGAGAACCTA
13401 CCTGCATGCT CATCCTGAGG TAGGCACTGT GAAGGCGTTA ACAGGCTCTG
13451 AAGCTACATG GCCCTGGTTT CAGTGAACCTC TGTGGTGTCA ACTTGGGCAA
13501 GTCACCTTCTT CTTCTATGAA ACGTGAATAA TCATAGTACT CACCTTAGAG
13551 GGCTGATTTG AAAGCAAATG AGCTCAAACA CAATGACATC TGTGCTTGGT
13601 GCATATATGG CAGACAACAG TGATTCCCAC TATTATAATT ATTACAGTCT
13651 TACCAAGGAG GAGCTTTCCA CAAATAATCA ATTACCTAAA ATGTCCAAAA
13701 ACAGGAAAAA AAAATCTCTT CCGATAATTC ATGTGTAATT TTCTTTTTTC
13751 TCTAGGAGCA TTGATCTCAA CCTGATGTAA AGCAAGCACT TTAAAAAGTC
13801 TTATAAAATT TTCTGGTAA ATGCAAACT TTCTGATAAA TAAATTCTCA
13851 CCTTTTTATC AATTGTGTTA TTCAACAAAA ATATACTACA TACCAACAGC
13901 ATGCAAAGCA CTATGCTAGA TTTTATAGAC TATGAAAAGA TAAATTGCCA
13951 TCTCTATGCA TAAAGGGTTT GCCATTAAAT AAAAGAGACT ATATATTTGC
14001 ATAAATATAT AGTGAATATA TTGCATAAAT ATATAATATA TGTTTACATT
14051 AAAGAATAAA AGGTATAAGA GGGATAAGAA AAATTGAGAC AGAGGGAAGA
14101 CAGGTCAGTT TGAGATTAAC GAATATCCCC AAAGAAGGTA TTATCTGAGA
14151 TTGGCCTTGA AGGATAGTTG TGATTGAGGA ACACAGAACT TGCAGAATGA
14201 GAAGGTTGTT ACAGACCAAA GGAACAGCCT GAGAGGCGTG AGTATGCAGG
14251 AAAATGAGGG CCATGCCCTGA AAGTACTGGT GGTGTTGAAG ATGGAGCCAG
14301 GCAAGTTGGT CACAGAGGGA GAGGACCTTG AATGTCCTAAC ATTGTGGACA
14351 GAGGCTCAAA GGCTCAAATT CCCTATTTTT ACCTTGAGTT CAATCCTTGT
14401 GGCAATGAAA CCTCAGTGAA GCTTTATTTA AGGCTAAAAG TGTCTTTTAA
14451 AAATCCCTCT TATATAATAT CCTTTGCATG TTAATCTTGT TGTAAATTAGG
14501 AGAAAGCAAT AGGATCTAAA GTTTTTTTTC ACAGCATGGT TTTGGTTTCT
14551 TTAATTCTAA GGAGCTCACC TGGTGTACG TTGGAAAAAA CAGCTTTTAT
14601 ATCTCATTTA TATTCCATAT GCCAGTCTGC AGTGACATAT CTATCTGAGG
14651 TTTACAGTGT TAGCCACAAA ACACTCCCTA AGTGAATACA TTGACTGCTG
14701 TAAGGGGAGC CAGTCAGGAA GCACCTGCAG AGAAAAGCAG GCAACATGTA
14751 TAAACAGAGT TAATTCAGGA ATGAAAGCTG AATGGCTGGG CGAGTCTGTT
14801 TGTTTGAGTT GACAGCCTCT CCCTCACTCT TTCATTAAAT ATCCAATAA
14851 CCTTCAATTG CCTTCTTGA ACTTAATCTC AGTGTAAATT CCAGCATGTC
14901 AAAATTATCA AGCAGAAAGA AACTACTACC TGAAAGAGGG TCTTTTGTTC
14951 AATGCTAGGA GACAAACTCC AACTACAAA TTCTAGAAAT GCCCTAAAAG
15001 GAGAGATAGG ATAGATTTAC AAATTGCTAA TGCTATTAGG TTGTATAGAT
15051 AACAATAGAT TTATAACAAC CTGGCACACA GCTTTAAATA TATAAGTTTC
15101 TCTGAAACTT CTGGGAACCT GGAATGCCAG AACGTTGGCA AAAAGAATGC
15151 TTCTAATAAT GAAAGCCATC ATCTGCCATG GAAACAATTT CAGGGTCTTT
15201 AGAAAGCTAG TTTATACATA AGCTCCATT CACAATAAAA CTTATGTTCA
15251 TGTTTTTTCT GATTTTCCTC CTGCTGTAAA TTCATTTTAT CAGAATTCCT
15301 TTTACCAGTC CCTCTGCCCC ATTTCTCAAA GCGTTGTCTT CAGACTACCT
15351 GTATCACCTA AAGATTCTAA GGCCTCCTCC GATGTAGTAA ATGAGACTTT
15401 TCTAGAGAGA GAGTCCTAGA ATTTTATAAA GAAGGATCCT TTTTATTATT
15451 GTGATCACCA AAGTTACTTC TGCTTAGATT CTCTCATGT TATTTTACA
15501 GCTCCTATCT TCCAGACAA CCTAACAATT CAAAGATAAA ATTGGTGCTT
15551 GGTTTAGACA TTCATAGCAG CCAAGGTGCC AGATTGATGA TGTATCCAG
15601 AGTCAAAAAC TTCATCCAAT GCCTTCACCA AAAAGTTACA AATGGCCAGG
15651 AATCAAATGT GGTGAACTT ATTCAGAGGG TAATTACAAA ACAAACTTCT
15701 TTAAATACCC AACTGCTATT TGCTTTTTTC CTCTAAATT GTATCACTTC
15751 TCTCCCTGTT CCATTTTGTG TGCTTTTTTA TTTTTTGGAA TCCCTCACCT
15801 CCATACTGAG TAGTAGAGCT GGCTGTGGGT GATGAGAGAG AAATTGTTAT
15851 AACAAAGTCA CCCTTTCAAA AACATGTCTT CCAAAAGAAT TTTGTTCTA
15901 GCAGATAAAC CCCACACCAC CTCAGCTAAA TGGGGCTTTC TTTATTTAAG
15951 TACCAATAAA GACATATTTT GGATACTAGC AATTTATTTT CCAAATGCTA
16001 TCTTTGATCT TAAGTTTAAG GCTATTACCA AATCTATATC TCTACAAGTT
16051 TTATACTTTA GGTCAATAAA TTACTTGATA ACTTATTACT ATGTGTTCTA
16101 CAAAAGAAAC CGAAGTAAA TTTACATCAC ATTTAACAGG GTGGTTGTGT
16151 GATTGAGTGG GAAGAGGCGG ACCCTACAGA TAGAAGACTT GGGTTTCAGT
16201 CCCAGCTTAC TAGTATCTGC GTGATGCCAG GGAAATTCAC ATAATGCCCTC
16251 TGAGTCACAG ATTTCTAACA GGAATGAAGA TACTTCTTCG CAGAATTGTC
16301 ATTAGAGTTA AAGAAGATAA CAAATAATGT GGTTCCTGAT GAGGTATTTA
16351 TGAATTCCTG AGCATGCTAA GGAAGTTATA ACTTGTCTCT TGATCCCTGA
16401 AACAGCTTTC CCTATATTTG TGTGTGTGTG TGTGTGTGTG TTTCACTCAT
16451 GCAAGTTGGT TTTCTTCTC ATTCCTTGAG AATTTAGGAT ATTTTGTGCG

FIGURE 3

16501 CACATTGGT TCTTCTGTCC AACATGAACT GTAGTACCTT ACCCACATTG
16551 AGATGACACT ATTTCTACCA AGTGAGTGCT AGGGGATACT GCAAGCCGAA
16601 TGCCAGGTGT GAGAGACCAC AGCATCACAA TACCGTGGCA GTAGATTAAA
16651 GCTGTGCATA TGGACTAAAA GCAGTGGCTT TGCTTCTCCT ACCTTGGTGA
16701 CATAAACTGA GTAACAAATT TGACCTAATA CTGGAATACC ACCTAATTCT
16751 TTTTTCCTCC CTGATTTACC CTAGAGTCCA CAATTGACAA TAATTTAAAA
16801 ATTTTGGCTC TCTCTTAAAT CCCTAATGCC TCCTCCTTAC ACCTTACAAG
16851 CAAAGACCTG CAGAGCTAAG ACCTGTAATG CCAGGATGGA GGCTAGAGGA
16901 CCATCAGCAA TTAACCTACCA AAACCTACCC AACATTTTAT ATCTGTTTAA
16951 CCTTCATAGC CTTATGAGTA GCAGATCAAT ATCTTTGTTT TACAGGTTAG
17001 AAAACTGAGG CTCAAATTGA TTCAGTAACT TTGCCAAGAT TGCCAGTTT
17051 GGGAAAAGTA GTATACGCTC AAATCCAGGA CTGAGGCAGG GTTTTCTTTG
17101 TCACCACTCA AAGCCTCTCT GAATATCCTA TCTCTGCTCT GTATCTCTCT
17151 GCTACTCCTT CTATGGTGT TTAGCAAGAT ATCTTCTACT CCAGAAACCT
17201 ACTCTAGCAC AGTAGAATTA CTTGGGTAGG TTTTAAATA ATATGAGTGC
17251 CTAGGTCCCC TCTAGACCAA TCGAAACCAA AATTCTTGGA GAGGATCCCT
17301 GGCATCCATA AATTTTTTTA ATTCATCAA TGATTCTGTT GCACTGTGAA
17351 AGCTGAGATC CACCAATTTA AATAATGATG TTAGTCTGT GAAAAAATT
17401 TTGATTGCTT TAACATTTAA TCAAGGATAT ATTCTATTA TAAATATAT
17451 TATTAAACACA TAGTTTCTCT CTTGTTGTGT AACAGGTGGA TGAGATATTT
17501 ATAGATTCAG CTTGGAAGAA AAATTATATC AAGAACCAAG TAGTCAGACT
17551 GACGTATGTA TGTTTGGGCA AAGGTGGAAT CACAAGACTG GAGGGAAAAG
17601 GAACAAAGGA GACAGGGACT CTCATGTATT GTATGTCTCC ATGGACTAGG
17651 CTTTGGCTA GAATTTTTCA TAAACATTAC CTTTAAAGCA GTCTTGAAGT
17701 ATAGGGCTGA CCACCGTTTT GTCAACAAA AGACTAAGAT TCAGGAAGGG
17751 TAAGAAATAT GTTCAAAGTT CACCAACTGA CAGTTTCCCA AAGTGACAGA
17801 ACCAGGAATC AAACCCCAT AACTTATTGT GAGGCCTGGA ACCTACCAGA
17851 ACCCATGACG TGGGGAAAAC CCAGCAGCTT GTCGTTGCAT GCACCAAGTT
17901 ATATTATGTT GACAATTATA TTATTTCAAC CACGTTAAGC AGGCAACTT
17951 GGCTATAAAA TGGGTTTACA AATTTTACCT GTAATGTAAC CGAATGACAT
18001 AAGGCATGCC TAAACAAAA GATATTCTCT TTGTAATAAA TTTTCTTCT
18051 GTCATGGTGG AGGGGGAAGA CTCATATCAG TTGCAGATAT TGCTCAGAAG
18101 TTTCAATTGT GTTATTTTGA AAAACTACAT AGCAGAACAC GCATGTCATA
18151 TACACAAATC CATGAGCCTG TATGACTCAT ATTTCTTAAA GATAAAGAAA
18201 AATAATATAT TCAGATTTTG ATTTATTTGA AGAAAATAAT TATCCCTTTC
18251 TCACCAATAG ACTAATAATG CTTTGTGGC AGGTGTACTC AAAGTTCTCT
18301 ATGTCTTGAC TGAGTAACTA GTGACTTCCG TAAGGATTTT ATAACATAAA
18351 TTGGGTAAAT CCTACAATAC TTAGGAGGGA AAAAGCATAT AAATGCTAGA
18401 ACTTTCTAGA TTTTATGTTT TCTGTTTTCA AATTCCTCTT TACCATATTA
18451 TTGTAGCAAC ATTATTATAC TCCTGTGAAC TCCTTTGGAT GGTAGCCATC
18501 ACTATATAAT ACCTGGTAAA AATGTTAATT CCTCAGATTT AAGAAGTAAA
18551 ATTAGTCATC TGTTTGCCAA TTTGACATAA AATTCATGTT ATTTAGATCT
18601 TTATATTCCA GAGCCTAAAT GAACAAAAAT ACATAAATTG TCTCAGAATT
18651 TCCTTTTAGC CAAAAGATTC AGGGAGATGG GCCTCTAGAG TTTTTCACAG
18701 TTTTTTTTTT TTTTGTAAA AAAAAGGATG TGTTTTTTTT TTTAAACAAA
18751 AGATCAATAT ATATTAGTTT CAAGGTTTTT TGTTTTTTTT TTTAAACAAA
18801 AACCTGTAAT TGCTTTTCCT ATTTTAAACAG TATTTAAAAG TTTAGTTCCT
18851 CAGGTAACAG AACTTGAACC TGTTTATATG ATCAAAGTTC AAGAAATGGG
18901 GCATGTTTAA TTTGGAGAAG ACTCGGGGAC CACAATATTG TTGTCTTCAA
18951 ATATTTGGGC TAGAGGAGGA AATTATTTTA TGTATGTTCC AACTGGTAGA
19001 CCTAAGCCTT ATGGAATGGG AGATATAGGG AGACATATTT CAACTCAAAA
19051 TGATGAACTC TTAAGAGCAG AGCTGACCAA AGAGAAACAA GCCTCTTTAG
19101 AAAATTAAAC TTAATATCTT TTTAATTACT GCACTGTCAT TAGAGGGCCA
19151 ATTGTCATGG ACCCTGTAGA AGTGATTCAG GTATCAAATA TACAATTGAT
19201 TAGCCTAAGA AAACATGAAG GCTTCTTCTA ACTCTCAGAG CTTGTAATTT
19251 TGATGATGAT TTTTATATAT TGTCTTCTCT AGCTGCTGTA ACAATCCTTC
19301 AAATTAATGG GGGAAATGCA CTGAAAACAT AATGAAAGCT AGAAGAGGGA
19351 ACATATGAAA TGACCTTGGG TCAGAATGAC ATGAGAGGAT CAGCACTTGA
19401 CACTCTCAGC AACTGAGGGA TCATTCAGGG GAGGAAGATA CAGGTAAGAC
19451 TGAAGGACAA TTCCAGGTGT ATTCCTTGAA AATGTACCTT TCTTTTGTGT
19501 GTCACAGTCC AGAGGAAGAT GGTGTGAAAG TAGATGTCAT TATGGTGTTC
19551 CAGTTCCCTT CTACTGAACA AAGGGCAGTA AGAGAGAAGA AAATCCAAAG
19601 CATCTTAAAT CAGAAGATAA GGAATTTAAG AGCCTTGCCA ATAAATGCCT
19651 CATCAGTTCA AGTTAATGGT AAGGAGGTCC CTTTCTATGT GATATGAAGT
19701 TGTCTATTAG GTCCATGTTT TGACGAATCT CAAATTTATT TGTCAATTAT
19751 TCCATTTCAA ATAATAGCTA GAATTCAGAT GAAAAAATTC AAGTTAAAGA

FIGURE 3.

19801 TGTGACATTT CAAGGTGTAT TAGTCTCTAA CGTAAGCATG TCTGAAGTTA
19851 GTCATCCAGT GGTTTTCCCG ACAGTAATTG ATTGGCACTC ATCCCAAAAT
19901 ATAGGCAAGC ATTTACAAC T AACAGAGAGT TAATCCCACC CAGGCACTGC
19951 CTCCATGACT AAGCAAGTGA AAATACTAGG GGTTTAGCAA TAATTGTTTT
20001 TCTGGGTGGG ACCTTCCTAA AACACAAATT CATGTGTTGC CATACTTTTA
20051 TTGATAGTTT CTATATATGG TGATATACAA TTTTGTAG CTTTTTTTCC
20101 TATGGGCATT TGGGAAAATG GCAAGCCAAC TTTGAAGTTG TTAGAGTCAT
20151 TTTACCATTA ATGCTTTAAA AATCACAGTC TAGGAAAACA TCACTGAAAC
20201 TATGTGTACA TTGTTCCACT TTTCTCTTTT TTTTGTTC CACTTAGCCC
20251 ATTATACCAT TATCACTTCC CTCAATTAAG GAGAACAAAC CTTTATCAAG
20301 GTCATCTCT ATGGCCTTTA CCTTAAGTAA CTAATTTCTT TTTATATTCC
20351 AGTGACGTAC GCAAATTCAC CTTTATAGAA GTGAAATTC CACAAAAAGA
20401 GTTGAGGAAT TCAGTAATTA AAAGGAGCTA AGAATCAAAT TTAAATCTCT
20451 AATTTCTTAA AAGGCTCCAA TTAATAAAGG TTTCTATAGT CAAACACATC
20501 TTAATAATTC TGGCTTTGAT ACTCGTTTCT TGGAAATTC TCCTTATAGT
20551 GTCATATTAA AAATTCCTAAG GCAGCCAGCT AGAGAGAAAC TTGTTTACCC
20601 TCGTCCGCTA AGCTGTTTGC ACAGCATCTT CTTCCAACAG ACAAGTATAG
20651 ATTTCTCCTA CAAATTTCAA TGGATACCAG ACCTAAGTGT TACAGAAGAG
20701 ATTCAGGGCA AGCGATTTTT ATCAGACATG AAACAGGACA CTCTGCCCTT
20751 GTAAGGGTCT AGCTGACACT TCAAGAGGAA ACCAGATAAG GAAGTAAAAA
20801 ATGTGAGGTA ATGGAATGGG CAGATGTTTG CTGATGTGAG AACGAGTCAG
20851 CTACTTAGGG AATAAAGCTG AGGACCTCTC CCAGCCAGAA GGGAGGAACC
20901 TGACAAGTGC TTAATCCATC TTTTGTGTTA GATGGGGAAG CAAATGAATA
20951 GAAGTTGTGA AACAAATGGG ATTCGTGATA TTTACATGAT GCTTTCTGTG
21001 TAATTTCCAA TAAATAGTTA ATTTGTCAGG AATGTAAAAG CCTGAACTAT
21051 CTGAAACCAG AGTAAAGCAT AAATGTTTCA TTGGCTGCCT GGTCTTTTTG
21101 TTTTTTGTAG GCTCAGCTTC TAAACTTCAG CTTATTTTAA TAATTGTACT
21151 AAATTAAATG GTAGGATATG CTAATGGAGA ACCTGATTG AGAGTCACCT
21201 GAGGCTGGGC ATGGTGGCTC AAGCCTATAA TTCCAGCACT TTGGGAGGCC
21251 GAGGCGGGTG GATCACCTGA GGTCAGGAGT TCAAGACCAG CCTGGCCAAT
21301 ATGGTGAAAC CCGTCTCTT CTAAAAATAC AAAATATTAG TCAGGCCTGG
21351 TGACGGGCAC CTGTAATCCC AGCTACTTGG GAGACTGAGG GGAAGAATC
21401 ACTTGAACCC GGGAGGCGGA GGTGTCAGTG AGCCAAGATC GCGCCACTGC
21451 ACTCAAGCCT GGGCTTGACA GAGCAAGACT CCATCTCCA AAAAATAAAA
21501 AATAAAAGAG TTACCTGACC AATTCTAACT CCACTAAGTC ACCACAGGAC
21551 CACCCAAATA ATTGGCTCAT GCCTTTGTCT TCATTTTCTC ATCTGTAAAA
21601 TTCCAATGGT AATGTTTGT CTTCCTGAAA TCACAGAGAG ATTATAACGA
21651 TATACAAGGA AATAGAAAAC ACAATGTGAA ATAAAGAGGC TGTACTAAT
21701 GAGAAACTA TTATGTTGTG CATATGCTTT GGAAACCTGA AATCATTAA
21751 TTGAGTGATT GACTAGTAGC AGAAAGATAG ATCCTTGAAA GTTTCAGAAT
21801 GTTCAATGTA GAAAGAACAG TGTTTGTAG TGATATGGGA GCCTAGGGGG
21851 TGTGCTTTT CTGGCCAGAA ACCTCTGTGG CCAGTGGTGG GTGCCTTTGC
21901 CCAAGTTTTG CTCTGGCCCA CTGGGCTTGT TCTGCCCACT TGACCTGGCA
21951 GACTGTGCCC ACCTTCCGCT ACCAGCCTGG ATCCCATGCC CACCAAGGCC
22001 AACCAGGCA TGGAGCTGTG AGGGTTGTCT GAGCGAGCAC AGGGTCTGGC
22051 CACTGCCAC AGCCAGGCAC ACTGGCTGCA GCATGACGGG CAGCTCCAGG
22101 CACTGGCACA GGTGTGCTGT CTCTCTGTGA GGCTGTGGCT GGACAAAGCT
22151 CACTGCAAGC AGCTTCCCTG GCAGGCACCT GGAATGTGG TGGCACCAG
22201 GAAGCTTGA GATGCCAGGA ACTGCAGGGT CCCAAAGAGG GAGTCACAAC
22251 CCTGGCTTGG GGAGCTCCCA GGTCTGGGAT CCCTAAAGGG CTGCAGCTTT
22301 TCTCTCTTT TACCCACAAT GTGGCCAGCA AGGGGTATGT TTCATTCTG
22351 TTTGTGTTAC AGCTCTTTTA GTCTTGCTAT TTGGCAGGTC CTGAGTTCTT
22401 GTCTGAGAC CAAGAAGAAT GAGGTATGCA GACAAGTGA GGGTGAGCAA
22451 GACGAAGAAA GGTTTACTGA GCAAGAGAAC AGCTCACAGG AGACCCACAG
22501 TGGGCAGCTC CTCTTCATAG CCAGGGTGT CCAACAAGTG TCCAGCTCCT
22551 AGCAAAGAGG AGGCCCTGGA GGTAGAAGCT CCTCTCTGCA GGCAGGTTGT
22601 CCTGTTGAGT GTTCAGCTTT CAGCACACAG TAGGCAGTAG GCCCTAGAGT
22651 GGTCTATCTC CTCTCTGCAG GCAGGTAGTC CCATGGTCTC CCAGTCACT
22701 CTCCATCTGC AAGGGTCCAA TGCTGCCTCC AGCACCTCTC TGCCCAACCC
22751 TCCGTGCTG ACCAAGCTGC TCCCCACCA GTGGGCAACT CAGCCAGGCC
22801 CCATTGTGGT AGCTCCAGG GTGGCAGGCT CTGGGGGGCT CCCAGGGATG
22851 GGCTCCAAGG ACTGTCCACC TTCTCCCCAC GCCCTCCCTG CAGTGGCCAT
22901 GGTCAAGAAT GGCAATGTGG GGCCAGGTT CCGAGCAGGA GAGGCTCCAG
22951 GCCTGGGAGC AGGTCTGCGG TGGTACGTG AGGTTGGGGG TGGCACAGTC
23001 GGCTGCCTCA GGGATGTGGG ACACAGGGGA CCCACCACCA TCACTGCTAC
23051 TCCCGCATCC GCTCCTGCTA CCACTGCTCC AGACAGCCTG TAGCTGCCAT

FIGURE 3

23101 CACTAGCACT TAAGAAAGGC ACATTCAGTG GACAGCTCAG GAAAATCTTT
23151 ACGTCAATTT TTTATAGGCA AAAACATTGT TTCCTGGGCA AACAAAATTT
23201 ATGGACTACC AATAAATAGA AAACGTAGA GATTCTAGAT TAAGTCTAGA
23251 AATAATCCTG TAGCCCAAGA TTTATTTATA ATTTGTCAAG AATCTGTATT
23301 TTGTTTTGAC AAAAAAAAAA CTGTGTGGTG TGGGTCCTTC AGGAGACACA
23351 GTGTGACAAA GCAAAGCTAA AATCAACTTC TTTGCATTGC AAACACCAAG
23401 GCTGTAGTCA AGCAGCTCAC TGCCTATGTG TCAGATGACT TTGCTTCATT
23451 TTTCATCATG ATACTTGTAG TCTATAGAGC CCTGAATATT AACTAGCTTT
23501 CTCCCAACTC AGAACCGTGT TAGGAGGTGG TTGCTTTCAA AACTAAAGTG
23551 TTAATGTTTA TTTCCATTTT TATACCAGGA AAGTAAAAAT CTTTGGTCAA
23601 AATTAGAAAT CTTTAACAAC TAGTTACTTG TGTATTGACA GTTTGTTTCC
23651 AGGTGTAAAT ATTCTCCCTT AAAATCCGGT TATATTCACG ACCATTATAC
23701 TTATCCTGGT ATCATTCCTG GAAATGGCTA ACTTGCATCC TGCTCAGACT
23751 AAGTTGACAA AGTTTCAATT GAAGAATTCT AACTTTATGC TATTTTCCAC
23801 TTTATTGCAT TACAAAGGAC AAAATATATA GTTTCTTAA AAATGAAATA
23851 AATTTACTGC CTTAAACTAC ATTTGACGGT AAACGTAGTT CCTTCCATAG
23901 AATAACCACT AACAGCAATC GATGGTCCTG AGCAATTGAC TCTTACCAT
23951 ACAATGATTT GGGATGCCTT TAAGGGTATA TTTGAATTGA ATATTTTCAA
24001 AAGCTCCAC TTTGTAGAGT TTATCATCAC TAGTTTCCCC AGTGGAATTT
24051 GTAGAAAGTT AGTAGAATGA AACAATCTTA TTTTGTATAA TGAGGAATAG
24101 AATACTGAGA ATGTGTCTGA GAAACATGGC ACTGGTAGGA AAAAGTAAAC
24151 AGTTTATTCT CATCTGCTCA ATAAGCTAAG TCATTTTAACT TTGAAATCA
24201 TCAAAATTTT CATGAAACCT TCCACCAACT TTATTTTCC CCAGCTTTAG
24251 TAAGATATAA TTGACAAATA AAAATGTAT ACTGTATACA ACATGATGCT
24301 TTGATACATG TATACAAGTT TAAATATTTG TGTTTCCCTA GTCAAACCTC
24351 TCACTTTTTT GGAAGTTGAC AGAATTTAAT CTTGGATTGT GTCCAATAAC
24401 TAGCTTTTAC CACTATTCAG TATATTTTGG ATAAGAAACA CATAACAGTT
24451 TATTCTTTAA AAAAGCAATT TTACTATTTA GGAACGTGT TTAAGCA
24501 TTTTAAATAT CATTTATGCA AGAGTTTCA AGGTTTTTTC ATTCTAAACC
24551 CTTTAAACCA AAAAAAAAAA AAAAGATTT ATGTGAAAT CGAAGTAAAT
24601 AGAAGAGATC AAAGCAGATC TGTTCTGGCT GAGGCTGAGT TTGAGACCTG
24651 TAAGACAGTC TACTTGCCAT ATGGCTTGGC TGTGTCCCCA CCCAAATCTC
24701 ATCTCGAATT GTAGCCCCCA TAATTCACAC ATGTTGTGAG AGGGACCTGG
24751 TGGGAGATAA ATTAAATCAT GGGTGCAGTT TCCCCATAC TGTCTATGG
24801 TAGTGAATGA GATCTGATGG TTTTATAAGA GGCTTCCCTT TTCCTTGGC
24851 TCACATTCTC TGACTTGCTT GCCACCATGT AAGACATGCC TTTTGCCTTC
24901 CTCCATGATT GTGAGGCCTC CCCAGCCACA TGGAACTCTG AGTCCATTAA
24951 ACCTCTTTTT CTTTATAAAT TACCCAGTCT CAGATATGTC TTTATCAGCA
25001 GTGTGAAAAC AAATAATAT AACCTGTTTC CTCTGTCCCA TTTATCCATC
25051 TTCTGAAGTG GAATGCAAAG AAGCTTTACC CCGAAGTCT GGAAGACCAT
25101 AGTTCTCTAT TAATACAAAC TATTTGTGGG CTTTAGTCAT CCACTATTG
25151 TGCCTTACTC ACCCATGCT TGTGATAGTA TCCACCTAAT TAGAGGCTGC
25201 CTATAAGTCT CTACAAAAC TGTACACAGA TGTGTTATA TCAGATAGCC
25251 ATTCTCCTAA TTAATCTATA TGTTCAACTG TCTAGAATCC ATATATGGTC
25301 AGTATCCTCT GATTATTCCT GGTCAATGAG ACCAACCAGG AAAATATCAA
25351 ATTATCACTA TTTGTTTTAT CTTCTTTTTC AGCAATGAGC TCATCAACAG
25401 GGGAGTTAAC TGTCCAAGCA AGTAAGTCAA GTTAGCTTAT ATAAACAAGT
25451 TCAATTTTCA CATCAGAAAG GACATTTTCA AATATTTGCT CATACTTGCC
25501 CATCTGTCTT CCAGATTTTC TTTGAGAGAT AATAACTATT TGTACGATAG
25551 ATTTAAATAC ATTTTTTTTC TAACTCATGG ACTGATCTTT TAGTCATGTT
25601 CAAGAAAAAA ATTGCCATGG TAACCTTCTG GGGCAATTTG AAGAAAGCAT
25651 TTATTTTTGA TTGGGAATAT TGGACTTGT TTTCTAATTT TTAAGAAATGC
25701 CATAAATGT ACTTTCTGCT ACAAATAAAA ATAATAAGAA AGTAATCAAT
25751 AGGAAGGACA TAAACCCAT TGTCTGTGAC TGACAATTTG TCTGTGAAAT
25801 ATGCTAAGGT CAGGAGTTCT AGACCAGCCT GACCAACATG GAGAAGAAAA
25851 CCCATCTCTA TTAAGAAATAC AAAAATTAGC CAGGTGCGGT GGCAGGTGCC
25901 TGTAGTCCCA GCTACTTGGG AGGCTGAGGC AGGAGAATCA CTTGAACCTG
25951 GGAGGCAGAG GTTGCAGTGA GCCAAGATTG CACCACTGCA CTCCAGCCTC
26001 AGOGACAGAG TGAGACTCCA TCTCAAAAAA GAAGAAAAAA ATATGCTTAA
26051 TAGATTCATC TTAATCGCTA ACAGTGGCTT CATTAAATCA CTTCAAATCA
26101 CTGTGGCCTA AATTTTGAAA GATTTTACAA AAAACAGTGA TGAATTTGAG
26151 CAATGATGTT CATGCATTTG CCTCTGTGAC TTGCAAACAC CCTAAGTATT
26201 TTTATCCATG TGTATTATCA TTCAACAATA TCTTTTAACT TCTACCAAGT
26251 GCCAGAAAT AGACCAGGAG TTGGTGGTAC CATGTGTAAT AAAACATGAT
26301 CCCTGCTCTA AAATTAGAAT TCCAAAGTAG AGAAAGATAT AAATAAATCA
26351 GGAAGTATGA AAATAATGTG ATTAATGCTA TGACAGAGGA AGTGATAGT

FIGURE 3

26401 GCTATGAGAG TTGATCAGAG AGTCAGCTAA CCTGTTCTCA CACAGTAAGA
26451 AAGTGAACCC TGAAATGTGA GAGAGAAGAG GCCATGAATC CAGTGACAGG
26501 TGGGGTAAGT GTCCTGGGCA GGAGGAGTAG TATACGAAAA TGTCTTCAGG
26551 CAAGTAAGAA TGGGGTCATT TCCTGTAAAT ACAAGATGTT TCTTATAACT
26601 TAATGATCTC ATCTTTTTTC AGGTTGTGGT AAACGAGTTG TTCCATTAAA
26651 CGTCAACAGA ATAGCATCTG GAGTCATTGC ACCCAAGGCG GCCTGGCCTT
26701 GGCAAGCTTC CCTTCAGTAT GATAACATCC ATCAGTGTGG GGCCACCTTG
26751 ATTAGTAACA CATGGCTTGT CACTGCAGCA CACTGCTTCC AGAAGTAAGT
26801 TATTGACCTT AAGTTAGAAC CCACCTCTGC TAAAAAGCCC TGAGTTTGT
26851 CATATTCTTG GTAACAATTA ATGTCTCAA TATTACTGAA GTAAAATAAG
26901 AAAAAGTTAT TTCAGGTTCT TTTCTAAAT AATGTTACAC TTGCATACTT
26951 AATCAGAAAT TTGATGGGAA TAAGTAACAG TCATTATCCT AGTATCCATC
27001 AATCATTTCC TCAAAGTTTT TAATAAGGAA ACTGTGTAAA GAAATCAGAA
27051 CTATTTTGTG ACATCCTAAC ACAAATATT CACTAATAAC ATGTACCATT
27101 AATCTTTTGT CAAACAATGC TCTCCACTTA AAACAGTGT CTGTTTCTGC
27151 CAAACACTTG GGCCAGTCTC ATACTGATCT TAAATAATCA AACTAATTCC
27201 AAAGTAAAAT GGAAATTTTC AATAAATGCC GGAAGTTGGT AACCGTGATG
27251 ATGGAGAACT GCAGATCAAA TTTAGAGCAT TGACATATGA AGATCTGTGG
27301 AATCAGAACA GTTTACAACC AAAATGAGAG ATTGCTAGCA TGATAAAGAC
27351 AGGCACCTCA AAAGAGATT CTCGGAGTAT CAAAGGATTC ATAGAGGCCC
27401 TTGGGCCACT CAATGTGACC TTCCCATAAAT AGAGCATCTC TTCACAATAG
27451 TGACACAAAA GACAAAGCTG AAGTGAAGAA TAGCAAATG TGCTATCCTA
27501 TAATTGTTTC TGAATGCATA CATTTTATTA AATATATGAT TAAATGACTT
27551 TTTATAACTT TTAATCTTAC TTTTCAAGAT AATAACCAGT CATTTTATC
27601 ACTATTACAT TTAGAATTTT AGATTTGTTT CTAAGTAGAT TAACTGTATC
27651 GCCTTTCTTC TTCATTGCCA ATTATTACAG TAATAACAAA GACTTCTTGA
27701 GTATCTCTAT ATAATAGGTG GCAGCAGGAT TTAGTGGGAA AAATATGTCC
27751 CAGGCAGTTG GAGAGCTGGG CAAATTATTG AACCTTAGTG TATTAGGTAA
27801 TAGATAGGCT AGATCTTTTC ACATTCTTTT TGACCTATAA AATTCTAACT
27851 TTTGTTACTA TAATAAATTT CATTTGCCTA GGAGCATAAA TCTTTATAGA
27901 GACTCTTAAT ATTCCAAAGA ATATACATAT TAAGAATCTA GGCTTGGCAT
27951 GGTGGCTCAT GCCTGTAATC CCAGCATTTT GGGAGGCCGA GGCAAGAGGA
28001 CCACTTGAGC TCAGGAGTTC AAGACCAGCT TGGGCAAGAT AGTGAAACCC
28051 CATTTGGCAT GGTGGTGAT ACCTATCATC CCAGCTACTT GGGAGGCTAA
28101 CGCAGGAGGA TCCCTTAAGC CCAGGAGTTT GAGGCTCTG CAAGCTATGA
28151 TTGCACCACT GCACTCCAGC CTGAGTGACA ATGCAAGACC CCATCTTAAA
28201 AAAATAGTAA TATATTTTAA AAAATAATCT ACATAAATTC TTAATGTTTG
28251 AAAGATGTGA GAGCTCAGTA AGCTGATATA TTAGAAAGCC AGAAATCCCT
28301 TATGCTGGTG TCTGGTTTTT CAAAGTAATG GGAAACTTAC TTTGCCAAAG
28351 TTAGCCATTT TTGTGGTAGA TAGTTCTATT TTTGCAAATA TCTTTATAGC
28401 ATTGAACACC AAATCTATAC TCTATTAAT TCTACCATCA ATATTTGTTT
28451 TTCPTTTAAT CTGGAACAAC AGGAACCAAT TTTATTTCTT CATTCATATA
28501 ACAGCTATT TTTAGTTTCT CTTTTTCAGA CCAAACATAA AATGAGGGAG
28551 AATATCCAAA CCATAAGTGA AAATAAATAT CATTACTGTG AGCTTTAGTT
28601 TGCTAAGGAT AATGACCTCC AGCCCTATCC ATGTCCCTGC AAAGGGCATG
28651 ATTTTGTCT TTTTATGGCT GCATAGCATT CCCATGGGT ATGTATACCA
28701 CATTTCTTT ATCCAGTCTA TCCTAATGG GCATTTAGGT TGATTCTATG
28751 TCTTTGCTAT ACCGAAGAGT GCTAGAGGGA GAGGATCAGG AAAATAACT
28801 AATGGTACT AGGCTTAATA CCTGGGTGAT GAAATAATAT GTACAACAAA
28851 ACCCCATGAC ACAAGTTTAC CTGTGTAACA AACCTGCACA TGTAACCCTG
28901 AACTTTGAAA AAAGTATATA TATGCACACA CATATATATG CATACATATA
28951 TATGTGTGTA TATATATGCA TATATGTGTG TGTGTATATA TAAAAAATA
29001 TATATATATA TATATATATA TATAATTACC TCATTTTCC AGAACCAACT
29051 TCCAGATGCC CTACCACATT GGTCTTTATT CTCTGAACAT TCGAGACTTT
29101 GTCAGTGTCT TCCTTAAAAAT ATGCTTCCAA TAACTAAATA CACCAAGACA
29151 GATGTGTGAC TAGTGTCA CAATAACAAA TAAAGCAGGA AGTCTTCTGA
29201 AAAATACAAA TAATGTAAAT TGGTGGGAGA CAGTGTTTTA TAAAGGGAAG
29251 AGCAGAGAGA GGCAGGCAGA TATGTGATGT GAATCAAATA GTTTAACCTA
29301 TCCAGGCTTT ATTTTCCTTA AGTATAAAAC ACAGTCTTTA CTAGATGATC
29351 TTTCAATGCT ACTAAATGAT TTTTCCGATT CCTGTATGTA CCATAATCCA
29401 CCCATTGCCC AAGCCACAAA GCTAGAAGTC AACCGCATTT ACCACATTTG
29451 ATCATCTCTC AAAGGACTAT GCAGTCATCT AATAGACTTT ACCACATCCA
29501 TTCCTGACCT TCAAGAATCT ACTCCCCAGA AAGAACAAAC ATGTTTTTTA
29551 AAAATGTAAA TGAGACTACA TTATTCTCTG GCTTAATTAT CCAGTAGATT
29601 CCCATATCAC TTCAATAAAA TTTAAGCACT TTATCATGAC CTATAAACA
29651 CTCTAAATC TAGTCCCTGC TTACCTCTCC AAGCTACCC CCAACCATTC

FIGURE 3

```

29701 TTTCCCTTGT GTTCTGACTG CAGCCCATCC AACCCAAGAC CTTGGGATTT
29751 TTGCCTGGAA ACTTGTTTCC CTCATCTCCT CACACTGACC CTCTTTTACT
29801 ATGTCTTAGC CCAAATGCGT TATCAAAATA ATCATAATGA CCTGTTAGTA
29851 CTCTATTCCG TTACCCTATT TTATTTTGT CATAGCCTTT ATCAATGTTT
29901 AAGATTATTT ATCTATTGT TTGCTTGCTT TGATCCTTTT CCTTCTCTGG
29951 AATCTTATAC TCCTGTGAGC AGGCACCTTA GGTCCTGTTC ATCACTTTAT
30001 CCCCAGCAGT TCAGATAAGG CTCAGCACAC AGATGCTCAG TAAATATTTG
30051 TGGAAGGGAT AAATGAATGA TATTTTATGT GTATTACAGT TCTAAAATTC
30101 AATAGTTTTG TATTAAATAT CAGTTCTAAT ATGGCATTTA TATGATTTTA
30151 TCTTTCAAAA CATTAGCAAT AGATTATATT TAAATGATAA AAGAAAACCTA
30201 TAACTGCAGC CAAGTATTCT CAGGATTGTA TTTCTCTTAT ATTAGCCTAA
30251 ATGCAATTAA TCTAGCTCAT ATACTTTGGG CAGCTTATAT ATATTCTGTT
30301 AATTTCTAAC CTTTTCAGG TATAAAAATC CACATCAATG GACTGTTAGT
30351 TTTGGAACAA AAATCAACCC TCCCTTAATG AAAAGAAATG TCAGAAGATT
30401 TATTATCCAT GAGAAGTACC GCTCTGCAGC AAGAGAGTAC GACATTGCTG
30451 TTGTGCAGGT CTCTTCAGA GTCACCTTTT CGGATGACAT ACGCCAGATT
30501 TGTTTGCCAG AAGCCTCTGC ACTCTTCCAA CCAAATTTGA CTGTCCACAT
30551 CACAGGATTT GGAGCACTTT ATCTATGGTGG TGGGTATCTC AGGATAGCTA
30601 ACAGAGCGCT AAGCCCTGTC TAAGGCAATG TGATTTTCATC TCCATCAATA
30651 TTATCCTGAC AGCCATTTCC ACACAGTCTG GTTGGATTAG TTAGGGTTCT
30701 TACTTTGTGT GACAGAAATT CAATTCACAT TAACCAGTGC AGAATAAAAA
30751 ACAAAGAAAC AAAAATCTCC ACAAATTTGG CTCATGTAAT TTGGAAGTCA
30801 AAAAAGTGTA GTAAGTTTCA CTTCAGACAC AGGGGTTTAT ATGATGTCAT
30851 CTGGCTCTGT GTCTCTGAAT TTGAATTTTT TGCCCTTCT TTTCTCTATG
30901 TTGGCTTCAT TCAGAGGGAT GCTAGCTTCA CCTAGTGTCA GAGGTGGCTA
30951 ACAACACCTC AACACATCAT CCTCAACAAA GAAAAAATAC ATAGAAAGGA
31001 ATATTTATTT CTTTCTTTG CCAGAATTCA CATTAATTTT TATTGTTCCA
31051 GCTGTGTCTA GGAGGACTCA GATTGAGTGG CTAACCTCAA TATTCTTTAT
31101 GCCTATGTAG CAAATTTGTC TTCAGTACTG AAGAAGCTAA TTTAAGTGTG
31151 ATGGTGAATA AGAATAGTGT AGAGATAAAT TGTCAAATA TTTGTCCCCT
31201 CTAAAAGTAT TCAACTTGAT ATACTAATTT AGTCTTGTA GAAATAATGA
31251 TGATTTAGTT ACTGAATGTT CTAGGCAATC TTAGTGAGAC ACGCTCTGGA
31301 TTCTAACATG TGGTCCAGGT ACATATGTAT AACAAAGCTA GAAAGTTTCT
31351 TTAACACTGG GCTTGAGAAA ATGCAAAAGG GCTTCTCTGAG AATGACTAAA
31401 TCTATTTGCA GGATTCTATA CAATTTATTT ACATACAAGA AATTATAAAG
31451 AATAAGCTTT TGATTCTCAG TCTACCATTA AGGAACTAGG AATAACCTTT
31501 CACTCACATA GGCAGGAATC GGTTTTAGGG TCTCTAGATT TTTTCCAGAT
31551 GTCCCATGTG GTTTGTGTTT ATCTTATACA GAGTGAGACA TGCATTGCTT
31601 TCTTTAAGGT TGTAATACCA ATCAGAGAAA ATATTACCTA TGGTTTATTA
31651 ATTCTAGTAG ATCCAGTGCT GCTGTAAGCC TGACACCTCC CTAGGTCTGC
31701 ACTCTCTTGG ATGGATTTTC TCTGAAGATA GGGCTTGCAT TCTCTGCTTC
31751 ATAGTGGTGG GAAAGACATC ACAAATCCCC TTTGGCTTGG TGGGAAAAAT
31801 CACTTTCAGG AGTTTGAGAC TGGCACAGAA ACATACCTGT CATAATGCGC
31851 TGTGAGTGGC AACAGAATCT GACACTTATA GAGCACTCCA CCTACTTGA
31901 ACACGGCCTC TCTTGGTGAG TGACCCACAG GTGCTTTTAA TCTATTAAAT
31951 AGATTAAATT AACCTATCAT TCTTAATCTG TTAAGTACAT TAATAGATTA
32001 AAAGCAGCCA TTCGTTACTC ACCAAGAGAG GCTATATTCA AGTCTGTAAA
32051 GCAAACCTTA AGAAGTTTTT TAAAATTGAA ATTGTACAAA GTATATTCTC
32101 TGATCATAAT GGAATCTAAC TAGACATCAG TAACAGAAAG ATAACATAAA
32151 AATCCCCAAA TGCTTACCAA TTAaaaaaCA TATGTAAATA AAGAGAATAT
32201 CTCGAAGAAA TTTGTAAAAA CAAATAGAAC TAAATGAAAA CAAAAATATA
32251 TAAATATATG CCAGATGCTG CTAAAATAGT GTAGAAAGGG AAATTTATAG
32301 AAAATGCATA TTATAAGGAA AGATATCAAA TCAATAATTA AGTTCTCACT
32351 TCAAGAAACT AGAAAAATAA AAAATAAACC TAAACAAAC ATAAGGAAGG
32401 AAATAATAAG AATAAGAAAT GAAATGAATA AAATTAAAAA TAACTATAG
32451 AAAATTGATA AATAAAAAGC TGATTATTTG ATAAAATCAA TATTTTGCTA
32501 GAAATGTCAT TAAGCATTTT TACAGAAGAT GAGATATAGC TCAGGGATGT
32551 CCAGAATTTA TGGGCTATGC TTTTCATGAC TTGGAATACA TTTTACCAAC
32601 CAGTTTAGTT TGCTGAAGAA GTTGTGGATT TGCACGTGCA CCTACTTACA
32651 ATACTTAGAT TGTCAGTTTC ACCTTACTCT TCTCACCATT ATTTTATTTT
32701 TATTTTATTT TTTATTTTAA TTTTGAACA GAGTCTCGCT CTGTCTCCA
32751 GGCTGGAGTG CAGTGGCGTG ATCTCGGCTC ACTGCAAACT CCGCCTCCCG
32801 GGTTACCGCC ATTCTCCTGC CTCAGCCTCC CGAGTAGCTG GGACTGCAGG
32851 CGCCACCAC CATGCCCGGC TAATTGTTTT GTAGTTTTAG TAAAGAAGGG
32901 GTTTCACCGT GTTAGCCAGG ATGGTTTTGA TCTCCTGACC TCGTGATCCA
32951 CCTGCCTCGG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACCGCGC

```

FIGURE 3

33001 GCCAGGCCAT GAATGTTTTT AATTGATGAT ATAGTAGGCA ATATAAATGT
33051 GTGTGTGTGT GTGTGTGTGT GTGTATAATA TATATAAACC AATTGTATTC
33101 AAATAACAGA ATAATTTGAA AAATCTCTTA GCATATTTCT GAGTTACACA
33151 CTTAAATCTT CCGAGCACTT TTAAATATGT GTTTACAAAC ATTTCTTCAG
33201 AAATAAATCT TGGAAATCGT CTTCTAAAGA AACTGGTGTA TTAGGGTTTT
33251 TTCAAATGTA CTTAGTTTTT TTTTAAATTG ATGTATAAAA TTGCATGTAC
33301 TTACCATGTG CAACATAATG TGTGGAAGTA TAGTATATGT AACTGTGAG
33351 TGTAAATCT AGTTAACTAA GAAGCGTCTT ATTTTACATA ATTATCATTT
33401 TTGTGGCAAG AACACTTAAT ATCTACTCTT GTAGCGTTTC TCAAGAATAC
33451 GATATATCAA CAGTAGGCAA CCAGAAGCTG GGGTCTTTA CAGGGGAAGG
33501 AGTTAGGGAG ATGCTGGTCA ACAAATTCAT ATTTGCAGTT AGGAAGAAAA
33551 AGTTCAAGAG ATCTCTCATC CATCATGGTG ACTATAGCTG ATGATATATC
33601 GTATTCTTGT ATTAGTTTTT TATAAATGTG TAACAAATAA TCACAAACAG
33651 TTAAAACAGC ACTCATTTAT TTTATCTCA CTGTTTTCAT GAGTCAGACG
33701 TTCAGACACA GCTTAGTTGA GTCCTCTTCT CAGGGTCTCA CCAAACGTGA
33751 ATCAAGGTGT CAGCTGGGGT TGTGGCCACA TCTGTGGCTC CTTTGAAGGT
33801 CTCCTCAAGG TTTGCTGGCA GAATTCCTTT ACTCGCAGCT GTAGAATGCA
33851 TGCCAGCTTG CTGCTTTAAC TCTTTAGGAA AGTGTCTCAA CTCCAGCAAG
33901 GCTCGCCCTT TTTGAAATGG CTCAGCTGAT TAGGTGAGGC CCACCTTTGA
33951 TAATCTCCTT TTGATGAATT CAAAGTCAA CTCATTAGAG GTCTTAATCG
34001 CATCTGTAAA ATTCCCTCAT CTGGCCATA TAACATAACC TAATCATGAG
34051 AATGGCATCC CTCATATTCA CAGATCCTGC CCATATTGG GAGGAGGGGA
34101 ATCACACAGG AATCTTGGGG ACTATCCTAG AATTCTGCCA ACCATGGGGT
34151 CATGGTTTCC CAATCAATAT ATGGTTTGGT ATAAAGAATC CCTGAATGCT
34201 TGTGCTATTC TTAGTTTTCT ACGTAGCCTG CCATAATAAT GGTTCCTAAA
34251 ACTCAGAACCC TAGCTTACAG TCTGCAGCCA CCAACTTGTA ATACATTGGA
34301 AGTGAAATCA TTGCGTTTA ATGCATTTAT ATATATATGA TGTATAATAT
34351 ATGTATATTT CACATATATC TTATATATGT GAAAGCTCAT CATAAACTTT
34401 AAATAATAAA ATAAATGFAC ATAGTATTAT AGGCATTTTA TCAAGCCAAT
34451 GGAGAAAACC ATCTAGGCAT GCAGAGTTTC TGGGAACAAT CTGGAACCCA
34501 CAAATAAAAG CTTTACAAAA GATAAAAGGC CTTCTGAAA TATATAAGCT
34551 GATTATTTTT AAGGTTAGAT TTTACCAGGA AAAAGAATCC AAATGGCTTT
34601 CTTGCTTTGA GAAGTTTTTA TAAAAATGTG ATTGGACAAT AATTATCGTT
34651 AGATGTGCCA GATTTAACCA GAAATTCCTT TTTCTAGAAA CTGCTTATAT
34701 TAACTTCATT CTGTATTGAC AATTTTACCA TGAaaaaaat ATTAGGAAAG
34751 TCTTCTCACT TCACTCTAGC CAAAGATGCT GATTGTAAAT ACTAGAATAA
34801 CTCTATTTTT CCTTAAGGGG AATCCCAAAA TGATCTCCGA GAAGCCAGAG
34851 TGAAAATCAT AAGTGACGAT GTCTGCAAGC AACCACAGGT GTATGGCAAT
34901 GATATAAAAC CTGGAATGTT CTGTGCCGGA TATATGGAAG GAATTTATGA
34951 TGCCTGCAGG GTAAGTTGGA GGGATTTTTT TATATTACTA ACTCAAAAAT
35001 TTGTATCTGG CTTAGAATAT ATTATATGTT CTTTACATAA GGACAAAACA
35051 TAGATATCAT GTCAGCTCAA AAAAGTTACA AATGCAAATT TCACAGCACA
35101 AAATACTTTT AAATGTTTTA TTAAGATAAA TGAAGTAAGA GTTTCTCTGA
35151 TGCTATCAAA CAAACAAAAT TAGAATTTCT TAACCAGAAA TCCAAAGATT
35201 AATAAAGCAG TTTATTTTCT CAAGCGGCTC ACATTCAAGA AAGAAAATAA
35251 TCATAAACAG AGAAGTATAA AGTGATGTTA TGAATAATAT AATGAAAAGC
35301 AAATATTTTT CTTGAAGGAA ACATTTTGGG AACAAGTATC AGAGAGATGA
35351 GACGTAAATA AGGCCTGAAG AATAAATAAC ATCCAATTTT AGAATAAGAA
35401 AATAATGTTA TAGAAAAGAC AAAAAGCATA GCCAAAATTA TGAAGGTGTG
35451 AAATTACAAT TCATATCTGA GGGAACTCCA AGTAATTGGT TGGTCTCAG
35501 CATGAGGAGG ATGAGAAGAG AAACAAGTAG ATAACCATGA GAAGGTGGAT
35551 TAGGCCATGT TGTGATTCCA TGGGCCCTCC CCAGTGCCCT CATCTGCCTT
35601 CTAACATGGA TGTTTTCCAG CGAAGGTACG TTTCTTCTG GAGACACTTG
35651 CTTTTTAACA TGAGATACTT TAGAACTCTA AGGAGGCCAC TCTATGTGGA
35701 AATGATGGAA TGGTATTGAT ATCAGGTGGC AGAAAGTCCT GTCCAGAGTC
35751 CCACAAACTG TACCACATGT GCGACCTCTA TCAGAAAAGG AGCAGGGACC
35801 TATGTGACAT AGAGGCTGGG CAAAAGCAGG ATCTGGTCCA CAGCCAGCCT
35851 CGGTTGCTAA TAATGTGGAG GGAGGCAGGC AGAATTTAGG GATTCCAACA
35901 AAAGGTCCAT ACCACGGGGA ACAGGTGGAA GGTGCAGGAG TCTTGGAGCA
35951 GACAGGACCG GGGAAATTCAG GTGAACCATG ACATTACTGA AAAGCCTTAG
36001 GAGGGATTGG TGGTCATAGA GATGCTTCAC TGGATTGGGG AGCAGAGGTA
36051 AACTTGCTGC CTAAGTGTGC AAAGTAAGTG ATAAAACAAG GCTTTAGTCA
36101 TAGAAAAATA CAGTAAGTTA TCAGGGCAGC GGTTCAGGTA CAAGGATCCA
36151 AGACAGGAAT ACAGTGATTG TAATTGGGGC ACATGGTGAG GGGCCTAGTC
36201 TGATACAACA GAAGTGCAAG CACCACCAAC ACCTCGTCTT TCTCCATAAG
36251 TCTTTCTCTC CAGAGCCCTC ATGACCTAAT CACCTCTTCT TAAGTCCCAT

FIGURE 3

36301 CTCTCAACAC TATTGTATTG GAGATTAAGT TTCCCAACC TATGAACTCT
36351 TGGGCTCACA TTCAAACCAT AGCACCACCC AGCACAAAAG CACAGAGCTT
36401 CCAATCTGGT TTCTAGCTCC ATACCCTAGA ACCAAACAGT AAGAATCACC
36451 TCTGGAAATG TAGCAATAAT ATAATCATAA TTTTAAAT CCAGTGGAAG
36501 GATTGGAAGA TAAATCAAG GAAATCTCTC AGAAAGAACA ACAACAACAA
36551 AAAAGACACA GAGGAGAAAA ATAATCAGAA AAATTAAGAA AACTAGAGGA
36601 TAAGCTCAGG AGATCCAACA CCAATGAAT AGGAGCTCTG AAAACATAAA
36651 ACGCGAGTGT ACAATATAAA AAAAAATAAA GAATGCTCCT AGTTCTGAAG
36701 CTTACATGCA TCCTATTGAA GAAAAGGTCC AAGTAGTGCT GGGCACAATA
36751 AATGAAGTAC TTCTTTCCAA GACATACCAT CATAAAGGT CAGAAGCCAG
36801 GGATAAGGAG AACAATCTTA AAACTTTGAA GGAAGAACCA TCAGAACTAC
36851 ATAGAACTCC TCAACAGTAA CTCTAGAAGG TAGACGATGG TGGAAAACAC
36901 ATTCAAATTT CAAAGGGAAG ATTATTTCAA CCTAGATTCC TACCCATGCT
36951 AACTAAATAT CAACTGTGAG GTTGGAATTA AGAAGTTTAG ACAAGCAATG
37001 ACTGAAAAAA ATGTACTTCT GATACCCTAC TTCTTAGGAA ACTACTTGAG
37051 AGGGTACCTC AGCAAAATGA GGGAAATAAT CAAGAAAGTG GAAGACGTAA
37101 GACCTGAAAC TGTTAGTCCA AACTAAAGA GTGGTATCAG ATAATCCCAA
37151 CACCATAGCT CTGCACCAGG CTTAAAGTAA CCAGCTCGAA TTTGAGCAGA
37201 AGTAAGAAAA GATTGTGTGT ATGTGTATGT GTATGTGTGT ATGTGTGTGT
37251 GTGTGTGTGT GTGTGTGTGT ATGGTGGAAC AGCTTCAGAG GAAGTAAAAG
37301 AACTAACAAG CTATCTGATG TCCTTGAACA TTAGTAAACA TTATTGTGAG
37351 GTGTTGGTAG ATCTTTTGGG GCATTCAGCA TTTACCAGGT ACATAGAAAA
37401 CTATCCACAT GAAAAAAGA GTTGTGTTAT TAATCTAGG AAAGCAAAAA
37451 AAGATTTCTG TAATCCAAAT ATGTTACTTG ACTCTCAAT TAATAAAATT
37501 TACACACTGG TACTAAATGT AGGCTGTAA TTTAACCAA AATAGAGATG
37551 CTATAATGTA AAGATGTGGT GTGGAAAAGT TGCAAGAAG TTGTAAAACA
37601 ACTAAATCCC TAACTACGTA AGAGAAAATA AATATTTACT GTCTAAACCT
37651 AGAAGCTGTA ATTTGAGCAT ATTATCTAGT GATAAGGAGT TAGATACTAT
37701 AAGAAATCAT TAAACAAGCA TGAAGTGGCT ACCTCTTGA GAACAGCTTG
37751 CGTGAGGTAA CATGGGACAT AACTGCTTTT CAAGCCTCTT CATGTTTTTT
37801 CGTTTTTGCC TTTTAACT AAGTGTGTT TACTCTAACA AAATAAATT
37851 TATTTTTTAA ATGTGAAAGT TGAACCTTAA GGCTCTTGT AATATTAAAA
37901 TCCATGTCTC AATTAATTAT TCTGTGTTGA TAGTCTATAC ATGTACTGTC
37951 TAGTAACAAA ATATGTGATT CATCAAAATA TCTTAAATAA TGAGCTTTAT
38001 GTTTAGCTAA TTTTCTTCT TTTTCTTAT GTTTTATTT TTAGGGTGAT
38051 TCTGGGGGAC CTTTAGTCAC AAGGGATCTG AAAGATACGT GGTATCTCAT
38101 TGGAATTGTA AGCTGGGGAG ATAACGTGGG TCAAAAGGAC AAGCCTGGAG
38151 TCTACACACA AGTGACTTAT TACCGAAACT GGATTGCTTC AAAACAGGC
38201 ATCTAATTCA CGATAAAAGT TAAACAAAGA AAGCTGTATG CAGGTCATAT
38251 ATGCATGAGA ATTCAACTAT TTAGTGGGTG TAGTACAACA AAGTGATATT
38301 AAATTACTGG ATCTAGTAAC ATGAAACACA CAACGTAAGT TATTTAGAAT
38351 CACTTTAATC AACCAATAAT CCTTAGCCAA TTTATAAGGG ACTTTTATTT
38401 GTAAAGTAAT GGATCTGGCT TGAAAAATAC GGTAGAGATA CTTAGCTCTT
38451 TAAATCACGA ATGTTGAAGT ACCAGTGAGA CTCAATACAT ATTTTGAAG
38501 ATAGTCCATG GGATTTTATG AATGTCGTTG TCAAGGGTCT CTTTTAACT
38551 GAGAACTTT TTGAATCAC AAAGTGTTC AAGAAACCTT GTATAATTCC
38601 CTACATTTCT CTCGAGCTCA CAAATACTTT TTTTCTTTT TCCTTATTCA
38651 ATCAGATTTT CCAAAGTACC TTTCCACCAT AAGAAATGAA TTTTCTACTT
38701 CTACACCCAT TTGAGAGACA CCAATAAAAG AAAGTCATAT GTAGGAAACA
38751 AAGTCTGATA GTAAACAAG CCAGAGATCT TCTAACTTTT TTTAGTTATA
38801 AAACCTCTAA TTTTGGTGA CTTTCTACA CACACACACA CATA (SEQ ID NO:3)

FEATURES:

Start: 3000
Exon: 3000-3093
Intron: 3094-4905
Exon: 4906-5024
Intron: 5025-17485
Exon: 17486-17553
Intron: 17554-19507
Exon: 19508-19668
Intron: 19669-25382
Exon: 25383-25421
Intron: 25422-26622
Exon: 26623-26794
Intron: 26795-30319

FIGURE 3

Exon: 30320-30579
 Intron: 30580-34817
 Exon: 34818-34960
 Intron: 34961-38044
 Exon: 38045-38203
 Stop: 38204

CHROMOSOME MAP POSITION:
 Chromosome 4

ALLELIC VARIANTS (SNPs):

DNA				Protein		
Position	Major	Minor	Domain	Position	Major	Minor
72	A	G	Beyond ORF(5')			
1894	C	T	Beyond ORF(5')			
1897	C	T	Beyond ORF(5')			
2123	T	C	Beyond ORF(5')			
2124	G	A	Beyond ORF(5')			
2648	A	C	Beyond ORF(5')			
2805	A	T	Beyond ORF(5')			
4036	A	G	Intron			
5056	-	A	Intron			
5445	C	T	Intron			
5608	T	C	Intron			
6243	G	A	Intron			
6273	C	G	Intron			
6294	A	G	Intron			
6312	A	G	Intron			
6506	C	-	Intron			
6714	C	G	Intron			
6815	G	C	Intron			
6994	A	G	Intron			
12478	T	C	Intron			
13493	T	G A C	Intron			
13522	C	G A T	Intron			
13916	T	C	Intron			
13974	A	G	Intron			
15081	G	A	Intron			
15907	A	G	Intron			
17884	G	A	Intron			
17908	G	T	Intron			
20551	T	C G	Intron			
21222	G	T A	Intron			
21232	G	A T	Intron			
21353	C	T A	Intron			
21904	C	T A	Intron			
22132	T	C G	Intron			
22369	T	A G C	Intron			
22742	-	G	Intron			
22882	C	T	Intron			
23316	A	-	Intron			
23867	A	G C	Intron			
23954	A	G	Intron			
26548	G	A	Intron			
26573	T	A G C	Intron			
27400	A	G C	Intron			
27788	G	-	Intron			
28069	T	G A	Intron			
29269	C	G	Intron			
29537	C	A	Intron			
29726	T	G C	Intron			
30496	C	T A	Exon	277	P	L Q
30695	A	C G	Intron			
30752	T	G C	Intron			
30849	A	T	Intron			

FIGURE 3

2124 TGCTGATCATAGGTGCCAGAAGAACAGCAAAGAGTTATTTTTTCCTCCAAAATTGTGGAA
AAATTTTTATCCCCGGTGTGATGCAATATAAAATACACAGCACCACCTTTGAAGTATTCT
TGCCAAATGAATTTAACCAAAATCTAATCAAGACTTCAGAGCTAAAGAAAATCTAAAGGT
AATCCAATTTATAGGAAATGAGGGATATAAAAGAACAAGTTAAATAATACCACAGGAAAG
CATTCAGACAAGTCCAGAAAGTAAGATATTCTAAAGGATGTTTAGCTTGATCTCTCAAC
[G, A]
GTCAATGTCTATTAAAACTAAAAAGAAGCAGGACTCTTTTAGATTAAAAAGAGATTAAAA
AGGCATAACAAACAAGTGCACTGCATGGTCTCGATTATGTCTTGGCTTTTACAAATCAT
GTGTAATTATAATGAAACCATGGAGGGAACCTTGAAGATGGACTGGGTATTAGATGATATG
GCAGAAATATCATTAAATTTTTTAGGAGTGTAAAGAGTATCATGGTTATGTTGGATATATC
CTAATTGTCTATAATAATGATTTGGTAAAAAGTCACGATGTTTTATTTCACATTAAAAATA

2648 GTTATGTTGGATATATCCTAATTGTCTATAATAATGATTTGGTAAAAAGTCACGATGTTT
TATTTTCACATTAAAAATATAGCAGCAGAAAAAATAAATGAGCCAAATACAGTAAAAATTTTC
AACAAATTGATATAATAATGTGATATATATATGGATGTTCAATTATACTATTCTTAGTAAT
TTTTTATGTCTGAACATTTTCATAATACTTAAAAATAAAAGATAAAAGATAAAAAATAAAT
GAGATAATAGATTTAAAAATCACTTTGTAACTCTAAAAGGATAGACAGATAAAAGAGATA
[A, C]
CAAAGTGCTGGAGAAAGGAGGAATGGTCCCTTTTCAAGCATGTATGCCACCTTGGACCAT
GCTGCTAAGAGAAACCATTCCTGACCACCACAAAGAGGCCACCAATGCCTCTAAAAATAG
AAAGCAGGAGCAACATTAGGATTTCCAGATCCTGATATTTTTTTTTTAACACATCTTCTC
AGACCAAGATGACATTGAACAAAATTAAAGACCTTTTTCAGGGGAAAGGTAGGCTACAGC
AACTTGAACCTTGTCTAAGGAGAGCTGGAAAACCTGCAAGCATTGCTATCTGAGAGTAACC

2805 TCAATTATACTATTCTTAGTAATTTTTTATGTCTGAACATTTTCATAATACTTAAAAATA
AAAGATAAAAGATAAAAAATAATGAGATAATAGATTTAAATCACTTTGTAAACTCTAAA
AGGATAGACAGATAAAAGAGATAACAAAGTGCTGGAGAAAGGAGGAATGGTCCCTTTTCA
AGCATGTATGCCACCTTGGACCATGCTGCTAAGAGAAACCATTCCTGACCACCACAAAGA
GGCCACCAATGCCTCTAAAAATAGAAAGCAGGAGCAACATTAGGATTCCCAGATCCTGAT
[A, T]
TTTTTTTTTTAACACATCTTCTCAGACCAAGATGACATTGAACAAAATTAAAGACCTTTT
TGCAGGGAAAGGTAGGCTACAGCAACTTGAACCTGTCTAAGGAGAGCTGGAAAACCTGCA
AGCATTGCTATCTGAGAGTAACCAAGTGGGCCCTTCCCTTTTCTCAGGACAGTGGGATTGG
CAGCCGAGCAGAAATGCTGAAGCCATGGATGATGCGGTTCTCATTGTGTGTCCCTGA
CAGTGGTGGCAGTGACCATAGGTCTCCTGGTTTCACTTCTTAGTATTTGGTAGGTAAATTT

4036 TTCTGGGGAGAATGCAAGCCATTTACATTTTTTTCACAAATCTCTACAATGTGACTCTCAC
ATGGATGTATGTGATAAAACAAATAACTCAGGCTGCTCACTTTAACGCTCTTATCTGCTG
TCACCTTCACAGAGTCAATGGGGGAGCAAGACTCTACTTGGAGCCTTAAAGGGCTTAAG
ATCATAGTCTTAGGCCTTATATGATAACCCAGCTGTAGTTTATACCATTGGCAAAAGAT
TCTCAGGTCACTTTATTTGGTTGCATAAAAGTCTCTTTACAATGAGAGTAAGGTTTGTTA
[A, G]
CAGTATGGATTATATGGGTAAGTAATCAGGATGTCCAAAATGTATTACAAGGTCCAGAG
ATTTCCCACTTAAGACATATGCCCTTCTGATATCCCTGTCTTCTTCTTGGTTTGTAGTC
TCGAAACCCACTCCCTCTTCCCTGAGCCAGGCTTCTCAAGGATTGAGGTTGTTTTGTATT
TTTCCCATTTCTCTATCTTAACTCTGTATCTTCTTACTCCCTCTGGGCCCTTACTCCTCA
GATTACCAAAATTCCTTAGGAGTCTCAACTGCTTTCCCTTTCTTACATTTCCCTAATAGATTT

5056 GATATAAAACATTAAGTGTATTTTTTAAATAAAACTCAATTATGAAGAGGCTCAGGGAC
ATATTCAAGATTTATATTGGCCCCATTGTAATTGAGTTCGAAATCTTTGTCCAAACCAT
TTAGTTTCTTATTTTTTCACTTCCATTGCAGACCAAAAAAAGGAGTACTATCATGGCTCCT
TTAAAATTTTAGATCCACAAATCAATAACAATTTCCGACAAAGCAACACATATCAACTTA
AGGACTTACGAGAGACGACCGAAAATTTGGTGAAGTCAAGTAAACTCTTTTATCATAGA
[-, A]
TAATGCAAGTGGAAGGGATTGTGTGGATCATTTCTCCATTTCTAAAAACATGATTTTCAG
ACCGCCAACATTAGAATCATCTTGCAGATTGCTAGGCCCATCCAGACCTGCTTAATCA
GAGTATGATGAGATGGGTAGGTGGGGAGAGGAGTAAGGGAATCTGCATGTCTAACAA
TGGGTGATTCTAATAAGCCTCTCTTTCTAACTCAGCTACCTTATTTAAAGGTAAGAGAAT
TGAGGCCAAGATATCCTAGCCCGTTTCTTCCCCAATTCCACCAGTTTCCCTGTAGAAA

5445 TTGCTAGGCCCATCCAGACCTGCTTAATCAGAGTATGATGAGATGGGTAGGTGGGGAG
AGGAGAGTAAGGGAATCTGCATGTCTAACAAATGGGTGATTCTAATAAGCCTCTCTTTCT
AACTCAGCTACCTTATTTAAAGGTAAGAGAATTGAGGCCAAGATATCCTAGCCCGTTTCT
TCCCCAATTCCACCAGTTTCCCTGTAGAAAAGCCTAATCATACCAAACTAGTTTTTA
TAAGTCCACACACTTGTGTGTAAGACCACATTTTAAGATTTTGAGTATTTTCAGAAATTA

FIGURE 3

6506 CAACATTACTGCTACTGTTGTTGTTGTAAGTTAACTAGGCAATTCTGTCTTTACTGAAGT
AAACGGACAAGAAATGCAATAGGTCTTAAAAGAAAGTGAGAGAAATGCAGAGGTGCATGTTG
AACAGAACTCTATTTAAAAGTGGAGTTTTAAGTTTCACCTAAGCATGTGTTCCCTTCAA
GGCTAAGGCTAAGTTAAGTAAGGACACATTATCATCATGGGTACCTGCAAGGCCCTTCTC
TGGTTGTCATTATTTATTTATCCTCCTTTATCACCATAGCATAAGCCCTTACCCTCCCC
[C, -]
TTGCAGGAAATCATTCTATGTTTCATGTGGTATTCCTTTGTTTGTATTCACTTCTACAAA
AATATGTTTTGCTATTTTGCCTACACTTGCTTTTAACTTACATTTTGTGTTATAAATCAC
TTTTGTTTCATCTCTTTTACTGAGAACTTTTAAAAGATATATGTTACTAAATATACCT
TTAGTTTATTGCTGTTAGCTGCTAATTCTAGTGTGTATCTTCCATATTTACCTGCCTGT
CATGCCAAGAAATGCCACACTAAACAGACTCCTACTTACCCCTTATAGACCTATGCAAG

6714 TTATCATCATGGGTACCTGCAAGGCCCTTCTCTGGTTGTCATTATTTATTTATCCTCCTT
TATCACCATAGCATAAGCCCTTACCCTCCCCCTTGCAGGAAATCATTCTATGTTTCATG
TGGTATTCTTTTGTGTTGTATTCACTTCTTACAAAAATATGTTTTGCTATTTTGCCTACACT
TGCTTTTAACTTACATTTTGTGTTATAAATCACTTTTGTGTTTCATCTCTTTTACTGAGAA
CTTTTAAAAGATATATGTTACTAAATATACCTTTAGTTTATTGCTGTAGCTGCTAATT
[C, G]
ATAGTGTGTATCTTCCATATTTACCTGCCTGTCTGCAAGAAATGCCACACTAAACAGA
CTCCTACTTACCCCTTATAGACCTATGCAAGTACTTCTGGAAGCAGAAATTAAGGTCA
TTGAATGTACATATACTTAACTTGACCAATTGGTGAGGTTTGTCTTTCAAATGGCTGA
CTCAGTGTGCACGCCCATCTACAATGCATGAGGATTTCTATGTCCCCACATCTAACCAAC
ACTTAGTGTCTTAGTATGTTTAGGCTACTACAACAAAAAATACCATAGGCTGGGTATCTT

6815 AATCATTCTATGTTTCATGTGGTATTCCTTTGTTTGTATTCACTTCTTACAAAAATATGTT
TTGCTATTTTGCCTACACTTGCTTTTAACTTACATTTTGTGTTATAAATCACTTTTGTGTT
CATCTCTTTTACTGAGAACTTTTAAAAGATATATGTTACTAAATATACCTTTAGTTTA
TTGCTGTTAGCTGCTAATTCTAGTGTGTATCTTCCATATTTACCTGCCTGTCTATGCCAA
GAAATGCCACACTAAACAGACTCCTACTTACCCCTTATAGACCTATGCAAGTACTTCTG
[G, C]
AAGCAGAAATTAAGGTCAATTGAATGTACATATACTTAACTTGACCAATTGGTGAGGTT
TGCTCTTCAAATGGCTGACTCAGTGTGCACGCCCATCTACAATGCATGAGGATTTCTAT
GTCCCCACATCTAACCAACACTTAGTGTCTTAGTATGTTTAGGCTACTACAACAAAAAT
ACCATAGGCTGGGTATCTTAAACAACAAACAATTATTTCTCATAGTTCTGGAGGCTGAAG
ATTCCAAGATGAAGATGATCAAGGCTCTAGCAGATGTCTGGTGAGAGCCTGCTTCTGGT

6994 ATTGCTGTTAGCTGCTAATTCTAGTGTGTATCTTCCATATTTACCTGCCTGTCTATGCCA
AGAAATGCCACACTAAACAGACTCCTACTTACCCCTTATAGACCTATGCAAGTACTTCT
GGAAGCAGAAATTAAGGTCAATTGAATGTACATATACTTAACTTGACCAATTGGTGAGG
TTTGCTCTTCAAATGGCTGACTCAGTGTGCACGCCCATCTACAATGCATGAGGATTTCT
ATGTCCCCACATCTAACCAACACTTAGTGTCTTAGTATGTTTAGGCTACTACAACAAAA
[A, G]
TACCATAGGCTGGGTATCTTAAACAACAAACAATTATTTCTCATAGTTCTGGAGGCTGAA
GATTCCAAGATGAAGATGATCAAGGCTCTAGCAGATGTCTGGTGAGAGCCTGCTTCTGG
TTCATAGAATACCATCTTGCTGTGTCCCTCATGGCAGAGCCATAAGAGAACTTTCTTTT
GTAAGGACACTAATGACTTTCATGAGAACTCCACCCTCATGACCTAATATCTTCCAAAG
GCCCCATCTCCTCTATCATCGGTTTGGGAGTTAAGGTCTCAAATATAAATTTAGGGGA

12478 TTCTCATTTCCTGTATCAGTTTTTGGTGAGGAAGGCAAAGGTAGGAGGAAGTGAATAG
AGAAAGATGAAGGAAGCTGATGGATATATTGACATGTGTATGTACATCTAGTGTGAACAA
TCTATAGTTGGAAGAAAGGTGTGGATGGGTATGCTTTTTGAGGGAAGTTTTGAGAAAAG
AAGTAATATGAATATTTCTAAATTTCTGATAAAGTTGTAAATACAGCATAGTCTTCAC
AGGAGAATCTATTTAGTTTATCATCATCATTCAGCAAATACAGCATGATGTTAGGCACTA
[T, C]
AAAAGGCTAAGAAAAATGATTCTCTCTCTCTCATAAACTAATCCAATTTAGAGATTTAGA
AGACAACAAATCTGGAGAGGACATGAACCTTCTAAATAATGACCTTCCCTTGCTTTGGGT
ATCCTGGTTTTAAATATTTTAGTACAGCTTTAAATAGATCCAAATGAGATATTTCTCTC
TTTTACAAAAGCAATTCAAAGATCTAGGTTTTGTTGTACACTGAGAAATTAATACTTTT
TCTTTAAAATCCTTAATTGCAAATCTTTAAATTTCTATAAATATTTGCTTGTGATCTCA

13493 GATCCAAAAAATAAATAAACACCTAGAGTTTATACAGATATGATACGAACTTAAAAG
GACTGCACTAAAAACTACCAAGATTATGATTTCTTTTTTGGAGAGTAAAGAAAATAGGC
TGCTTTGGAGAGGGGTGCAACAGTTTCTGATCCTCTTACAACTGCTTGCTGCCCATCA
GTGGGTAGGAGTCTTAGTGAGAACCTACCTGCTATGCTCATCTGAGGTAGGCACTGTGA
AGGCGTTAACAGGCTCTGAAGCTACATGGCCCTGGTTTTCAGTGAACCTCTGTGGTGTCAAC

FIGURE 3

- [T, G, A, C]
TGGGCAAGTCACTTCCTCTTCTATGAAACGTGAATAATCATAGTACTCACCTTAGAGGGC
TGATTTGAAAGCAAATGAGCTCAAACACAATGACATCTGTGCTTGGTGCATATATGGCAG
ACAACAGTGATTCCCACTATTATAATTATTACAGTCTTACCAAGGAGGAGCTTCCACAA
ATAATCAATTACCTAAAATGTCCAAAAACAGGAAAAAAATCTCTCCGATAATTCATG
TGTAATTTCTTTTTCTCTAGGAGCATTGATCTCAACCTGATGTAAAGCAAGCACTTTA
- 13522 GTTTTATACAGATATGATACGAACTTAAAAGGACTGCACTAAAACTACCAAGATTATGA
TTCTTATTTTTGGAGAGTAAAGAAAATAGGCTGCCCTTGGAGAGGGGTGCAACAGTTTCT
GATCCTCTTACAACTGCTTGCTGCCCATCAGTGGGTAGGAGGTCTTAGTGAGAACCTAC
CTGCATGCTCATCCTGAGGTAGGCACTGTGAAGGCGTTAACAGGCTCTGAAGCTACATGG
CCCTGGTTTCAGTGAACCTCTGTGGTGTCAACTTGGGCAAGTCACTTCCTCTTCTATGAAA
[C, G, A, T]
GTGAATAATCATAGTACTCACCTTAGAGGGCTGATTGAAAGCAAATGAGCTCAAACACA
ATGACATCTGTGCTTGGTGCATATATGGCAGACAACAGTGATTCCCACTATTATAATTAT
TACAGTCTTACCAAGGAGGAGCTTTCACAAATAATCAATTACCTAAAATGTCCAAAAAC
AGGAAAAAAATCTCTTCCGATAATTCATGTGTAATTTCTTTTTCTCTAGGAGCATT
GATCTCAACCTGATGTAAAGCAAGCACTTTAAAAAGTCTTATAAAATTTCTCTGGTAAAT
- 13916 AACAGTGATTCCCACTATTATAATTATTACAGTCTTACCAAGGAGGAGCTTTCACAAAT
AATCAATTACCTAAAATGTCCAAAAACAGGAAAAAAATCTCTCCGATAATTCATGTG
TAATTTCTTTTTCTCTAGGAGCATTGATCTCAACCTGATGTAAAGCAAGCACTTTAAA
AAGTCTTATAAAATTTCTCTGGTAAATGCAAACTTTCTGATAAATAAATTCACCTTT
TTATCAATTTGTTAATTCAACAAAAATATACTACATACCAACAGCATGCAAGCACTATG
[T, C]
TAGATTTTATAGACTATGAAAAGATAAATTGCCATCTCTATGCATAAAGGGTTTGCCATT
TAATAAAGAGACTATATATTTGCATAAATATATAGTGAATATATTGCATAAATATATAA
TATATGTTTACATTAAAGAATAAAAGGTATAAGAGGGATAAGAAAAATTGAGACAGAGGG
AAGACAGGTCACTTTGAGATTACGAATATCCCCAAAGAAGGTATTATCTGAGATTGGCC
TTGAAGGATAGTTGTGATTACAGGAACACAGAACTTGCAGAATGAGAAGGTTGTTACAGAC
- 13974 ATAATCAATTACCTAAAATGTCCAAAAACAGGAAAAAAATCTCTCCGATAATTCATG
TGTAATTTCTTTTTCTCTAGGAGCATTGATCTCAACCTGATGTAAAGCAAGCACTTTA
AAAAGTCTTATAAAATTTCTCTGGTAAATGCAAACTTTCTGATAAATAAATTCACCT
TTTTATCAATTTGTTAATTCAACAAAAATATACTACATACCAACAGCATGCAAGCACTA
TGCTAGATTTTATAGACTATGAAAAGATAAATTGCCATCTCTATGCATAAAGGGTTTGCC
[A, G]
TTTAATAAAGAGACTATATATTTGCATAAATATATAGTGAATATATTGCATAAATATAT
AATATATGTTTACATTAAAGAATAAAAGGTATAAGAGGGATAAGAAAAATTGAGACAGAG
GGAAGACAGGTCACTTTGAGATTACGAATATCCCCAAAGAAGGTATTATCTGAGATTGG
CCTTGAAGGATAGTTGTGATTACAGGAACACAGAACTTGCAGAATGAGAAGGTTGTTACAG
ACCAAAGGAACAGCCTGAGAGGCGTGAGTATGCAGGAAATGAGGGCCATGCCTGAAAGT
- 15081 AATGGCTGGGCGAGTCTGTTTGTGTTGAGTTGACAGCCTCTCCCTCACTCTTTCAATTAAAT
ATCCAACCTAACCTTCAATTGCCCTCTTGGAACTTAATCTCAGTGTAATTTCCAGCATGTC
AAAATTATCAAGCAGAAAGAGATACTACCCTGAAAGAGGGTCTTTTGTTCATGCTAGGA
GACAACTCCAACCTACAAAATCTAGAAATGCCCTAAAGAGAGAGATAGGATAGATTTAC
AAATGCTAATGCTATTAGGTTGTATAGATAACAATAGATTTATAACAACCTGGCACACA
[G, A]
CTTTAAATATATAAGTTTCTCTGAACTTCTGGAACCTTGGAAATGCCAGAACGTTGGCAA
AAAGAATGCTTCTAATAATGAAAGCCATCATCTGCCATGGAACAATTTACAGGCTCTTA
GAAAGCTAGTTTATACATAAGCTCCATTCTACAATAAACTTATGTTTATGTTTCTG
ATTTTCTCCTGCTGTAAATTCATTTTATCAGAATCTTTTTTACCAGTCCCTCTGCCCA
TTTCTCAAAGCGTTGTCTCAGACTACCTGTATCACCTAAAGATTCTAAGGCCTCCTCCG
- 15907 AAACCTTCATCCAATGCCTTCACCAAAAAGTTACAAATGGCCAGGAATCAAATGTGGTTGA
ACTTATTCAGAGGGTAATTACAAAACAACTTCTTTAAATACCAACTGCTATTTGCTTT
TTTCCCTCTAAATTGTATCACTTCTCTCCCTGTTCCATTTTGTGTTGCTTTTATTTTT
GGAATCCCTCACCTCCATACTGAGTAGTAGAGCTGGCTGTGGGTGATGAGAGAGAAATTG
TTATAACAAAGTCACCTTTTCAAAAACATGTCTTCCAAAGAATTTGTTTCTAGCAGAT
[A, G]
AACCCACACACCCTCAGCTAAATGGGGCTTCTTTATTTAAGTACCAATAAAGACATAT
TTTGATACTAGCAATTTATTTTCCAAATGCTATCTTTGATCTTAAGTTAAGGCTATTA
CCAAATCTATATCTCTACAAGTTTATACTTTAGGTCAATAAATTACTTGATAACTTATT
ACTATGTGTTCTACAAAAGAAACCGAAGTAAATTTACATCACATTTAACAGGGTGGTTG
TGTGATTGAGTGGGAAGAGGCGGACCCTACAGATAGAAGACTTGGGTTTCAAGTCCAGCT

FIGURE 3

17884 AAGACTGGAGGGAAAAGGAACAAAGGAGACAGGGACTCTCATGTATTGTATGTCTCCATG
GACTAGGCTTTTGGCTAGAATTTTTTCATAAACATTACCTTTAAAGCAGTCTTGAAGTATA
GGGCTGACCACCGTTTTGTCAACAAAAGACTAAGATTTCAGGAAGGGTAAGAAATATGTT
CAAAGTTCACCAACTGACAGTTTTCCCAAAGTGACAGAACCAGGAATCAAACCCCATTAAC
TTATTGTGAGGCCTGGAACCTACCAGAACCATGACGTGGGGAAAACCCAGCAGCTTGTC
[G, A]
TTGCATGCACCAAGTTATATTATGTTGACAATTATATTATTTCAACCACGTTAAGCAGGC
AAACTTGGCTATAAAATGGGTTCAAAATTTTACCTGTAATGTAACCGAATGACATAAGG
CATGCCATAACAAAAGATATTCTGTGTGTAATAAATTTCTTTCTGTCTATGGTGGAGGG
GGAAGACTCATATCAGTTGCAGATATTGCTCAGAAGTTTCAATTGTGTTATTTTGAAAA
CTACATAGCAGAACACGCATGTCATATACACAAATCCATGAGCCTGTATGACTCATATTT

17908 GGAGACAGGGACTCTCATGTATTGTATGTCTCCATGGACTAGGCTTTTGGCTAGAATTTT
TCATAAACATTACCTTTAAAGCAGTCTTGAAGTATAGGGCTGACCACCGTTTTGTCAACA
AAAAGACTAAGATTTCAGGAAGGGTAAGAAATATGTTCAAAGTTCACCAACTGACAGTTTC
CCAAAGTGACAGAACCAGGAATCAAACCCCATTAACCTATTGTGAGGCCTGGAACCTACC
AGAACCCATGACGTGGGGAAAACCCAGCAGCTTGTGTTGCATGCACCAAGTTATATTAT
[G, T]
TTGACAATTATATTATTTCAACCACGTTAAGCAGGCAAACTTGGCTATAAAATGGGTTCA
CAAATTTTACCTGTAATGTAACCGAATGACATAAGGCATGCCATAACAAAAGATATTCC
TGTGTGTAATAAATTTCTTTCTGTCTATGGTGGAGGGGGAAGACTCATATCAGTTGCAGAT
ATTGCTCAGAAGTTTCAATTGTGTTATTTTGAAAACTACATAGCAGAACACGCATGTCA
TATACACAAATCCATGAGCCTGTATGACTCATATTTCTTAAAGATAAAGAAAAATAATAT

20551 ATTATACCATTATCACTTCCCTCAATTAAGGAGAACAAACCTTTATCAAGGTCTATCTCT
ATGGCCTTTACCTTAAGTAACATAATTTCTTTTATATTCCAGTGACGTACGCAAATTCAC
CTTTATAGAAGTGAAATTCACACAAAAGAGTTGAGGAATTCAGTAATTAAGGAGGCTA
AGAATCAAATTTAAATCTCTAATTTCTTAAAGGCTCCAATTAAGGAGGTTTCTATAGT
CAAACACATCTTAAAAATCTGGCTTTGATACTCGTTTCTTGGAATTTCTTCTTATAGT
[T, C, G]
TCATATTAAAAATTTAAGGCAGCCAGCTAGAGAGAACTTGTTTACCTCGTCCGCTAA
GCTGTTTGCACAGCATCTTCTTCCAACAGACAAGTATAGATTTCTCTACAAATTTCAAT
GGATACCAGACCTAAGTGTACAGAAGAGATTTCAGGGCAAGCGATTTTATCAGACATGA
AACAGGACACTCTGCCCTTGTAAAGGCTTAGCTGACACTTCAAGAGGAAACCAGATAAGG
AAGTAAAAAATGTGAGGTAATGGAATGGGCAGATGTTTGCTGATGTGAGAACGAGTCAGC

21222 TCTTGTGTAGATGGGGAAGCAAATGAATAGAAGTTGTGAAACAATGGGCATTCTGATAAT
TTACATGATGCTTTCTGTGTAATTTCCAATAAATAGTTAATTTGTGAGGAATGTAAAAGC
CTGAACATCTGAAACCAGAGTAAAGCATAAATTTGTTCAATTGGCTGCCTGGTCTTTTGT
TTTTTGTAGGCTCAGCTTCTAAACTTCAGCTTATTTTAATAATTGTACTAAATTAATGG
TAGGATATGCTAATGGAGAACCTGATTTGAGAGTCACCTGAGGCTGGGCATGGTGGCTCA
[G, T, A]
GCCTATAATTCAGCACTTTGGGAGGCCGAGGCGGGTGGATCACCTGAGGTCAGGAGTTC
AAGACCAGCCTGGCCAATATGGTGAAACCCCGTCTCTTCTAAAAATACAAAATATTAGTC
AGGCTTGGTGACGGGCACCTGTAATCCCAGCTACTTGGGAGACTGAGGGGGAAGAAATCAC
TTGAACCCGGGAGGCGGAGGTTGCAGTGAGCCAAGATCGCGCCACTGCACTCAAGCCTGG
GCTTGACAGAGCAAGACTCCATCTCCAAAAAATAAAAAATAAAGAGTTACCTGACCAA

21232 ATGGGGAAGCAAATGAATAGAAGTTGTGAAACAATGGGCATTCTGATAATTTACATGATG
CTTCTGTGTAATTTCCAATAAATAGTTAATTTGTGAGGAATGTAAAAGCCTGAACTATC
TGAAACCAGAGTAAAGCATAAATTTGTTCAATTGGCTGCCTGGTCTTTTTGTTTTTGTAGG
CTCAGCTTCTAAACTTCAGCTTATTTTAATAATTGTACTAAATTAATGGTAGGATATGC
TAATGGAGAACCTGATTTGAGAGTCACCTGAGGCTGGGCATGGTGGCTCAAGCCTATAAT
[G, A, T]
CCAGCACTTTGGGAGGCCGAGGCGGGTGGATCACCTGAGGTCAGGAGTTCAAGACCAGCC
TGGCCAATATGGTGAAACCCCGTCTCTTCTAAAAATACAAAATATTAGTCAGGCTGGTG
ACGGGCACCTGTAATCCCAGCTACTTGGGAGACTGAGGGGGAAGAAATCACTTGAACCCGG
GAGGCGGAGGTTGCAGTGAGCCAAGATCGCGCCACTGCACTCAAGCCTGGGCTTGACAGA
GCAAGACTCCATCTCCAAAAAATAAAAAATAAAGAGTTACCTGACCAATTTCACTCC

21353 GAAACCAGAGTAAAGCATAAATTTGTTCAATTGGCTGCCTGGTCTTTTTGTTTTTGTAGGC
TCAGCTTCTAAACTTCAGCTTATTTTAATAATTGTACTAAATTAATGGTAGGATATGCT
AATGGAGAACCTGATTTGAGAGTCACCTGAGGCTGGGCATGGTGGCTCAAGCCTATAAT
CCAGCACTTTGGGAGGCCGAGGCGGGTGGATCACCTGAGGTCAGGAGTTCAAGACCAGCC
TGGCCAATATGGTGAAACCCCGTCTCTTCTAAAAATACAAAATATTAGTCAGGCTGGTG

FIGURE 3

- [C, T, A]
CGGGCACCTGTAATCCCAGCTACTTGGGAGACTGAGGGGGAAGAATCACTTGAACCCGGG
AGGCGGAGGTTGCAGTQAGCCAAGATCGCGCCACTGCACTCAAGCCTGGGCTTGACAGAG
CAAGACTCCATCTCCAAAAAATAAAAAATAAAGAGTTACCTGACCAATTCTAACTCCA
CTAAGTCACCAACAGGACCACCCAAATAATTGGCTCATGCCCTTGTCTTCATTTCTCATC
TGTAATAATCCAATGGTAATGTTTGTCTCTCTGAAATCACAGAGAGATTATAACGATAT
- 21904 CAATGGTAATGTTTGTCTCTCTGAAATCACAGAGAGATTATAACGATATACAAGGAAAT
AGAAAACACAATGTGAAATAAAGAGGCTGTTACTAATGAGAAAACATTATGTTGTGCAT
ATGCTTTGGAAACCTGAAATCATTAAATTTGAGTGATTGACTAGTAGCAGAAAGATAGATC
CTTGAAAGTTTCAGAATGTTCAATGTAGAAAGAACAGTGTTTGTAGTGATATGGGAGCC
TAGGGGGTGTGCTTTTCTGGCCAGAAACCTCTGTGGCCAGTGTTGGTGCCCTTGCCCA
[C, T, A]
GTTTTGCTCTGGCCCACTGGGCTTGTCTGCCCCTTGACCTGGCAGACTGTGCCCACCT
TCCGCTACCAGCCTGGATCCCATGCCACCAAGGCCAACCCAGGCATGGAGCTGTGAGGG
TTGTCTGAGCGAGCACAGGGTCTGGCCACTGCCCACAGCCAGGCACACTGGCTGCAGCAT
GACGGGCAGCTCCAGGCACTGGCACAGGTGTGCTGTCTCTCTGTGAGGCTGTGGCTGGAC
AAAGCTCACTGCAAGCAGCTTCCCTGGCAGGCACCTGGGAATGTGGTGGCACCCAGGAAG
- 22132 GATATGGGAGCCTAGGGGGTGTGCTTTTCTGGCCAGAAACCTCTGTGGCCAGTGCTTGG
TGCTTTTGCCCAAGTTTGTCTCTGGCCCACTGGGCTTGTCTGCCCCTTGACCTGGCAG
ACTGTGCCCACCTTCCGCTACCAGCCTGGATCCCATGCCACCAAGGCCAACCCAGGCAT
GGAGCTGTGAGGGTGTCTGAGCGAGCACAGGGTCTGGCCACTGCCCACAGCCAGGCACA
CTGGCTGCAGCATGACGGGCAGCTCCAGGCACTGGCACAGGTGTGCTGTCTCTCTGTGAG
[T, C, G]
CTGTGGCTGGACAAAGCTCACTGCAAGCAGCTTCCCTGGCAGGCACCTGGGAATGTGGTG
GCACCCAGGAAGCTTGGAGATGCCAGGAAGTGCAGGGTCCCAAAGAGGGAGTCACAACCC
TGGCTTGGGGAGCTCCAGGTCTGGGATCCCTAAAGGGCTGCAGCTTTTCTCTCTTTTA
CCCACAATGTGGCCAGCAAGGGGTATGTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
CTTGCTATTTGGCAGGTCTTGAGTTCCTGTCTCTGAGACCAAGAAGATGAGGTATGCAGA
- 22369 ACACTGGCTGCAGCATGACGGGCAGCTCCAGGCACTGGCACAGGTGTGCTGTCTCTCTGT
GAGGCTGTGGCTGGACAAAGCTCACTGCAAGCAGCTTCCCTGGCAGGCACCTGGGAATGT
GGTGGCACCCAGGAAGCTTGGAGATGCCAGGAAGTGCAGGGTCCCAAAGAGGGAGTCACA
ACCCTGGCTTGGGGAGCTCCAGGTCTGGGATCCCTAAAGGGCTGCAGCTTTTCTCTCTT
TTTACCCACAATGTGGCCAGCAAGGGGTATGTTTCTCTCTCTCTCTCTCTCTCTCTCT
[T, A, G, C]
AGTCTTGCTATTTGGCAGGTCTTGAGTTCCTGTCTCTGAGACCAAGAAGAATGAGGTATGC
AGACAAGTGGAGGTTGAGCAAGACGAAGAAGGTTTACTGAGCAAGAGAACAGCTCACAG
GAGACCCACAGTGGGCAGCTCCTCTCTCATAGCCAGGGTGTCCCAACAAGTGTCCAGCTCC
TAGCAAGAGGAGGCCCCTGGAGGTAGAAGCTCCTCTCTGAGGCAGGTGTCTCTGTGAG
TGTTGAGCTTTGAGCACACAGTAGGCAGTAGGCCCTAGAGTGGTCTATCTCTCTCTGCA
- 22742 GGTGAGCAAGACGAAGAAGGTTTACTGAGCAAGAGAACAGCTCACAGGAGACCCACAGT
GGGCAGCTCCTCTCTCATAGCCAGGGTGTCCCAACAAGTGTCCAGCTCCTAGCAAGAGGA
GGCCCTGGAGGTAGAAGCTCCTCTCTGAGGAGGTTGTCTGTGAGTGTTCAGCTTTC
AGCACACAGTAGGCAGTAGGCCCTAGAGTGGTCTATCTCTCTCTGAGGCAGGTAGTCC
CATGGTCTCCAGTCACCTCTCCATCTGCAAGGGTCCAATGCTGCCTCCAGCACCTCTCT
[-, G]
CCCACCCCTCCGTGCTGACCAAGCTGCTCCCCCAGTGGGCAACTCAGCCCAGCCCC
ATTGTGGTAGCTCCAGGGTGGCAGGCTCTGGGGGGCTCCAGGGATGGGCTCAAGGAC
TGTCCACCTTCTCCCCACGCCCTCCCTGCACTGGCCATGGTCAAGAATGGCAATGTGGGG
CCAGGTTCCGGAGCAGGAGAGGCTCCAGGCCTGGGAGCAGGTCTGCTGGTCACTGAG
GTTGGGGGTGGCACAGTGGGCTGCCTCAGGGATGTGGGACACAGGGGACCCACCACATC
- 22882 CTCTCTGAGGCAGGTGTCTGTGAGTGTTCAGCTTTTCAACACACAGTAGGCAGTAGG
CCCTAGAGTGGTCTATCTCTCTCTGAGGCAGGTAGTCCCATGGTCTCCAGTCACCTC
TCCATCTGCAAGGGTCCAATGCTGCTCCAGCACCTCTCTGCCCACCCCTCCGTGCTGA
CCAAGCTGCTCCCCCAGTGGGCAACTCAGCCCAGCCCCATTGTGGTAGCTCCAGGG
TGGCAGGCTCTGGGGGGCTCCAGGGATGGGCTCCAAGGACTGTCCACCTTCTCCCCACG
[C, T]
CCTCCCTGCACTGGCCATGGTCAAGAATGGCAATGTGGGGCCAGGTTCCGGAGCAGGAGA
GGCTCCAGGCTGGGAGCAGGTCTGCTGCTGCTGAGGTGGGGGTGGCACAGTCCG
CTGCTCAGGGATGTGGGACACAGGGGACCCACCACCATCACTGCTACTCCCGCATCCGC
TCCTGCTACCACTGCTCCAGACAGCCTGTAGCTGCCATCACTAGCACTTAAGAAAGGCAC
ATTGAGTGGACAGCTCAGGAAAATCTTTACGTCAATTTTATAGGCAAAAACATTGTTT

FIGURE 3

23316 GTGGGACACAGGGGACCCACCACCATCACTGCTACTCCCGCATCCGCTCCTGCTACCACT
GCTCCAGACAGCCTGTAGCTGCCATCACTAGCACTTAAGAAAGGCACATTCACTGSGACAG
CTCAGGAAAATCTTTACGTCAATTTTTATAGGCAAAAACATTGTTTCTGGGCAAAACAA
AATTTATGGACTACCAATAAATAGAAAACCTGTAGAGATTCTAGATTAAGTCTAGAAATAA
TCCTGTAGCCCAAGATTTATTTATAATTTGTCAAGAATCTGTATTTTGTGTTTGACAAAAA
[A, -]
AAAACCTGTGTGGTGTGGGTCCTTCAGGAGACACAGTGTGACAAAGCAAAGCTAAAATCAA
CTTCTTTGCATTGCAAACACCAAGGCTGTAGTCAAGCAGCTCACTGCCTATGTGTCAGAT
GACTTTGCTTCATTTTCATCATGATACTTGTAGTCTATAGAGCCCTGAATATTAAGTAG
CTTCTCCCAACTCAGAACCGTGTAGGAGGTGGTGTCTTCAAACTAAAGTGTAAATG
TTATTTCCATTTCTATACCAGGAAAGTAAAAATCTTTGGTCAAAATTAGAAATCTTTAA

23867 TTTCTATACCAGGAAAGTAAAAATCTTTGGTCAAAATTAGAAATCTTTAACAACCTAGTTA
CTTGTGTATTGACAGTTTGTGTTCCAGGTGTAATCATTCTCCCTTAAATCCGGTTATATT
CACGACCATTATACTTATCCTGGTATCATTCTGGAAATGGCTAACTTGCATCCTGCTCA
GACTAAGTTGACAAAGTTTCAATTGAAGAATTCTAACTTTATGCTATTTTCCACTTTATT
GCATTACAAAGGACAAAATATATAGTTTCTTAAATGAAATAAATTTACTGCCTTAAA
[A, G, C]
TACATTTGACGGTAAACTGAGTTCCTTCCATAGAATAACCACTAACAGCAATCGATGGTC
CTGAGCAATTGACTCTTCACCATACAATGATTTGGGATGCCCTTAAAGGTATATTTGAAT
TGAATATTTTCAAAGCTCCCACTTTGTAGAGTTTATCATCACTAGTTTCCCACTGGAA
TTTGTAGAAAGTTAGTAGAATGAAACAATCTTATTTGTATAATGAGGAATAGAATACTG
AGAATGTGTCTGAGAAACATGGCACTGGTAGGAAAAGTAAACAGTTTATTCTCATCTGC

23954 TGTAATCATTCTCCCTTAAATCCGGTTATATTCAAGACCATTATACTTATCCTGGTATC
ATTCTGGAAATGGCTAACTTGCATCCTGCTCAGACTAAGTTGACAAAGTTTCAATTGAA
GAATTCFAACTTTATGCTATTTTCCACTTTATTGCTTACAAAGGACAAAATATATAGTT
TTCTTAAATGAAATAAATTTACTGCCTTAACTACATTTGACGGTAACTGAGTTCTT
TCCATAGAATAACCACTAACAGCAATCGATGGTCTGAGCAATTGACTCTTCACCATACA
[A, G]
TGATTTGGGATGCCCTTAAAGGTATATTTGAATTGAATATTTTCAAAGCTCCCACTTTG
TAGAGTTTATCATCACTAGTTTCCCACTGGAAATTTGTAGAAAGTTAGTAGAATGAAACA
ATCTTATTTGTATAATGAGGAATAGAATACTGAGAAATGTGTCTGAGAAACATGGCACTG
GTAGGAAAAGTAAACAGTTTATTCTCATCTGCTCAATAAGCTAAGTCATTTTAACTTGA
AAATCATCAAAATTTTTCATGAAACCTTCCACCACTTTATTTTCCCACTTTAGTAAG

26548 AGTGCCAGAAATTAGACCAGGAGTTGGTGGTACCATTGTGAATAAAACATGATCCCTGCT
CTAAATTAGAATTTCAAAGTAGAGAAAGATATAAATAAATCAGGAAGTATGAAATAAT
GTGATTAATGCTATGACAGAGGAAGTGCATAGTGTCTATGAGAGTTGATCAGAGAGTCAGC
TAACCTGTTCTCACACAGTAAGAAAGTGAACCTTGAATGTGAGAGAGAAGAGGCCATGA
ATCCAGTGACAGGTGGGGTAAAGTGTCTTGGGCAGGAGGAGTAGTATACGAAAATGTCTTC
[G, A]
GGCAAGTAAGAATGGGGTCAATTTCTGTGAATTACAAGATGTTTCTTATAACTTAATGATC
TCATCTTTTTCAGGTTGTGGTAAACGAGTTGTTCATTAAACGTCAACAGAATAGCATC
TGGAGTCATTGCACCCCAAGGCGGCTGGCCTTGGCAAGCTTCCCTTCAGTATGATAACAT
CCATCAGTGTGGGGCCACCTTGATTAGTAACACATGGCTTGTCACTGCAGCACACTGCTT
CCAGAAGTAAGTTATTGACCTTAAGTTAGAACCACCTTCTGCTAAAAGCCCTGAGTTTT

26573 GGTGGTACCATTGTGAATAAAACATGATCCCTGCTCTAAAATTAGAATTCCAAAGTAGAG
AAAGATATAAATAAATCAGGAAGTATGAAATAATGTGATTAATGCTATGACAGAGGAAG
TGCATAGTGTCTATGAGAGTTGATCAGAGAGTCAGCTAACCTGTTCTCACACAGTAAGAAA
GTGAACCTGAAATGTGAGAGAGAAGAGGCCATGAATCCAGTGACAGGTGGGGTAAAGTGT
CCTGGGCAGGAGGAGTAGTATACGAAAATGTCTTCAAGCAAGTAAGAATGGGGTCATTTT
[T, A, G, C]
TGTAATTACAAGATGTTTCTTATAACTTAATGATCTCATCTTTTTTTCAGGTTGTGGTAAA
CGAGTTGTTCCATTAAACGTCAACAGAATAGCATCTGGAGTCATTGCACCCCAAGGCGGCC
TGGCCTTGGCAAGCTTCCCTTCAGTATGATAACATCCATCAGTGTGGGGCCACCTTGATT
AGTAACACATGGCTTGTCACTGCAGCACACTGCTTCCAGAAGTAAGTTATTGACCTTAAG
TTAGAACCACCTTCTGCTAAAAGCCCTGAGTTTTGTATATTCTTGGTAACAATTAATG

27400 TAATCTTTTGTCAAACAATGCTCTCCACTTAAACTAGTGTCTGTTTCTGCCAAACACTT
GGGCCAGTCTCATACTGATCTTAAATAATCAAACCTAATTCAAAGTAAATGGAAATTTT
CAATAAATGCCGGAAGTTGGTAACCGTGATGATGGAGAACTGCAGATCAAATTTAGAGCA
TTGACATATGAAGATCTGTGGAATCAGAACAGTTTACAACCAAAATGAGAGATTGCTAGC
ATGATAAAGACAGGCACCTTCAAAGAGATTCTCGGAGTATCAAAGGATTCTAGAGGCC

FIGURE 3

[A, G, C]
TTGGGCCACTCAATGTGACCTTCCCATATAAGAGCATCTCTTCACAATAGTGACACAAAA
GACAAAGCTGAAGTGAAGAATAGCAAATTGTGCTATCCTATAATTGTTTCTGAATGCATA
CATTTTATTAAATATATGATTAAATGACTTTTTATAACTTTTAATCTTACTTTTCAAGAT
AATAACCAGTCATTTTTATCACTATTACATTTAGAAATTTAGATTTGTTTCTAAGTAGAT
TAACTGTATCGCCTTTCTTCTTCATTGCCAATTATTACAGTAATAACAAAGACTTCTTGA

27788 TTGTGCTATCCTATAATTGTTTCTGAATGCATACATTTTATTAAATATATGATTAAATGA
CTTTTTATAACTTTTAATCTTACTTTTCAAGATAATAACCAGTCATTTTTATCACTATTA
CATTTAGAATTTTAGATTTGTTTCTAAGTAGATTAACGTATCGCCTTTCTTCTTCATTG
CCAATTATTACAGTAATAACAAAGACTTCTTGAGTATCTCTATATAATAGGTGGCAGCAG
GATTTAGTGGGAAAAATATGTCCAGGCAGTTGGAGAGCTGGGCAAAATTATTGAACCTTA
[G, -]
TGTATTAGGTAATAGATAGGCTAGATCTTTTACATTCTTTTGGACCTATAAAATTCTAA
CTTTTGTACTATAATAAATTTTCAATTTGCCTAGGAGCATAAATCTTTATAGAGACTCTTA
ATATTCAAAGAATATACATATTAAGAATCTAGGCTTGGCATGGTGGCTCATGCCTGTAA
TCCCAGCATTTTGGGAGGCCGAGGCAAGAGGACCCTTGAGCTCAGGAGTTCAAGACCAG
CTTGGGCAAGATAGTGAAACCCCATTTGGGCATGGTGGTGCATACCTATCATCCCAGCTAC

28069 GGCAAAATTATTGAACCTTAGTGATTTAGGTAATAGATAGGCTAGATCTTTTACATTCTT
TTTGACCTATAAAATTCTAATTTTGTACTATAATAAATTTTCAATTTGCCTAGGAGCATA
AATCTTTATAGAGACTCTTAATATTCAAAGAATATACATATTAAGAATCTAGGCTTGGC
ATGGTGGCTCATGCCTGTAAATCCCAGCATTTTGGGAGGCCGAGGCAAGAGGACCCTTGA
GCTCAGGAGTTCAAGACCAGCTTGGGCAAGATAGTGAAACCCCATTTGGGCATGGTGGTGC
[T, G, A]
TACCTATCATCCCAGCTACTTGGGAGGCTAAGCAGGAGGATCCCTTAAGCCCAGGAGTT
TGAGGCTCCTGCAAGCTATGATTGCACCACTGCACTCCAGCCTGAGTGACAATGCAAGAC
CCCATCTTAAAAAATAGTAATATATTTTAAAAATAATCTACATAAATCTTAATGTTT
GAAAGATGTGAGAGCTCAGTAAGCTGATATATTAGAAAGCCAGAAATCCCTTATGCTGGT
GTCTGGTTTTTCAAAGTAATGGGAACTTACTTTGCCAAAGTTAGCCATTTTGTGGTAG

29269 CATATATGTGTGTGTGTATATATAAAAAAATATATATATATATATATATATAATTA
CCTCATTTTTCCAGAACCACTTCCAGATGCCCTACCACATTGGTTCTTATCTCTGAAC
ATTCGAGACTTTGTCAAGTGTCTTCTTAAATATGCTTCCAATAACTAAATACACCAAGA
CAGATGTGTGACTAGTGTACACATAACAAAATAAAGCAGGAAGTCTTCTGAAAAATACA
AATAATGTAAATTGGTGGGAGACAGTGTTTTATAAAGGGAAGAGCAGAGAGAGGCAGGCA
[C, G]
ATATGTGATGTGAATCAAATAGTTTAACTATCCAGGCTTTATTTTCTTAAGTATAAAA
CACAGTCTTTACTAGATGATCTTTTCAATGCTACTAAATGATTTTTCCGATTCCTGTATGT
ACCATAATCCACCCATGCCCCAAGCCCACAAGCTAGAAGTCAACCGCATTTACCACATTT
GATCATCTCTCAAAGGACTATGCAGTCATCTAATAGACTTTACCACATCCATTCCTGACC
TTCAAGAATCTACTCCCCAGAAAGAACAAACATGTTTTTTAAAAATGTAAATGAGACTAC

29537 TTTATAAAGGGAAGAGCAGAGAGAGGCAGGCAGATATGTGATGTGAATCAAATAGTTTAA
CCTATCCAGGCTTTATTTTCTTAAAGTATAAAACACAGTCTTTACTAGATGATCTTTTCA
TGCTACTAAATGATTTTTCGATTCTGTATGTACCATAATCCACCCATTGCCCCAAGCCC
ACAAGCTAGAAGTCAACCGCATTTACCACATTTGATCATCTCTCAAAGGACTATGCAGTC
ATCTAATAGACTTTACCACATCCATTCCTGACCTTCAAGAATCTACTCCCCAGAAAGAAC
[C, A]
AACATGTTTTTTAAAAATGTAAATGAGACTACATTATTCTCTGGCTTAATTATCCAGTAG
ATTCCCATATCACTTCAATAAAATTTAAGCACTTTATCATGACCTATAAAACACTCTAAA
ATCTAGTCCCTGCTTACCTCTCCAAGCTCACCCCCAACCATTCTTTCCCTTGTGTTCTGA
CTGCAGCCCATCCAACCCAGACCTTGGGATTTTTGCCTGGAACTTGTTTCCCTCATCT
CCTCACACTGACCCTCTTTTACTATGTCTTAGCCCAAATGCGTTATCAAAATAATCATAA

29726 AAGTCAACCGCATTTACCACATTTGATCATCTCTCAAAGGACTATGCAGTCATCTAATAG
ACTTTACCACATCCATTCCTGACCTTCAAGAATCTACTCCCCAGAAAGAACAAACATGTT
TTTTAAAAATGTAAATGAGACTACATTATTCTCTGGCTTAATTATCCAGTAGATTCCCAT
ATCACTTCAATAAAATTTAAGCACTTTATCATGACCTATAAAACACTCTAAAATCTAGTC
CCTGCTTACCTCTCCAAGCTCACCCCCAACCATTCTTTCCCTTGTGTTCTGACTGCAGCC
[T, G, C]
ATCCAACCCAGACCTTGGGATTTTTGCCCTGGAACTTGTTTCCCTCATCTCCTCACACT
GACCTCTTTTACTATGTCTTAGCCCAAATGCGTTATCAAAATAATCATAATGACCTGTT
AGTACTCTATTCCGTTACCCTATTTTATTTTGTTCATAGCCTTTATCAATGTTTAAAGATT
ATTTATCTATTGTTTGTCTGCTTTGATCCCTTTCTCTTCTGGAATCTTATACTCCTGT
GAGCAGGCACCTTAGGTCCTGTTTCACTTTATCCCCAGCAGTTCAAGATAAGGCTCAGC

FIGURE 3

- 30496 AACTATAACTGCAGCCAAGTATTCTCAGGATTGTATTTCTCTTATATTAGCCTAAATGCA
ATTAATCTAGCTCATATACTTTGGGCAGCTTATATATATTCTGTTAATTTCTAACCTTTT
CCAGGTATAAAAATCCACATCAATGGACTGTTAGTTTGGAAACAAAATCAACCCTCCCT
TAATGAAAAGAAATGTCAGAAGATTTATTATCCATGAGAAGTACCGCTCTGCAGCAAGAG
AGTACGACATTGCTGTTGTGCAGGTCTCTCCAGAGTCACCTTTTGGGATGACATACGCC
[C, T, A]
GATTTGTTTGGCAGAAGCCTCTGCATCCTTCCAACCAAATTTGACTGTCCACATCACAGG
ATTTGGAGCACTTTACTATGGTGGTGGGTATCTCAGGATAGCTAACAGAGCGCTAAGCCC
TGTCTAAGGCAATGTGATTTCACTCTCCATCAATATTATCTGACAGCCATTTCCACACAG
TCTGGTTGGATTAGTTAGGGTTCTTACTTTGTGTGACAGAAATTCAATTCACATTAACCA
GTGCAGAATAAAAAACAAAGAAACAAAACCTTCCACAAATTTGGCTCATGTAATTTGGAA
- 30695 AAGATTTATTATCCATGAGAAGTACCGCTCTGCAGCAAGAGAGTACGACATTGCTGTTGT
GCAGGTCTCTTCCAGAGTCACCTTTTGGGATGACATACGCCAGATTTGTTTGGCAGAAGC
CTCTGCATCCTTCCAACCAAATTTGACTGTCCACATCACAGGATTTGGAGCACTTTACTA
TGGTGGTGGGTATCTCAGGATAGCTAACAGAGCGCTAAGCCCTGTCTAAGGCAATGTGAT
TTCATCTCCATCAATATTATCTGACAGCCATTTCCACACAGTCTGGTTGGATTAGTTAG
[A, C, G]
GTTCTTACTTTGTGTGACAGAAATTCAATTCACATTAACCAGTGCAGAATAAAAAACAAA
GAAACAAAACCTTCCACAAATTTGGCTCATGTAATTTGGAAGTCAAAAAAGTGTAGTAAG
TTTCACTTCAGACACAGGGGTTTATATGATGTCATCTGGCTCTGTGTCTCTGAATTTGAA
TTTTTTGCCCCCTTCTTTTCTCTATGTTGGCTTCATTTCAGAGGGATGCTAGCTTCACCTAG
TGTGAGAGGTGGCTAACACACCTCAACACATCATCCTCAACAAAGAAAAAATACATAGA
- 30752 TGTGCAGGTCTCTTCCAGAGTCACCTTTTGGGATGACATACGCCAGATTTGTTTGGCAGA
AGCCTCTGCATCCTTCCAACCAAATTTGACTGTCCACATCACAGGATTTGGAGCACTTTA
CTATGGTGGTGGGTATCTCAGGATAGCTAACAGAGCGCTAAGCCCTGTCTAAGGCAATGT
GATTTTCATCTCCATCAATATTATCTGACAGCCATTTCCACACAGTCTGGTTGGATTAGT
TAGGGTTCTTACTTTGTGTGACAGAAATTCAATTCACATTAACCAGTGCAGAATAAAAAA
[T, G, C]
AAAGAAACAAAACCTTCCACAAATTTGGCTCATGTAATTTGGAAGTCAAAAAAGTGTAGT
AAGTTTCACCTTCAGACACAGGGGTTTATATGATGTCATCTGGCTCTGTGTCTCTGAATTT
GAATTTTGGCCCCCTTCTTTTCTCTATGTTGGCTTCATTTCAGAGGGATGCTAGCTTCACC
TAGTGTGAGAGGTGGCTAACACACCTCAACACATCATCCTCAACAAAGAAAAAATACAT
AGAAAGGAATATTTATTTCTTTTCTTTGCCAGAATTCACATTAATTTCTATTGTTCCAGC
- 30849 ATCACAGGATTTGGAGCACTTTACTATGGTGGTGGGTATCTCAGGATAGCTAACAGAGCG
CTAAGCCCTGTCTAAGGCAATGTGATTTTCATCTCCATCAATATTATCTGACAGCCATTT
CCACACAGTCTGGTTGGATTAGTTAGGGTTCTTACTTTGTGTGACAGAAATTCAATTCAC
ATTAACCAGTGCAGAATAAAAAACAAAGAAACAAAACCTTCCACAAATTTGGCTCATGTA
ATTTGGAAGTCAAAAAAGTGTAGTAAGTTTCACTTCAGACACAGGGGTTTATATGATGTC
[A, T]
TCTGGCTCTGTGTCTCTGAATTTGAATTTTTTGGCCCCCTTCTTTTCTCTATGTTGGCTTCA
TTCAGAGGGATGCTAGCTTCACCTAGTGTGAGAGGTGGCTAACACACCTCAACACATCA
TCCTCAACAAAGAAAAAATACATAGAAAGGAATATTTATTTCTTTTCTTTGCCAGAATTC
ACATTAATTTCTATTGTTCCAGCTGTGTCTAGGAGGACTCAGATTGAGTGGCTAACTCAA
ATATTCTTTATGCCTATGTAGCAAAATTTGCTTCAGTACTGAAGAAGCTAATTTAAGTGT
- 30900 AACAGAGCGCTAAGCCCTGTCTAAGGCAATGTGATTTTCATCTCCATCAATATTATCCTGA
CAGCCATTTCCACACAGTCTGGTTGGATTAGTTAGGGTTCTTACTTTGTGTGACAGAAAT
TCAATTCACATTAACCAGTGCAGAATAAAAAACAAAGAAACAAAACCTTCCACAAATTTG
GCTCATGTAATTTGGAAGTCAAAAAAGTGTAGTAAGTTTCACTTCAGACACAGGGGTTTA
TATGATGTCATCTGGCTCTGTGTCTCTGAATTTGAATTTTTTGGCCCCCTTCTTTTCTCTAT
[G, A]
TTGGCTTCATTTCAGAGGGATGCTAGCTTCACCTAGTGTGAGAGGTGGCTAACACACCTC
AACACATCATCCTCAACAAAGAAAAAATACATAGAAAGGAATATTTATTTCTTTTCTTTG
CCAGAATTCACATTAATTTCTATTGTTCCAGCTGTGTCTAGGAGGACTCAGATTGAGTGG
CTAACTCAAATATTCTTTATGCCTATGTAGCAAAATTTGCTTCAGTACTGAAGAAGCTAA
TTAAGTGTGATGGTGAATAAGAAATAGTGTAGAGATAAATTTGTCAAATATTGTTCCCT
- 30904 GAGCGCTAAGCCCTGTCTAAGGCAATGTGATTTTCATCTCCATCAATATTATCCTGACAGC
CATTTCCACACAGTCTGGTTGGATTAGTTAGGGTTCTTACTTTGTGTGACAGAAATTCAA
TTCACATTAACCAGTGCAGAATAAAAAACAAAGAAACAAAACCTTCCACAAATTTGGCTC
ATGTAATTTGGAAGTCAAAAAAGTGTAGTAAGTTTCACTTCAGACACAGGGGTTTATATG
ATGTCATCTGGCTCTGTGTCTCTGAATTTGAATTTTTTGGCCCCCTTCTTTTCTCTATGTTG

FIGURE 3

[G, T]
CTTCATT CAGAGGGATGCTAGCTTCACCTAGTGT CAGAGGTGGCTAACACACCTCAACA
CATCATCTCAACAAAGAAAAATACATAGAAAGGAATATTTATTTCTTTCTTTGCCAG
AATT CACATTAATTTCTATTGTTCCAGCTGTGTCTAGGAGGACTCAGATTGAGTGGCTAA
CTCAAATATTCTTTATGCCTATGTAGCAAAATTTGCTTCAGTACTGAAGAAGCTAATTTA
AGTGTGATGGTGAATAAGAATAGTGTAGAGATAAATTGTCAAAC TATTGTCCCCTCTAA

31664 TGAGAAAATGCAAAAGGGCTTTCTGAGAATGACTAAATCTATTTGCAGGATTCTATACAA
TTTATTTTACATACAAGAAATTATAAAGAATAAGCTTTTGATTCTCAGTCTACCATTAAAGG
AACTAGGAATAACCTTTCACTCACATAGGCAGGAATCGGTTT TAGGGTCTCTAGATTTT
TCCAGATGTCCCATGTGGTTTTGTTTTATCTTATACAGAGTGAGACATGCATTGCTTTCT
TTAAGGTTGTATTACCAATCACAGAAAATATTACCTATGGTTTATTAATTCTAGTAGATC
[T, C]
AGTGTGCTGTGTAAGCCTGACACCTCCCTAGGTCTGCACTCTCTTGATGGATTTTCTCTG
AAGATAGGGCTTGCAATTCTCTGCTTCATAGTGGTGGGAAAGACATCACAATCCCCTTTG
GCTTGGTGGGAAAAATCACTTTCAGGAGTTTGAGACTGGCACAGAAACATACCTGTCATA
ATGCGCTGTGAGTGGCAACAGAATCTGACACTTATAGAGCACTCCACCCTACTTGAACAC
GGCCTCTCTTGGTGAGTGACCCACAGGTGCTTTTAATCTATTAAATAGATTAAATTAACC

32014 GATTTTCTCTGAAGATAGGGCTTGCACTCTCTGCTTCATAGTGGTGGGAAAGACATCACA
AATCCCCCTTTGGCTTGGTGGGAAAAATCACTTT CAGGAGTTTGAGACTGGCACAGAAACA
TACCTGT CATAATGCGCTGTGAGTGGCAACAGAATCTGACACTTATAGAGCACTCCACCC
TACTTGAACACGGCCTCTCTTGGTGAGTGACCCACAGGTGCTTTTAATCTATTAAATAGA
TTAAATTAACCTATCATTCTTAATCTGTTAAGTACATTAATAGATTAAAAGCAGCCATTC
[T, C, G]
TTACTACCAAGAGAGGGCTATATTCAAGTCTGTAAAGCAAACCTTAAGAAGTTTTTAA
ATTGAAATGTACAAAGTATATTCTCTGATCATAATGGAATCTAACTAGACATCAGTAAC
AGAAAGATAACATAAAAATCCCCAAATGCTTACCAATTAAAAACATATGTAAATAAAGA
GAATATCTCGAAGAAATTTGTAAAAACAAATAGAACTAAATGAAAACAAAATATATAAA
TATATGCCAGATGCTGCTAAAATAGTGTAGAAAGGGAAATTTATAGAAAATGCATATTAT

32197 TTGAACACGGCCTCTCTTGGTGAGTGACCCACAGGTGCTTTTAATCTATTAAATAGATTA
AATTAACCTATCATTCTTAATCTGTTAAGTACATTAATAGATTAAAAGCAGCCATTCGTT
ACTCACCAAGAGAGGGCTATATTCAAGTCTGTAAAGCAAACCTTAAGAAGTTTTTAA
TGAAATTTGTACAAAGTATATTCTCTGATCATAATGGAATCTAACTAGACATCAGTAACAG
AAAGATAACATAAAAATCCCCAAATGCTTACCAATTAAAAACATATGTAAATAAAGAGA
[A, G]
TATCTCGAAGAAATTTGTAAAAACAAATAGAACTAAATGAAAACAAAAATATATAAATAT
ATGCCAGATGCTGCTAAAATAGTGTAGAAAGGGAAATTTATAGAAAATGCATATTATAAG
GAAAGATATCAATCAATAATTAAGTTCTCACTTCAAGAACTAGAAAAATAAAAAATAA
ACCTAAAACAAACATAAGGAAGGAAATAATAAGAATAAGAATAGAAATGAATAAAATTAA
AAATAAACTATAGAAAATTGATAAATAAAAGCTGATTATTTGATAAAATCAATATTTTG

33074 TCGGCTCACTGCAAACTCGGCCTCCCGGTTTCAGCCATTCTCCTGCCTCAGCCTCCCGA
GTAGCTGGGACTGCAGGCGCCCAACCATGCCC GGCTAATTGTTTTGTAGTTTTAGTAA
AGAAGGGGTTT CACCGTGTAGCCAGGATGGTTTTGATCTCTGACCTCGTGATCCACCT
GCCTCGGCCTCCCAAAGTGTGGGATTACAGGCGTGAGCCACCGCGCGCCAGGCCATGAA
TGTTTTTAATTGATGATATAGTAGGCAATATAAATGTGTGTGTGTGTGTGTGTGTGTG
[-, T]
ATAATATATATAAACCAATTGTATTCAAATAACAGAATAATTTGAAAAATCTCTTAGCAT
ATTTCTGAGTTACACACTTAAATCTTCCGAGCACTTTTAAATATGTGTTTACAAACATTT
CTTCAGAAATAAATCTTGAAATCGTCTTCTAAAGAACTGGTGATTAGGGTTTTTTCA
AATGTACTTAGTTTTTTTTTTTAAATTGATGTATAAAATTGCATGTACTTACCATGTGCAAC
ATAATGTGTTGAAGTATAGTATATGTACACTGTGAGTGTAAATCTAGTTAACTAAGAAG

33505 AAATCTTGGAATCGTCTTCTAAAGAACTGGTGTATTAGGGTTTTTTCAAATGTACTTA
GTTTTTTTTTTAATTGATGTATAAAATTGCATGTACTTACCATGTGCAACATAATGTGTT
GAAGTATAGTATATGTACACTGTGAGTGTAAATCTAGTTAACTAAGAAGCGTCTTATTT
TACATAATTATCATTTTTTGTGGCAAGAACACTTAAATCTACTCTTGTAGCGTTTCTCAA
GAATACGATATATCAACAGTAGGCAACCAGAAGCTGGGGGTCTTTACAGGGGAAGGAGTT
[C, T, A]
GGGAGATGCTGGTCAACAAATTCATATTTGCAGTTAGGAAGAAAAAGTTCAAGAGATCTC
TCATCCATCATGGTGA CTATAGCTGATGATATATCGTATTCTTGATTAGTTTTTTATAA
ATGTGTAACAAATAATCACAACAGTTAAAACAGCACTCATTTATTTTTATCTCACTGTT
TTCATGAGTCAGACGTT CAGACACAGCTTAGTTGAGTCTCTCTCAGGGTCTCACCAA
CTGTAATCAAGGTGTCAGCTGGGGTTGTGGCCACATCTGTGGCTCCTTTGAAGGTCTCCT

FIGURE 3

33551 TTCAAATGTACTTAGTTTTTTTTTTAATTGATGTATAAAATTGCATGTACTTACCATGTG
CAACATAATGTGTTGAAGTATAGTATATGTACACTGTGAGTGTAAATCTAGTTAACTAA
GAAGCGTCTTATTTTACATAATTATCATTTTTGTGGCAAGAACACTTAATATCTACTCTT
GTAGCGTTTTCTCAAGAATACGATATATCAACAGTAGGCAACCAGAAGCTGGGGGTCTTA
CAGGGGAAGGAGTTAGGGAGATGCTGGTCAACAAATTATATTTGCAGTTAGGAAGAAAA
[A, T]
GTTCAAGAGATCTCTCATCCATCATGGTGAAGTATAGCTGATGATATATCGTATTCTTGTA
TTAGTTTTTTATAAATGTGTAACAAATAATCACAAACAGTTAAAACAGCACTCATTTATT
TTTATCTCACTGTTTTCATGAGTCAGACGTTAGACACAGCTTAGTTGAGTCCTCTTCTC
AGGGTCTCACCAACTGTAATCAAGGTGTCAGCTGGGGTTGTGGCCACATCTGTGGCTCC
TTTGAAGGTCTCTCAAGGTTTGTGGCAGAAATCTTTACTCGCAGCTGTAGAATGCAT

33801 AGTTAGGGAGATGCTGGTCAACAAATTATATTTGCAGTTAGGAAGAAAAAGTTCAAGAG
ATCTCTCATCCATCATGGTGAAGTATAGCTGATGATATATCGTATTCTTGATTAGTTTTT
TATAAATGTGTAACAAATAATCACAAACAGTTAAAACAGCACTCATTTATTTTATCTCA
CTGTTTTCATGAGTCAGACGTTAGACACAGCTTAGTTGAGTCCTCTTCTCAGGGTCTCA
CCAACTGTAATCAAGGTGTCAGCTGGGGTTGTGGCCACATCTGTGGCTCCTTTGAAGGT
[C, A, G, T]
TCCTCAAGGTTTGTGGCAGAAATCTTTACTCGCAGCTGTAGAATGCATGCCAGCTTGC
TGCTTTAACTCTTTAGGAAAGTGTCTCAACTCCAGCAAGGCTCGCCCTTTTGAAGTGGC
TCAGCTGATTAGGTGAGGCCACCTTTGATAATCTCCTTTGATGAATTCAAAGTCAAAC
TCATTAGAGGTCTTAATCGCATCTGTAAATCTCCTCATCTTGGCCATATAACATAACCT
AATCATGAGAATGGCATCCCTCATATTCACAGATCTGCCCATATTTGGGAGGAGGGGAA

34648 TATATGTATATTTACATATATCTTATATATGTGAAAGCTCATCATAAACTTTAAATAAT
AAAATAAATGTACATAGTATTATAGGCATTTTATCAAGCCAATGGAGAAAACCATCTAGG
CATGCAGAGTTTCTGGGAACAATCTGGAACCCACAAATAAAAGCTTTACAAAAGATAAAA
GGCCTTCTGAAATATATAAGCTGATTATTTTAAAGGTTAGATTTTACCAGGAAAAAGAA
TCCAAATGGCTTTCTTGCTTTGAGAAGTTTTTATAAAAATGTGATTGGACAATAATTATC
[T, C, G]
TTAGATGTGCCAGATTTAACCAGAAATCTTTTTTCTAGAACTGCTTATATTAACCTCA
TTCTGTATTGACAATTTTACCATGAAAAAATATTAGGAAAGTCTTCTCACTTCACTCTA
GCCAAAGATGCTGATTGTAAATACTAGAATAACTCTATTTTCTTAAAGGGGAATCCCAA
AATGATCTCCGAGAAGCCAGAGTGAAAAATCATAAGTGACGATGTCTGCAAGCAACCACAG
GTGTATGGCAATGATATAAAACCTGGAATGTTCTGTGCCGATATATGGAAGGAATTTAT

34754 GAAAACCATCTAGGCATGCAGAGTTTCTGGGAACAATCTGGAACCCACAAATAAAAGCTT
TACAAAAGATAAAAGGCCTTCTGAAATATATAAGCTGATTATTTTAAAGGTTAGATTTT
ACCAGGAAAAAGAAATCCAAATGGCTTTCTTGCTTTGAGAAGTTTTTATAAAAATGTGATT
GGACAATAATTATCGTTAGATGTGCCAGATTTAACCAGAAATCTTTTTTCTAGAACTG
CTTATATTAACCTTCACTCTGTATTGACAATTTTACCATGAAAAAATATTAGGAAAGTCT
[G, T]
CTCACTTCACTCTAGCCAAAGATGCTGATTGTAAATACTAGAATAACTCTATTTTCTCT
AAGGGGAATCCCAAATGATCTCCGAGAAGCCAGAGTGAAAATCATAAGTGACGATGTCT
GCAAGCAACCACAGGTGTATGGCAATGATATAAAACCTGGAATGTTCTGTGCCGATATA
TGGAAGGAATTTATGATGCCTGCAGGGTAAAGTTGGAGGGATTTTTTATATTACTAACTC
AAAAATTTGTATCTGGCTTAGAATATATTATATGTTCTTTACATAAGGACAAAACATAGA

34867 AGATTTTACCAGGAAAAAGAATCCAAATGGCTTTCTTGCTTTGAGAAGTTTTTATAAAAA
TGTGATTGGACAATAATTATCGTTAGATGTGCCAGATTTAACCAGAAATCTTTTTTCTA
GAACTGCTTATATTAACCTTCACTCTGTATTGACAATTTTACCATGAAAAAATATTAGG
AAAGTCTTCTCACTTCACTCTAGCCAAAGATGCTGATTGTAAATACTAGAATAACTCTAT
TTTTCTTAAAGGGGAATCCCAAATGATCTCCGAGAAGCCAGAGTGAAAATCATAAGTGA
[T, C]
GATGTCTGCAAGCAACCACAGGTGTATGGCAATGATATAAAACCTGGAATGTTCTGTGCC
GGATATATGGAAGGAATTTATGATGCCTGCAGGGTAAAGTTGGAGGGATTTTTTATATTA
CTAACTCAAAAATTTGTATCTGGCTTAGAATATATTATATGTTCTTTACATAAGGACAAA
ACATAGATATCATGTGAGCTCAAAAAAGTTACAAATGCAAAATTCACAGCACAAAATACT
TTTAAATGTTTTATTAAAGATAAATGAAGTAAGAGTTTCTCTGATGCTATCAAACAAACAA

35013 GTATTGACAATTTTACCATGAAAAAATATTAGGAAAGTCTTCTCACTTCACTCTAGCCA
AAGATGCTGATTGTAAATACTAGAATAACTCTATTTTCTTAAAGGGGAATCCCAAATG
ATCTCCGAGAAGCCAGAGTGAAAATCATAAGTGACGATGTCTGCAAGCAACCACAGGTGT
ATGGCAATGATATAAAACCTGGAATGTTCTGTGCCGATATATGGAAGGAATTTATGATG
CCTGCAGGGTAAAGTTGGAGGGATTTTTTATATTACTAACTCAAAAATTTGTATCTGGCT

FIGURE 3

[C, T]
AGAATATATTATATGTTCTTTACATAAGGACAAAACATAGATATCATGTCAGCTCAAAAA
AGTTACAAATGCAAATTTACAGCACAAAATACTTTTAAATGTTTTATTAAGATAAATGA
AGTAAGAGTTTTCTCTGATGCTATCAAACAAACAAAATTAGAATTTCTTAACCAGAAATCC
AAAGATTAATAAAGCAGTTTTATTTCTCAAGCGGCTCACATTCAAGAAAGAAAATAATCA
TAAACAGAGAAGTATAAAGTGATGTTATGAATAATATAATGAAAAGCAAATATTTTCTT

35225 GCCGGATATATGGAAGGAATTTATGATGCCTGCAGGGTAAGTTGGAGGGATTTTTTATA
TTACTAACTCAAAAATTTGTATCTGGCTTAGAATATATTATATGTTCTTTACATAAGGAC
AAAACATAGATATCATGTCAGCTCAAAAAAGTTACAAATGCAAATTTACAGCACAAAAT
ACTTTTAAATGTTTTATTAAGATAAATGAAGTAAGAGTTTCTCTGATGCTATCAAACAA
CAAAATTAGAATTTCTTAACCAGAAATCCAAAGATTAATAAAGCAGTTTATTTTCTCAAG
[C, A, G, T]
GGCTCACATTCAAGAAAGAAAATAATCATAAACAGAGAAGTATAAAGTGATGTTATGAAT
AATATAATGAAAAGCAAATATTTTCTTGAAGGAAACATTTTGGAAACAAGTATCAGAGA
GATGAGACGTAAATAAGGCCTGAAGAATAAATAACATCCAATTTCAAGATAAGAAAATAA
TGTTATAGAAAAGACAAAAGCATAGCCAAAATTATGAAGGTGTGAAATTACAATTCATA
TCTGAGGGAACCTCCAAGTAATTTGGTTGGGTCTCAGCATGAGGAGGATGAGAAGAGAAACA

35517 TTCTCAAGCGGCTCACATTCAAGAAAGAAAATAATCATAAACAGAGAAGTATAAAGTGAT
GTTATGAATAATATAATGAAAAGCAAATATTTTCTTGAAGGAAACATTTTGGAAACAAG
TATCAGAGAGATGAGACGTAAATAAGGCCTGAAGAATAAATAACATCCAATTTCAAGATA
AGAAAATAATGTTATAGAAAAGACAAAAGCATAGCCAAAATTATGAAGGTGTGAAATTA
CAATTCATATCTGAGGGAACCTCCAAGTAATTTGGTTGGGTCTCAGCATGAGGAGGATGAGA
[A, C, T, G]
GAGAAACAAGTAGATAACCATGAGAAGGTGGATTAGGCCATGTTGTGATTCCATGGGCCC
TCCCCAGTGCCCTCATCTGCCTTCTAACATGGATGTTTTCCAGCGAAGGTACGTTTCTTC
CTGGAGACACTTGCTTTTTAACATGAGATACTTTAGAACTCTAAGGAGGCCACTCTATGT
GGAAATGATGGAATGGTATGATATCAGGTGGCAGAAAGTCCGTGTCCAGAGTCCCACAAA
CTGTACCACATGTGCGACCTCTATCAGAAAAGGAGCAGGGACCTATGTGACATAGAGGCT

36885 TAAGAAAACCTAGAGGATAAGCTCAGGAGATCCAACACCAAATGAATAGGAGCTCTGAAAA
CATAAAACGCGAGTGTAATATAAAAAAAATAAAGAATGCTCCTAGTTCTGAAGCTTA
CATGCATCCTATTGAAGAAAAGGTCCAAGTAGTGCTGGGCACAATAAATGAAGTACTTCT
TTCCAAGACATACCATCATAAAGGGTCAGAAGCCAGGGATAAGGAGAACAATCTTAAAC
TTTGAAGGAAGAACCATCAGAACTACATAGAACTCCTCAACAGTAACTCTAGAAGGTAGA
[C, G]
GATGGTGGAAAACACATTCAAATTTCAAAGGGAAGATTATTTCAACCTAGATTCTTACCC
ATGCTAACTAAATATCAACTGTGAGGGTGAATTAAGAAGTTTAGACAAGCAATGACTGA
AAAAATGTACTTCTGATACCTACTTCTTAGGAAACTACTTGAGAGGGTACCTCAGCAA
AATGAGGGAATAAATCAAGAAAGTGAAGACGTAAGACCTGAAACTGTTAGTCCAACACT
AAAGAGTGGTATCAGATAATCCCAACACCATAGCTCTGCACCAGGCTTAAAGTAACCAGC

38527 AAGAAAGCTGTATGCAGGTATATATGCATGAGAATTCAACTATTTAGTGGGTGTAGTAC
AACRAAGTGATATTAAATTACTGGATCTAGTAACATGAAACACACAACGTAAGTTATTTA
GAATCACTTTAATCAACCAATAATCCTTAGCCAATTTATAAGGGACTTTTATTTGTAAAG
TAATGGATCTGGCTTGAAAAATACGGTAGAGATACTTAGCTCTTTAAATCACGAATGTTG
AAGTACCAGTGAGACTCAATACATATTTTGAAGATAGTCCATGGGATTTTGAATGTC
[G, A]
TTGTCAAGGGTCTCCTTTTAACTGAGAACTTTTTGAACTCACAAAGTGTTCAAGAAACC
CTTGATAATTCCTACATTTCTCTCGAGCTCACAATACTTTTTTTCTTTTCTTTAT
TCAATCAGATTTTCAAAGTACCTTTCCACCATAAGAAATGAATTTTCTACTTCTACACC
CATTTGAGAGACACCAATAAAGAAAGTCATATGTAGGAAACAAAGTCTGATAGTAAAC
AAGCCAGAGATCTTCTAACTTTTTTAGTTATAAAACCTCTAATTTTTGGTGACTTTTCT

FIGURE 3

SEQUENCE LISTING

<110> PE CORPORATION (NY)

<120> ISOLATED HUMAN PROTEASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS, AND
USES THEREOF

<130> CL000862PCT

<140> TO BE ASSIGNED

<141> 2001-09-27

<140> 60/235,557

<141> 2000-09-27

<140> 09/734,675

<141> 2000-12-13

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1225

<212> DNA

<213> Human

<400> 1

```

cgcccttatg ctgaagccat ggatgattgc cgttctcatt gtgttgtecc tgacagtggg 60
ggcagtgacc ataggtctcc tggttcactt cctagtattt gaccaaaaaa aggagtacta 120
tcatggctcc tttaaaattt tagatccaca aatcaatttc aatttcggac aaagcaacac 180
atatcaactt aaggacttac gagagacgac cgaaaatttg gtggatgaga tatttataga 240
ttcagcctgg aagaaaaatt atatcaagaa ccaagtagtc agactgactc cagaggaaga 300
tgggtgtgaaa gtagatgtca ttatgggtgt ccagttcccc tctactgaac aaagggcagt 360
aagagagaag aaaatccaaa gcatcttaaa tcagaagata aggaatttaa gagccttgcc 420
aataaatgcc tcatcagttc aagttaatgc aatgagctca tcaacagggg agttaactgt 480
ccaagcaagt tgtggtaaac gagttgttcc attaaacgtc aacagaatag catctggagt 540
cattgcaccc aaggcggcct ggccttggca agcttccctt cagtatgata acatccatca 600
gtgtggggcc accttgatta gtaacacatg gcttgtcact gcagcacact gcttccagaa 660
gtataaaaat ccacatcaat ggactgttag ttttgaaca aaaatcaacc ctcccttaat 720
gaaaagaaat gtcagaagat ttattatcca tgagaagtag cgctctgcag caagagagta 780
cgacattgct gttgtgcagg tctcttccag agtcaccttt tcggatgaca tacgccggat 840
ttgtttgcca gaagcctctg catccttcca accaaatttg actgtccaca tcacaggatt 900
tggagcactt tactatgggt gggaatccca aaatgatctc cgagaagcca gagtgaaaat 960
cataagtgac gatgtctgca agcaaccaca ggtgtatggc aatgatataa aacctggaat 1020
gttctgtgcc ggatatatgg aaggaattta tgatgcctgc aggggtgatt ctgggggacc 1080
tttagtcaca agggatctga aagatacgtg gtatctcatt ggaattgtaa gctggggaga 1140
taactgtggt caaaaggaca agcctggagt ctacacacaa gtgacttatt accgaaactg 1200
gattgcttca aaaacaggca tctaa                                     1225

```

<210> 2

<211> 405

<212> PRT

<213> Human

<400> 2

```

Met Leu Lys Pro Trp Met Ile Ala Val Leu Ile Val Leu Ser Leu Thr
  1           5           10          15
Val Val Ala Val Thr Ile Gly Leu Leu Val His Phe Leu Val Phe Asp

```

			20					25					30				
Gln	Lys	Lys	Glu	Tyr	Tyr	His	Gly	Ser	Phe	Lys	Ile	Leu	Asp	Pro	Gln		
		35					40					45					
Ile	Asn	Phe	Asn	Phe	Gly	Gln	Ser	Asn	Thr	Tyr	Gln	Leu	Lys	Asp	Leu		
	50					55					60						
Arg	Glu	Thr	Thr	Glu	Asn	Leu	Val	Asp	Glu	Ile	Phe	Ile	Asp	Ser	Ala		
65				70					75						80		
Trp	Lys	Lys	Asn	Tyr	Ile	Lys	Asn	Gln	Val	Val	Arg	Leu	Thr	Pro	Glu		
			85					90						95			
Glu	Asp	Gly	Val	Lys	Val	Asp	Val	Ile	Met	Val	Phe	Gln	Phe	Pro	Ser		
		100					105						110				
Thr	Glu	Gln	Arg	Ala	Val	Arg	Glu	Lys	Lys	Ile	Gln	Ser	Ile	Leu	Asn		
		115					120						125				
Gln	Lys	Ile	Arg	Asn	Leu	Arg	Ala	Leu	Pro	Ile	Asn	Ala	Ser	Ser	Val		
	130					135						140					
Gln	Val	Asn	Ala	Met	Ser	Ser	Ser	Thr	Gly	Glu	Leu	Thr	Val	Gln	Ala		
145				150						155					160		
Ser	Cys	Gly	Lys	Arg	Val	Val	Pro	Leu	Asn	Val	Asn	Arg	Ile	Ala	Ser		
			165					170						175			
Gly	Val	Ile	Ala	Pro	Lys	Ala	Ala	Trp	Pro	Trp	Gln	Ala	Ser	Leu	Gln		
		180					185						190				
Tyr	Asp	Asn	Ile	His	Gln	Cys	Gly	Ala	Thr	Leu	Ile	Ser	Asn	Thr	Trp		
	195					200						205					
Leu	Val	Thr	Ala	Ala	His	Cys	Phe	Gln	Lys	Tyr	Lys	Asn	Pro	His	Gln		
	210				215						220						
Trp	Thr	Val	Ser	Phe	Gly	Thr	Lys	Ile	Asn	Pro	Pro	Leu	Met	Lys	Arg		
225				230					235						240		
Asn	Val	Arg	Arg	Phe	Ile	Ile	His	Glu	Lys	Tyr	Arg	Ser	Ala	Ala	Arg		
			245					250						255			
Glu	Tyr	Asp	Ile	Ala	Val	Val	Gln	Val	Ser	Ser	Arg	Val	Thr	Phe	Ser		
		260				265						270					
Asp	Asp	Ile	Arg	Arg	Ile	Cys	Leu	Pro	Glu	Ala	Ser	Ala	Ser	Phe	Gln		
	275					280						285					
Pro	Asn	Leu	Thr	Val	His	Ile	Thr	Gly	Phe	Gly	Ala	Leu	Tyr	Tyr	Gly		
	290				295						300						
Gly	Glu	Ser	Gln	Asn	Asp	Leu	Arg	Glu	Ala	Arg	Val	Lys	Ile	Ile	Ser		
305				310						315					320		
Asp	Asp	Val	Cys	Lys	Gln	Pro	Gln	Val	Tyr	Gly	Asn	Asp	Ile	Lys	Pro		
			325					330						335			
Gly	Met	Phe	Cys	Ala	Gly	Tyr	Met	Glu	Gly	Ile	Tyr	Asp	Ala	Cys	Arg		
		340				345						350					
Gly	Asp	Ser	Gly	Gly	Pro	Leu	Val	Thr	Arg	Asp	Leu	Lys	Asp	Thr	Trp		
	355				360						365						
Tyr	Leu	Ile	Gly	Ile	Val	Ser	Trp	Gly	Asp	Asn	Cys	Gly	Gln	Lys	Asp		
	370				375					380							
Lys	Pro	Gly	Val	Tyr	Thr	Gln	Val	Thr	Tyr	Tyr	Arg	Asn	Trp	Ile	Ala		
385				390					395						400		
Ser	Lys	Thr	Gly	Ile													
			405														

<210> 3
 <211> 38844
 <212> DNA
 <213> Human

<400> 3
 ttatattcat aaaagtaggc agtaagttga agatttatcc atataggatt tagtagctgc 60
 agctttaacc tgtggcttct gtagcttttg taatctggca gtgcgcacat gctatattat 120
 ctaaagtgtt cctcaaaagg agaaacactc taacaactta tcaccctagt ctgctggcca 180
 ccattttccc tcagatgctc acagcttctt ccgtgggatt tgaagatatg acttccatga 240

cacttgatca gtatgtcaat ggggtattgaa ccactcttca gctctgatcc cacgggttcag 300
ttcctttcag tgtgactatg tgtccttggtg gtgggagatg tgattctttt atctactttc 360
tccatttatc ttactcagag gaactgtgct ctaataggga aatagattga aagcttataa 420
atttccttga gttttaactt ttctcctttg gtcttttttt cttttcaa at gacttgaaga 480
cacattgata agattctatg agaaaatgaa gagttgaaca aattgaatat gtatgagtga 540
atgaatagat taatacataa atgataaatt tattaataaa tttgaacgaa atcaatcgag 600
aggcacccag aataaatttg tgtcctagaa gtaagaagac ctgagtttga gataactagt 660
agttctatta tactggagaa attactta at catcactgga cttcattttt ctcatatgga 720
aagtaattca atcacactaa acaatcttta aggtctcctt cacttataaa tgtatgtttt 780
aagccattta ggagggttaaa taatgtcatg tcccatggga cttctgtttg ttgttctatt 840
caagcatggt agcttggttc tatcacagga cctgctgcct ttccgcagcc agttctctag 900
attattttta atcagtcggt gcacacatgg tcaatattta ctcaatagaa ttcagggttc 960
ccaaattcca tgaggattct tgatttaatt tattacttat gccaaaacta ttatcttctt 1020
aactatttta ggtccaaaca gttttaactt ttatcctggc atttataat ataaaaactt 1080
tgtaagaccg ggtgcagtgg ctcatgcctg taatcccagc actttgggag gccgagggtg 1140
gtggatcacc aggtcaggag atggagacca tcctggctaa caccatgaaa ccctgtttct 1200
actaaaaata caaaaaatta gccgggcgtg gtgggtggacg cctttagtcc cagctattca 1260
ggaggctgag gcaggagaat ggcgtgaacc tgggaggcag agcttgcatg gagcagagat 1320
cacaccactg cactccagcc tggcagcctg gatgacacag cgagactccg tctcaaaaaa 1380
aaaaaaaaaa aaaagaaaaa aactgtttta tagtcaaaag aaaaactttc tataaatcaa 1440
ccaatcctgt gaagaaaata tgaaaaatat cctctgtttc caaaaaaatt taggctatca 1500
atatatacac ataaagagat aaactctgat aaattggata aataaaaatt actataatag 1560
caagtttttag agaacaagca cgggagttag tgcacctggg cccttaaaaca gatatcctct 1620
ctctcatcct gtgttatttc ctgtgtaatg ttggtatcat tcctgcctga ctctcataga 1680
tttatatgat tctactctg tccaggtgcc ttattgggtc tttagcgtaa aaagatgaac 1740
aaggctaatt cagcccattg agaagctatc tgtaagtga catacatgca aactaatact 1800
tgattcaatg tgagaagcac tgttgctgat cataggtgcc agaagaacag caaagagtta 1860
tttttctctc caaaattgtg gaaaaatttt tatccccggt gtgatgcaat ataaaaataca 1920
cagcaccacc tttgaagtat tcttgccaaa tgaatttaac caaatctaa tcaagacttc 1980
agagctaaag aaaatctaaa ggtaatccaa ttatagggaa atgagggata taaaagaaca 2040
agttaaataa taccacagga aagcattcag acaagtcctg aaagtaagat attctaaagg 2100
atgttttagct tgatctcttc aacagtcaat gtcattaaaa actaaaaaag aagcaggact 2160
cttttagatt aaaagagatt aaaaaggcat aacaaacaag tgcactgcat ggtcctcgat 2220
tatgtcttgg cttttacaaa tcatgtgtaa ttataatgaa accatggagg gaacttgaag 2280
atggactggg tattagatga tatggcagaa atatcattaa ttttttagga gtgttaagag 2340
tatcatgggt atgttggata tatcctaatt gtctataata atgatttggt aaaaagtcac 2400
gatgttttat ttcacattaa aatatagcag cagaaaaaat aaatgagcca aatacagtaa 2460
aattttcaac aattgatata ataattgtgat atatatatgg atgttcaatt atactattct 2520
tagtaatttt ttatgtctga acattttcat aataactaaa aataaaaagat aaaagataaa 2580
aataaatgag ataattagatt taaaatcact ttgtaaactc taaaaggata gacagataaa 2640
agagataaca aagtgtctgga gaaaggagga atgggtccctt ttcaagcatg tatgccacct 2700
tgaccatgct tgctaagaga aaccattcct gaccaccaca aagaggccac caaatgcctc 2760
taaaatagaa agcaggagca acattaggat tcccagatcc tgatattttt tttttaacac 2820
atcttctcag accaagatga cattgaacaa aattaaagac ctttttgcag ggaaaggtag 2880
gctacagcaa cttgaacttg tctaaggaga gctggaaaac ctgcaagcat tgctatctga 2940
gagtaaccag tgggcccttc cttttctcag gacagtggga tttggcacc cctgacagtg gtggcagtga 3060
tgctgaagcc atggatgatt gccgttctca ttgtgtgtc aaattaaaga tttcactcta 3120
ccataggtct cctgggtcac ttctagtat ttggtaggt taaatgtaac ttcactctaa 3180
tttgatttta tttttctgca aagctccatt tacatatatg taaatgtaac ttcactctaa 3240
aaattgcaca tttaccttca aatttccaca gagtatattt aactgtttca gtcatttcat 3300
caacaaacaa gtactaaatt cttattatat gtgagtactt ttctggatat tcaagataca 3360
gctttaagca aagtagacag atttctaatt tccttagagc tctcaacca gaattctttt 3420
gagaatctac acaaaaagat caaaaattgt aattgtctga aacttactag taattataat 3480
aaacaactca tcaattatta tatattaaaa tgaaaagcta tgataaatta gttattaaaa 3540
ttggctcttt tactcatgaa ccatcatttt ctgtccaaca tttctaaggc aaaagaaaaa 3600
cacttgctta ataaaaataag gaatttcaaa atgattgaaa acctatacgt atgacacaat 3660
attatcattt attttttagag aaaaaaatt ttactctttc caaaacaata ttcagggtatt 3720
atatttttat caactaatat atttgtaatt acacaaataa tgcacttcaa gattctcttt 3780
ttacattcag tctctttctg gggagaatgc aagccattta cattttttca caaatctcta 3840
caatgtgact ctcacatgga tgtatgtgat aaaacaaata actcaggctg ctcactttaa 3900
cgctcttatc tgctgtcacc ttcacagagt caatggggga gcaaagactc tacttggagc 3900

cttaaagggc ttaagatcat agtcctagggc cttatatgat aaccccagct gtagtttata 3960
ccattggcaa aagattctca ggtcacttta tttggttgca taaaagtctc tttacaatga 4020
gagtaagggt tgttaacagt atggattata tgggtaagta atcaggatgt ccaaaaatgt 4080
attacaaggc ccagagattt cccacttaag acatatgcct tcctgatata cctgtttctt 4140
tccttggttt gtagtctcga aacccactcc ctcttccttg agccaggctt ctcaaggatt 4200
gaggttggtt tgtatttttc ccattctcta tctttaactc tgtatctttc ttactccctc 4260
tgggccttac tcctcagatt accaaattcc ttaggagttc caactgcttt cctttcttac 4320
atctcctaag agatttatcc ctgtttcatg ctctgtcttg cttcaatctc agacagctct 4380
tctctacact ttcttttcag gtttttctta gtgtgcctgg ctctcttggt aaaaatcaaa 4440
attcacaagg acattcactt atctctactt ccactagagt gtatgatggg acacatttca 4500
actcagcaag gagcaatgta gcaatgaaat gttcaagctc tacagctaga ctggatttaa 4560
aacttggaac ggccacctac tagttacaga acaatttact taatgcctct gtgccttaat 4620
ttccttatct gtaaaatgaa ggtgatacca atcttagaga gctgggtgtg ggattaaatg 4680
ggctaataca taaaagtgc acaggacagt gcctgccata ttgtagaaac tcaataaatg 4740
gcagctatta taattgatat aaaacattaa ctgttatttt ttaataaaaa ctcaattatg 4800
aagaggtcca gggacatatt caagatttat attggcccca ttgtaattga gttctgaaat 4860
ctttgtccaa accatttagt ttcttatttt tcatttccat tgcagaccaa aaaaaggagt 4920
actatcatgg ctcttttaaa attttagatc cacaaatcaa taacaatttc ggacaaagca 4980
acacatatca acttaaggac ttacgagaga cgaccgaaaa tttggtgagt caggtaaact 5040
tctttttatc atagaataat gcaagtggaa gggattttgt ggatcatttc tccatttcta 5100
aaaacatgat tttcagaccg ccaacattag aatcatcttg cagattgcta ggccccatcc 5160
cagacctgct taatcagagt atgatgagat gggtaggtgg ggagaggaga gtaagggaat 5220
ctgcatgtct aacaaatggg tgattctaata aagcctctct ttctaactca gctaccttat 5280
ttaaaggtaa gagaattgag gccaaagatat cctagccctg ttcttcccca attccaccac 5340
gtttcccttg tagaaaagcc taatcatacc aaaactagtt tttataagtc cacacacttg 5400
tttgtaagac cacattttaa gattttgagt attttcagaa tttacgttca tcttgtaagt 5460
atattgataa agacaaaaaa ccagacttat tttgtagtaa tcaagtcaaa tgctaataat 5520
tttgtaaaag ctaaagtgc aagactgctc caaaaagaaa aaaagcacac tcagttgtat 5580
aatcattcca ctcaaatgc ccatgaactc tcaactcaaaa actaggttca aattaatttt 5640
tctaacaagg aagcacagaa gcagagactt attttaaaaa gaaagaaatg acaaatgtat 5700
tggtttgttt taatcaaaga accattttta agacacttcc tttcccaaat catctaccat 5760
tttttctgt catcatttgc tctttgtcca tagtatacct aatggcatca tatttacaat 5820
aatattgtag agtttataat ctctattttc agttaacatt aaatcattca caatttctta 5880
attttgtggt ttcatcttcc ccaaccaata ataatgtct acagattgat atagattctg 5940
cattctttca catgcagagc atcttataaa agagcatttg caatcagttc ttaagttatg 6000
ctaggatgaa cggggagcct gcaccaatac acccaaatac ctctctact cctccagtcc 6060
taagtgactc cacataacct cctcgatgca aaaagagaaa actcttaact tgccttagtt 6120
aaaaagataa acacaccttt gaatgatgga aaatgttaca atttactggg aaattttgaa 6180
atttgtttca tttatatatt atggccaaca ttactgctac tgttggtgtt gtaagttaac 6240
taggcaattc tgtctttact gaagtaaagc gacaagaatg caataggtct taaaagaagt 6300
gagagaaatg cagaggtgca tgttgaacag aaactctatt taaaagtgga gttttaagtt 6360
tcacctagc atgtgttctc tcaaaggcta aggctaagtt aagtaaggac acattatcat 6420
catgggtacc tgcaaggccc ttctctggtt gtcattattt atttatctc ctttatcacc 6480
atagcataag cccttaccct cccctctggt aggaaatcat tctatgtttc atgtggtatt 6540
cttttgtttg tattcattct tacaataata tgttttgcta ttttgcttac acttgctttt 6600
aacttacatt ttgtgttata aatcactttt gtttcatctc tttttactga gaacttttta 6660
aaagatatat gttactaaat atacctttag tttattgctg ttagctgcta attcatagtg 6720
tgtatcttcc atatttacct gcctgtcatg ccaagaaatg ccacactaaa cagactccta 6780
cttaccctct tatagacctt tgcaagtact tctggaagca gaattactag gtcattgaat 6840
gtacatatat ttaacttgac caattggtgc aggtttgctc ttcaaatgg ctgactcagt 6900
gtgcacgccc atctacaatg catgaggatt tctatgtccc cacatctaac caacacttag 6960
tgtcttagta tgttttaggt actacaacaa aaaataccat aggtgggta tcttaaaca 7020
caaacaatta tttctcatag ttctggaggc tgaagattcc aagatgaaga tgatcaaggc 7080
tctagcagat gtctggtgag agcctgcttc ctggttcata gaataccate ttgctgtgtc 7140
cctcatggca gaagccataa gagaactttc ttttgtaagg acactaatga ctttcatgag 7200
aactccaccc tcatgacctt actatctctc aaaggcccca tctcctctat catcggtttg 7260
ggagttaagg tctcaaaata taaatttcag ggaacacaa acattcagtc cacagcactt 7320
ggtattattt ggttttctaa atttgccacc ctaatatgta taaagtagta ttttatttgt 7380
gatttaattt gcatgtttct aattactaat gagtttgtgc attgttacgt ataattatta 7440
actttttgga ctttcatctc tataaattgc ctgtacatat tatttgccta ttttctgtt 7500
aaacttgctt tttcacctta tttgtattgc tttgcagaag ttctttacat tttctggata 7560

ttgatagtgt gttgggtgtg gacactgctg ttatccattc tgtcttctac taatatggac 7620
cgtgttgttc tttatgaaac cgaaatctgt aactgaagta atcatttttt cactgttttg 7680
ccttatgatt gtatttttgaa gcttttcttt aagaagtcct tcttcccttc taagacataa 7740
aaatatttta ctatgttact tattaacctt atagttttat cttttacatt aggtctccaa 7800
tacatgtgga atccaccttt ggatgtgtta ggtagattca gttttttaat tcatatagt 7860
agccagtttt tgaatataac tagttaaaat atcttggctt ttcctaatat atggtattat 7920
tattgagttc attgcatgca tttcttggca cctgggtctt gcagaaaagg aaacatgaat 7980
ctgtctcttc aaattgcttc caatcttttt ggaaagatgt gagtaacaca catggaattg 8040
aatatcatga catgatataa ttaagggcta aattacatgt tgaggacagt aagtacagaa 8100
aaacttcaaa accaaacaag ggttcccatg gtcagaaaag gcttttatatt attttacctt 8160
tgtttaaatg agacaggtgt ttttctcttc ccatcccgcg ccagggttagc tttagaagaa 8220
ttacaggaag agtttatgcc tcatcctgag ccacacctgt ttgttgttgc taaatcccaa 8280
tgaatacaac cagattcttc tctctgtcct atatgggtgc taattagaca accaaggaag 8340
aacaggttgc acgtcctgtt ctctctcaca ttgggcttta ctgatttgaa tgcaaatga 8400
gatgcaaaag taaaaatgag ttcataattt gatattgcta taatccgccc ctgttccctg 8460
agatagtgga gcagacatat ctcatctctc atatcattct tcagagaagg gtccattaat 8520
cagacattac tgatgtctga ttactgccgg ctggccatcc tgcaggtgga gaagcatggc 8580
atccagcaga aactgacagc atgcactttg agggagggaa ggataagcca ggaatttatg 8640
ctgaataagc tgcctaagta tacatgttca ataagttcta ggggaagtca caaataacta 8700
tgaaaggaga aacataacta tgtgcaattg agctttatgt ctcttcatgt gttgcatgtt 8760
caaaaaatgg tggcattagc atgatccaag ggtggagtgt tcagccattt gatgttcaaa 8820
ggtgaagcag aggacacaaa acccttacta tgcattctct gtgagtcagc caaaaccagt 8880
ctggactgct agctagatta acaaagaaaa aaagagaaag aagatacaaa taagcacgat 8940
cagaaatgat agaggtaaca ttacaaccaa tcccacagaa atacaaaaga tctgtctgaga 9000
ctcttatgaa cacttctatg tagataaact agaaaatcta gaggaaatgg gtaaattcct 9060
ggaaaaacac aatcttccaa gattgaatca gaaagaaatt gaaaccctga acagaccaat 9120
attgagttca tacttaaatc agtaatttaa aaaacttacc agccaaaagg aaaaaaaaag 9180
gccccaaacta gatggattca cagccaaatt ctaccagacg tacaagaaat agctaggacc 9240
aattctagtg aaactattcc aaagaattga gaagagactt cttcttaaat cattctatga 9300
agtcagcatt accctaacgc caaaacctca caaagacaga atgaaaaaag aaaattacag 9360
gccaatatcc ctgatgaaca tagatataaa aatcctcaac caaataccag caaaccaaat 9420
ccagcagcac atcaaaaagt taattttcca aaatcaagta ggctttattt ctgtgatgca 9480
agactggttc aacatatgta aatcaataaa tgcgatttac cacataaacc gaattaaaaa 9540
caaaaatcat acaattagcc aggcattggtg gctcacactt gtaatcccag cactttggga 9600
gaccatggtg ggcaaatcac ctgaggtcag aagttcgaga ccaacctggc caacatggtg 9660
aaaccccatc tgtattaaaa atacgaaaaat tagccgggca tgggtggcagg tgcctgtaat 9720
cccagctact cggagggctg aggcaggaga atcacttgaa cccaggaggc agaggttgca 9780
gtgagccgag atcgtgccat tgcactccag cctgggtgac agagcaaaaa tccatctcaa 9840
aaaaattaaa aatttaagaa aattaaaatc atacaatcat ctcaatatat gtagaaaaag 9900
cttttgataa aattaaacat cccttcataa taaaaacact tagactaggc atcgaagaaa 9960
catacttcaa aataataaga gccatctgtg acaaaccac agccatcatc acactgaatg 10020
ggcaaaagct ggaggcacta tccttaagaa cagggaaaaa gacaagaatg ttcactctca 10080
ctactcctat tcaacatagt actagaagtt ctgaaagag caatcgagca ggagaaagaa 10140
ggaaaatgca tccaaatacg aaaagaggaa gtcaaattat ctctctttac tgacaatatg 10200
attatatgcc tagaaaacc taaagacttt acaaaaagtt tccaaaactg ataaacaact 10260
tcagtaaagt ttcaggatac aaaatcaatg tacaataatc agtagcattt ctaaacaata 10320
atgtccaagc tgagaaccaa atcaagaaca caatcccatt ttcaatagcg acacacacac 10380
acaaatgaaa tacctaggaa tacatctaac caaggaggta aaagatctct ataaggagaa 10440
taaaaaaaca ctattgaaag aaatcggaga tgacacaaat gaatgcaaaa acattccatg 10500
ctcatggatt ggaagaatca atattgttaa aatgtcccta ctgcccagag caatctacag 10560
attcaatgct attcctatca aactaccaac ataattttcc acacaaagtt agaaaaagct 10620
tttgtaaatt tcatatggta caaaaaaaa aagccccaat agccaaagga ctcctaataa 10680
aaaagaacag agccagaggc ctacacattat ctgacttcaa actatacttt aaggctacag 10740
taatcaaaac agaattggcat tgggtcaaaaa cagacatata aaccaataga acagaataga 10800
gaaccagaa ataaagccac acatctacag ccatcagata ttcaataaaa ttaacaaaaa 10860
taagcaatgg ggagagaact ttctattcaa taaatgggtg tggaatagct agctagtcag 10920
aagcagaaaa atgaaattgg actcctatca ctaaatacaa aaactaactc aagatgcagt 10980
aaagaattaa atgtaagacc acaaacaatt aatacaagaa ccctagaaga aaacctagga 11040
aatactgttg tagacatcag tcttggcaca gaatttagga ctaagtcttc aaaagcaact 11100
gcaacaaaaa caaaaattga taagttggac ctaattaaac taaagaactt ctgcacaata 11160
aaagaaacta tcaacagagt aaacaaacaa cctacagact gggagaaaat atttgcaaac 11220

tatgcatctg	aaaaggtcta	atgtccagaa	tctgtaaaga	acttaaacia	ctcaacaagc	11280
aaaagaaacc	aagtaacgcc	attaaaaagt	aggcaaagaa	catgaacaga	tgcttcacaa	11340
aagaagacat	acaacgcagt	caagaaacat	atgaacaaat	gctccacatc	actaattatc	11400
caagtaatgc	aaatcaaaac	tacagtgaga	taatattctca	taccagttac	aatggctatt	11460
attaaagatt	aaaaaaataa	catgctgatg	agactgcgga	ggaaagagaa	tgcttaaata	11520
ctgttggaag	cgtaaatggg	ttcagccact	gtggaaagca	gtttggagac	ttctcaaagt	11580
acttaaaatg	gaactactat	tcaacctagc	aatcctactt	actgggtgta	tacccaaagg	11640
agtataaact	tttttcccag	aaagacagct	gcactctcac	attaattacc	acagtattca	11700
caatagcaaa	gatgtggaat	caacctagat	atccatcaat	ggtggattgg	acaaagaaac	11760
tgtgagatat	atatgtatat	atatctatat	ataccatgga	atactatgta	gccataaaaa	11820
aggatgaaat	catgtccttt	gcagcaacat	ggatgtaaca	ccacaaggaa	ggcactttta	11880
tctcctcttt	acaggtaaga	gaaccaagct	tctgaaatta	aggtccatag	ctggaaaatg	11940
atggagggga	gatttgaagt	catctaggca	actccacaca	tgtgctcttt	ccactaaatt	12000
gttctactgt	caggaaggga	ctcagctaag	acagaagata	aaattattaa	aatctaaatc	12060
aattcttctc	tcatttccatt	ttttaaatcc	atgaagatta	taaattcctct	atgctgtgct	12120
agctaaacttt	ttcttgacag	atacattagg	tatacttatt	agagaaaaat	attctctttc	12180
tcatttccct	gtatcagttt	ttgggtgagga	aggcaaagggt	aggaggaact	gtaatagaga	12240
aagatgaagg	aagctgatgg	atatattgac	atgtgtatgt	acatctagtg	tgaacaatct	12300
atagttggaa	gaaagggtgtg	gatgggtatg	ctttttgagg	gaagtttttg	agaaaagaag	12360
taatatgaac	tatttctaaa	tttcctgata	aagttgtaaa	tacagcatag	tcttcacagg	12420
agaatctatt	tagtttatca	tcattcattca	gcaaatacag	catgatgtta	ggcactataa	12480
aaggctaaga	aaaatgattc	tctctctctc	ataaactaat	ccaatttaga	gatttagaag	12540
acaacaaatc	tggagaggac	atgaaccttc	taaataatga	ccttcccttg	ctttgggtat	12600
cctggtttta	aatattttta	gtacagcttt	aaatagatcc	aaatgagata	ttttcctctt	12660
ttacaaaagc	aattcaaaga	tctaggtttt	tgtgttacac	tgagaattaa	tacttttttc	12720
tttaaaatcc	ttaattgcaa	atcttttaat	tctataaata	ttttgccttg	tgatctcaga	12780
aatataagcc	aatttgggat	atggatatct	aatatattgc	tacttggtac	acgtgagtag	12840
tgacagatgt	ctgtccattt	ctttctgaca	ttccacaaag	aaacactgaa	gaaggaccag	12900
tgcaatcaaa	gaaatgactg	atggcatcac	aaaatatcac	atcccatttg	atgatctgat	12960
tacctttttg	tttaggggtga	tcagaaagtc	acagtttcat	ggcaccctcc	acaccacac	13020
accttgtatg	acactggatc	caactgcttt	ctccaataga	cacagcactt	aaagatgtgg	13080
cagttaggct	tgaccccaag	aaggccaaaa	agccttctgt	gagcatcact	cagtgtctcag	13140
gttgactaag	ctctatccag	gcttgagaga	atggttcata	gctgacttct	tggatccaaa	13200
aaaaaaaaaa	aaacacctag	agttttatac	agatatgata	cgaacttaaa	aggactgcac	13260
taaaaactac	caagattatg	attctttattt	ttggagagta	aagaaaatag	gctgcctttg	13320
gagaggggtg	caacagtttc	tgatcctctt	acaaactgct	tgctgcccac	cagtgggtag	13380
gaggtcttag	tgagaacctc	cctgcatgct	catcctgagg	taggcactgt	gaaggcgta	13440
acaggctctg	aagctacatg	gccctgggtt	cagtgaactc	tgtgggtgca	acttgggcaa	13500
gtcacttctc	cttctatgaa	acgtgaataa	tcatagtact	caccttagag	ggctgatttg	13560
aaagcaaatg	agctcaaaca	caatgacatc	tgtgcttggt	gcataatagg	cagacaacag	13620
tgattcccac	tattataatt	attacagtct	taccaaggag	gagctttcca	caaataatca	13680
attacctaaa	atgtccaaaa	acaggaaaaa	aaaatctctt	ccgataattc	atgtgtaatt	13740
ttcttttttc	tctaggagca	ttgatctcaa	cctgatgtaa	agcaagcact	ttaaaaagtc	13800
ttataaaatt	ttcctggtaa	atgcaaaaact	ttctgataaa	taaattctca	cctttttatc	13860
aattttgtta	ttcaacaaaa	atatactaca	taccaacagc	atgcaaagca	ctatgctaga	13920
ttttatagac	tatgaaaaga	taaattgcca	tctctatgca	taaaggggtt	gccatttaat	13980
aaaagagact	atatatttgc	ataaatatat	agtgaatata	ttgcataaat	atataatata	14040
tgttttacatt	aaagaataaa	aggtataaga	gggataagaa	aaattgagac	agaggggaaga	14100
caggtcagtt	tgagattaac	gaatatcccc	aaagaaggta	ttatctgaga	ttggccttga	14160
aggatagtgt	tgattcagga	acacagaact	tgacagaatga	gaaggttgtt	acagaccaa	14220
ggaacagcct	gagaggcgtg	agtatgcagg	aaaatgaggg	ccatgcctga	aagtactggg	14280
ggtgttgaa	atggagccag	gcaagttggg	cacagaggga	gaggaccttg	aatgtctaac	14340
attgtggaca	gaggctcaaa	ggctcaaat	ccctattttt	accttgagtt	caatccttgt	14400
ggcaatgaaa	cctcagtgaa	gctttattta	aggctaaaag	tgtcttttaa	aaatccctct	14460
tatataatat	cctttgcatg	ttactcttgt	tgtaattagg	agaaagcaat	aggatctaaa	14520
gttttttttc	acagcatggg	tttggtttct	ttaatcttaa	ggagctcacc	tggtgttacg	14580
ttggaaaaaa	cagcttttat	atctcattta	tattccatat	gccagtctgc	agtacatat	14640
ctatctgagg	tttacagtg	tagccacaaa	acactcccta	agtgaataca	ttgactgctg	14700
taaggggagc	cagtcaggaa	gcacctgcag	agaaaagcag	gcaacatgta	taaacagagt	14760
taattcagga	atgaaagctg	aatggctggg	cgagtctgtt	tgtttgagtt	gacagcctct	14820
ccctcactct	ttcattaaat	atccaactaa	ccttcaattg	ccctcttggg	acttaatctc	14880

agtgttaattt ccagcatgtc aaaattatca agcagaaaga gatactaccc tgaaagaggg 14940
tcttttgttc aatgctagga gacaaactcc aactacaaaa ttctagaaat gccctaaaga 15000
gagagatagg atagatttac aaattgctaa tgctattagg ttgtatagat aacaatagat 15060
ttataacaac ctggcacaca gctttaaata tataagtttc tctgaaactt ctgggaactt 15120
ggaatgccag aacgttgcca aaaagaatgc ttctaataat gaaagccatc atctgccatg 15180
gaaacaattt cagggctctt agaaagctag ttatacata agctccattc tacaataaaa 15240
cttatgttca tgttttttct gattttcctc ctgctgtaaa ttcattttat cagaattctt 15300
tttaccagtc cctctgcccc atttctcaaa gcgttgctct cagactacct gtatcaccta 15360
aagattctaa ggccctctcc gatgtagtaa atgagacttt tctagagaga ggtccctaga 15420
attttataaa gaaggatcct ttttattatt gtgatcacca aagttacttc tgcctagatt 15480
cttctcatgt tattttttaca gctcctatct tcccagacaa cctaacaatt caaagataaa 15540
attggtgctt ggttttagaca ttcatagcag gcacgggtgcc agattgatga tgtcatccag 15600
agtcaaaaac ttcatccaat gccttcacca aaaagttaca aatggccagg aatcaaatgt 15660
ggttgaactt attcagaggg taattacaaa acaacttct ttaaataccc aactgctatt 15720
tgcttttttc cttctaaatt gtatcacttc tctccctgtt ccattttgtt tgccttttta 15780
ttttttggaa tccctcacct ccatactgag tagtagagct ggctgtgggt gatgagagag 15840
aaattgttat aacaaagtca ccctttcaaa aacatgtctt ccaaaagaat tttgtttcta 15900
gcagataaac cccacaccac ctacagctaaa tggggctttc tttatttaag taccaataaa 15960
gacatatttt ggatactagc aatttatttt cctacaagtt ttatacttta ggtcaataaa ttacttgata 16020
gctattacca aatctatatc tctacaagtt ttaacttta tttacatcac atttaacagg 16140
acttattact atgtgttcta caaaagaaac cgaagtaaaa tagaagactt gggtttcagt 16200
gtggttgtgt gattgagtgg gaagaggcgg accctacaga tagaagactt gggtttcagt 16260
cccagcttac tagtatctgc gtgatgccag ggaaattcac ataatgcctc tgagtcacag 16320
atttctaaca ggaatgaaga tacttcttcg cagaattgtc attagagtta agaagataa 16380
caaataatgt ggttcctgat gaggtattta tgaattcctg agcatgctaa ggaagttata 16440
acttgtttct tgatccctga aacagctttc cctatatattg tgtgtgtgtg tgtgtgtgtg 16500
tttcagtcac gcaagttggt ttttcttctc attccttgag aatttaggat attttgtgag 16560
cacatttggg tcttctgtcc aacatgaact gtagtacctt acccacattg agatgacact 16620
atttctacca agtgagtgtc aggggatact gcaagccgaa tgccaggtgt gagagaccac 16680
agcatcacia taccgtggca gtagattaaa gctgtgcata tggactaaaa gcagtggctt 16740
tgcttctcct accttgggtga cataaactga gtaacaaatt tgacctaata ctggaatacc 16800
acctaatctt ttttctcctc ctgatttacc cttagagtcca caattgacaa taatttaaaa 16860
attttggctc tctcttaaat ccctaagtcg ggctagagga ccatcagcaa ttaactacca 16920
cagagctaag acctgtaatg ccaggatgga ccttcatagc cttatgagta gcagatcaat 16980
aaacttacct aacattttat atctgtttta ctcaaattga ttcagtaact ttgccaagat 17040
atctttgttt tacagggttag aaaactgagg gtatacgtc aaatccagga ctgaggcagg gttttctttg 17100
tgcccagttt gggaaaagta gtatacgtc tctctgtctc gtatctctct gctactcctt 17160
tcaccactca aagcctctct gaatatecta ctaggtcccc actctagcac agtagaatta 17220
ctatgggtgt ttagcaagat atcttctact ccagaaacct tctagaccaa tcgaaaccaa 17280
cttgggttagg ttttttaaaa atatgagtgc aattttttta attcatcaaa tgattctgtt 17340
aattcttggg agctgagatc caccaattta aataatgatg ttagttctgt gaaaaaattt 17400
gtactgtgaa taacatttaa tcaaggatat attcctatta taaaatatat tattaacaca 17460
ttgattgctt cttgttgtgt aacagggtgga tgagatatatt atagattcag cctggaagaa 17520
tagtttctct aaagaaccaag tagtcagact gacgtatgta tgtttgggca aaggtggaat 17580
aaattatata cagggaagaa gaacaaagga gacagggaact ctcattgtatt gtatgtctcc 17640
cacaagactg ggggaaaag gaatttttca taaacattac ctttaaagca gtcttgaagt 17700
atggactagg ctcttggtga gtcaacaaaa agactaagat tcaggaaggg taagaaatat 17760
atagggctga ccaccgtttt cagtttccca aagtgcagaa accaggaatc aaacccatt 17820
gttcaaagtt gaggcctgga acctaccaga acccatgacg tggggaaaac ccagcagctt 17880
aacttattgt gcaccaagtt atattatgtt gacaattata ttatttcaac cacgttaagc 17940
gtcgttgcat ggctataaaa tgggttcaca aattttacct gtaatgtaac cgaatgacat 18000
aggcaaactt taacaaaaaa gatattcctg ttgtaataaa ttttctttct gtcattgtgg 18060
aaggcatgcc ctcatatcag ttgcagatat tgctcagaag tttcaattgt gttattttga 18120
agggggaaga agcagaacac gcatgtcata tacacaaatc catgagcctg tatgactcat 18180
aaaactacat gataaagaaa aataatatat tcagattttg atttatttga agaaaataat 18240
atctctttaa tcaccaatag actaataatg ctttgttggc aggtgtactc aaagtctctt 18300
tatcccttcc tgagtaacta gtgacttccg taaggatttt ataacataaa ttgggttaatt 18360
atgtcttgac ttaggagggg aaaagcatat aaatgctaga actttctaga tttcatgttt 18420
cctacaatac aattctcctt taccatatta ttgtagcaac attattatac tcctgtgaac 18480
tctgttttca tcttttggat actatataat acctggtaaa aatgttaatt cctcagattt 18540

aagaagtaaa attagtcac tgtttgccaa tttgacataa aattctagtt atttagatct 18600
ttatatccca gagcctaaat gaacaaaaat acataaattg tctcagaatt tccttttagc 18660
caaaagattc agggagatgg gcctctagag tttttcacag tttttttttt ttttgtaaaa 18720
aaaaaaaaa aaaaaaaaaa gagagataac agatcaatat atattagttt caaggttttt 18780
tgtttttttt tttaaacaaa aacctgtaat tgcttttcct attttaacag tatttaaaag 18840
tttagttcct caggtaacag aacttgaacc tgtttatatg atcaaagttc aagaaattgg 18900
gcatgtttta tttggagaag actcggggac cacaatattg ttgtcttcaa atatttgggc 18960
tagaggagga aattatttta tgtatgttcc aactggtaga cctaagcctt atggaatggg 19020
agatataggg agacatattt caactcaaaa tgatgaactc ttaaaagcag agctgaccaa 19080
agagaaacaa gcctcttttag aaaattaaac ttactatctt ttttaattact gcactgtcat 19140
tagagggccca attgtcatgg accctgtaga agtgattcag gtatcaaata tacaattgat 19200
tagcctaaga aaacatgaag gcttcttcta actctcagag cttgttaattt tgatgatgat 19260
tttttatatc tgtcattcct agctgctgta acaatccttc aaattaatgg gggaaatgca 19320
ctgaaaacat aatgaaagct agaagaggga acatatgaaa tgacctggg tcagaatgac 19380
atgagaggat cagcacttga cactctcagc aactgaggga tcattcaggg gaggaagata 19440
caggtaagac tgaaggacaa ttccaggtgt attctttgaa aatgtacctt tcttttgtgt 19500
gtcacagtcc agaggaagat ggtgtgaaag tagatgtcat tatggtgttc cagttcccct 19560
ctactgaaca aagggcagta agagagaaga aaatccaaag catcttaaat cagaagataa 19620
ggaatttaag agccttgcca ataaatgcct catcagttca agttaatggg aaggagggtcc 19680
ccttctatgt gatatgaagt tgtctattag gtccatgttt tgacgaatct caaatttatt 19740
tgtcattatt tccatttcaa ataatagcta gaattcagat gaaaaaattc aagttaaaga 19800
tgtgacattt caaggtgtat tagtctctaa cgtaagcatg tctgaagtta gtcacccagt 19860
ggttttcccg acagtaattg attggcactc atcccaaat ataggcaagc atttacaact 19920
aacagagagt taatcccacc caggcactgc ctccatgact aagcaagtga aaatactagg 19980
ggtttagcaa taattgtttt tctgggtggg accttcctaa aacacaaatt catgtgttgc 20040
catactttta ttgatagttt ctatatatgg tgatatacaa tttttgttag ctttttttcc 20100
tatgggcatt tgggaaaatg gcaagccaac tttgaagttg tttagagtcac tttaccatta 20160
atgctttaaa aatcacagtc taggaaaaca tcaactgaaac tatgtgtaca ttgttccact 20220
tttctctttt tttttgttca cccttagccc attataccat tatcacttcc ctcaattaag 20280
gagaacaaac ctttatcaag gtctatctct atggccttta ccttaagtaa ctaatttctt 20340
tttatattcc agtgacgtac gcaaattcac ctttatagaa gtgaaattca cacaaaaaga 20400
gttgaggaat tcagtaatta aaaggagcta agaatacaat ttaaatctct aatttcttaa 20460
aaggctccaa ttaaaaaagg tttctatagt caaacacatc ttaaaaattc tggctttgat 20520
actcgtttct tggaaattct tcttatagtc gtcataatga aaattctaa ggcagccagct 20580
agagagaaac ttgtttaccc tctcctgcta agctgtttgc acagcatctt cttccaacag 20640
acaagtatag atttctccta caaatttcaa tggataccag acctaagtgt tacagaagag 20700
attcagggca agcgattttt atcagacatg aaacaggaca ctctgccctt gtaagggtct 20760
agctgacact tcaagaggaa accagataag gaagtaaaaa atgtgaggta atggaatggg 20820
cagatgtttg ctgatgtgag aacgagtcag ctacttaggg aataaagctg aggacctctc 20880
ccagccagaa gggaggaacc tgacaagtgc ttaatccatc ttctttgtta gatggggaag 20940
caaatgaata gaagtgtgta aacaatgggc attctgataa ttacatgat gctttctgtg 21000
taatttccaa taaatagtta atttgtcagg aatgtaaaag cctgaactat ctgaaaccag 21060
agtaaagcat aaattgttca ttggctgcct ggtctttttg tttttgtag gctcagcttc 21120
taaacttcag cttattttta taattgtact aaattaaatg gtaggatatg ctaatggaga 21180
acctgatttg agagtcacct gaggtgggc atggtggctc aagcctataa ttccagcact 21240
ttgggaggcc gaggcgggtg gatcacctga ggtcaggagt tcaagaccag cctggccaat 21300
atggtgaaac cccgtctctt ctaaaaatac aaaatattag tcaggcctgg tgacgggcac 21360
ctgtaatccc agctacttgg gagactgagg gggaagaatc acttgaaccc gggaggcgga 21420
ggttgcaagt agccaagatc gcgccactgc actcaagcct gggcttgaca gagcaagact 21480
ccatctccaa aaaaataaaa aataaaagag ttacctgacc aattctaact ccactaagtc 21540
accacaggac cacccaaata attggctcat gcctttgtct tcattttctc atctgtaaaa 21600
ttccaatggg aatgtttgtt cttcctgaaa tcacagagag attataacga tatacaagga 21660
aatagaaaac acaatgtgaa ataaagaggc tgttactaat gagaaaacta ttatgttgtg 21720
catatgcttt ggaaacctga aatcattaat ttgagtgatt gactagtagc agaaagatag 21780
atccttgaaa gtttcagaat gttcaatgta gaaagaacag tgtttgttag tgatatggga 21840
gcctaggggg tgttgctttt ctggccagaa acctctgtgg ccagtgggtg gtgcctttgc 21900
ccaagttttg ctctggccca ctgggcttgt tctgccact tgacctggca gactgtgccc 21960
accttccgct accagcctgg atcccatgcc caccaaggcc aaccaggca tggagctgtg 22020
agggttgtct gagcgagcac agggctctggc cactgcccac agccaggcac actggctgca 22080
gcatgacggg cagctccagg cactggcaca ggtgtgtgt ctctctgtga ggctgtggct 22140
ggacaaagct cactgcaagc agcttccctg gcaggcacct gggaatgtgg tggcaccag 22200

gaagcttggg	gatgccagga	actgcagggg	cccaaagagg	gagtcacaac	cctggccttg	22260
ggagctccca	ggtctgggat	ccctaaaggg	ctgcagcttt	tctctctttt	taccacacat	22320
gtggccagca	aggggtatgt	ttcattcctg	tttgtgttac	agctctttta	gtcttgctat	22380
ttggcaggtc	ctgagttctt	gtcctgagac	caagaagaat	gaggtatgca	gacaagtgga	22440
gggtgagcaa	gacgaagaaa	ggtttactga	gcaagagaac	agctcacagg	agaccacag	22500
tgggcagctc	ctcttcatag	ccagggtgtc	ccaacaagtg	tccagctcct	agcaaagagg	22560
aggccctgga	ggtagaagct	cctctctgca	ggcaggttgt	cctgttgagt	gttcagcttt	22620
cagcacacag	taggcagtag	gccctagagt	ggtctatctc	ctctctgcag	gcaggtagtc	22680
ccatggtctc	ccagtcacct	ctccatctgc	aagggtccaa	tgctgcctcc	agcacctctc	22740
tgcccacccc	tccgtgcctg	accaagctgc	tccccacca	gtgggcaact	cagcccagcc	22800
ccattgtggt	agctcccagg	gtggcaggct	ctgggggggt	cccagggatg	ggctccaagg	22860
actgtccacc	ttctccccac	gccctccctg	cagtggccat	ggtcaagaat	ggcaatgtgg	22920
ggccaggttc	cggagcagga	gaggctccag	gcctgggagc	aggctcctgc	tggtcacgtg	22980
agggtggggg	tggcacagtc	ggctgcctca	gggatgtggg	acacagggga	cccaccacca	23040
tcactgctac	tcccgcctcc	gtcctgtcta	ccactgctcc	agacagcctg	tagctgccat	23100
cactagcact	taagaaaggc	acattcagtg	gacagctcag	gaaaatcttt	acgtcaattt	23160
tttataggca	aaaacattgt	ttcctgggca	aacaaaattt	atggactacc	aataaataga	23220
aaactgtaga	gattctagat	taagtctaga	aataatcctg	tagcccaaga	tttatttata	23280
atgtgtcaag	aatctgtatt	ttgttttgac	aaaaaaaaaa	ctgtgtggtg	tgggtccttc	23340
aggagacaca	gtgtgacaaa	gcaaagctaa	aatcaacttc	tttgatttgc	aaacaccaag	23400
gctgtagtca	agcagctcac	tgccatagt	tcagatgact	ttgcttcatt	tttcatcatg	23460
atactttag	tctatagagc	cctgaatatt	aactagcttt	ctcccaactc	agaaccgtgt	23520
taggaggtgg	ttgctttcaa	aactaaagt	ttaatgttta	tttccatttc	tataccagga	23580
aagtaaaaat	ctttggtcaa	aattagaaat	ctttaacaac	tagttacttg	tgtattgaca	23640
gtttgtttcc	aggtgtaatc	attctccctt	aaaatccggt	tatattcacg	accattatac	23700
ttatcctggg	atcattcctg	gaaatggcta	acttgcctcc	tgctcagact	aagttgacaa	23760
agtttcaatt	gaagaattct	aactttatgc	tattttccac	tttattgcat	tacaaaggac	23820
aaaatatata	gttttcttaa	aaatgaaata	aatttactgc	cttaaaactac	atttgacggt	23880
aaactgagtt	ccttccatag	aataaccact	aacagcaatc	gatggctcctg	agcaattgac	23940
tcttcaccat	acaatgattt	gggatgcctt	taagggtata	tttgaattga	atattttcaa	24000
aagctcccac	ttttagaggt	ttatcatcac	tagtttcccc	agtggaaattt	gtagaaagtt	24060
agtagaatga	aacaatctta	ttttgtataa	tgaggaatag	aatactgaga	atgtgtctga	24120
gaaacatggc	actggttagga	aaaagtaaac	agtttattct	catctgctca	ataagctaag	24180
tcattttaac	ttgaaaatca	tcaaaatttt	catgaaacct	tccaccaact	ttatttttcc	24240
ccagctttag	taagatataa	ttgacaaata	aaaattgtat	actgtataca	acatgatgct	24300
ttgatacatg	tatacaagtt	taaatatttg	tgtttcctta	gtcaaaactcc	tcactttttt	24360
ggaagttgac	agaatttaat	cttggattgt	gtccaataac	tagctttttac	cactattcag	24420
tatatttttg	ataagaaaca	cataacagtt	tattctttta	aaaagcaatt	ttactattta	24480
ggaactgtgt	ttaaaaagca	ttttaaatat	catttatgca	agagttttca	aggttttttc	24540
attctaaacc	ctttaacca	aaaaaaaaaa	aaaaagattt	atgtgaaatt	cgaagtaaat	24600
agaagagatc	aaagcagatc	tgttctggct	gaggctgagt	ttgagacctg	taagacagtc	24660
tacttgccat	atggcttggc	tggtgtccca	cccaaatctc	atctcgaatt	gtagcccca	24720
taattcccac	atgttgtgag	agggacctgg	tgggagataa	attaaatcat	gggtgcagtt	24780
tccccatac	tgttctatgg	tagtgaatga	gatctgatgg	ttttataaga	ggcttcccct	24840
ttcacttggc	tcacattctc	tgacttgctt	gccaccatgt	aagacatgcc	ttttgccttc	24900
ctccatgatt	gtgaggcctc	cccagccaca	tggaactctg	agtccattaa	acctcttttt	24960
ctttataaat	taccagtcct	cagatatgtc	tttatcagca	gtgtgaaaac	aaactaatat	25020
aacctgtttc	ctctgtccca	tttatccatc	ttctgaagt	gaatgcaaag	aagctttacc	25080
cgaactgct	ggaaaacat	agttctctat	taatacaaac	tatttgtggg	ctttagtcat	25140
ccactatttg	tgctttactc	accatttgct	tgtgatagta	tccacctaat	tagaggctgc	25200
ctataagtct	ctacaaaaac	tgtacacaga	tgttgttata	tcagatagcc	attctcctaa	25260
ttaatctata	tgttcaactg	tctagaatcc	atatatgggt	agtatcctct	gattattcct	25320
ggtcattgag	accaaccagg	aaaatatcaa	attatcacta	tttgttttat	cttctttttc	25380
agcaatgagc	tcatcaacag	gggagttaac	tgtccaagca	agtaagtcaa	gttagcttat	25440
ataaacaagt	tcaattttca	catcagaaag	gacattttca	aatatttgct	catacttgcc	25500
catctgtcct	ccagattttc	tttgagagat	aataactatt	tgtacgatag	atttaaatac	25560
attttttttc	taactcatgg	actgatcttt	tagtcatggt	caagaaaaaa	attgccatgg	25620
taaccttctg	gggcaatttg	aagaaagcat	ttatttttga	ttgggaatat	tggacttggt	25680
tttctaattt	ttaaaaatgc	cataaaatgt	actttctgct	acaaaaataa	ataataagaa	25740
agtaatcaat	aggaaggaca	taaaacccat	tgtctgtgac	tgacaatttg	tctgtgaaat	25800
atgctaaggt	caggagttcg	agaccagcct	gaccaacatg	gagaagaaaa	cccatctcta	25860

```

ttaaaaatac aaaaattagc caggtgcggt ggcaggtgcc tgtagtccca gctacttggg 25920
aggctgagggc aggagaatca cttgaacctg ggaggcagag gttgcagtga gccaaagattg 25980
caccactgca ctccagcctc agcgacagag tgagactcca tctcaaaaaa gaagaaaaaa 26040
atatgcttaa tagattcatc ttaatcgcta acagtggctt cattaaatca cttcaaataca 26100
ctgtggccta aattttgaaa gattttacaa aaaacagtga tgaatttgag caatgatgtt 26160
catgcatttg cctctgtgac ttgcaaacac cctaagtatt tttatccatg tgtttattca 26220
ttcaacaata tcttttaaca tctaccaagt gccagaaatt agaccaggag ttggtggtac 26280
cattgtgaat aaaacatgat ccctgctcta aaattagaat tccaaagtag agaaagatat 26340
aaataaatca ggaagtatga aaataatgtg attaatgcta tgacagagga agtgcatagt 26400
gctatgagag ttgatcagag agtcagctaa cctgttctca cacagtaaga aagtgaaccc 26460
tgaaatgtga gagagaagag gccatgaatc cagtgcaggg tggggtaagt gtcctgggca 26520
ggaggagtga tatacgaaaa tgtcttcagg caagtaagaa tggggtcatt tcctgtaatt 26580
acaagatgtt tcttataact taatgatctc atcttttttc aggttgtggt aaacgagttg 26640
ttccattaaa cgtcaacaga atagcatctg gagtcattgc acccaaggcg gcctggcctt 26700
ggcaagcttc ccttcagtat gataacatcc atcagtgtgg ggccaccttg attagtaaca 26760
catggcttgt cactgcagca cactgcttcc agaagtaagt tattgacctt aagttagaac 26820
ccacttctgc taaaaagccc tgagttttgt catattcttg gtaacaatta atgtctcaaa 26880
tattactgaa gtaaaaataag aaaaagttat ttcaggttct tttctaaaat aatgttacac 26940
ttgcatactt aatcagaaat ttgatgggaa taagtaacag tcattatcct agtatccatc 27000
aatcattttcc tcaaagtttt taataaggaa actgtgtaaa gaaatcagaa ctatttttgtg 27060
acatccctaac acaaaatatt cactaataac atgtaccatt aatcttttgt caaacaatgc 27120
tctccactta aaactagtgt ctgtttctgc caaacacttg ggccagtctc atactgatct 27180
taaataatca aactaattcc aaagtaaaat ggaaattttc aataaatgcc ggaagttggt 27240
aaccgtgatg atggagaact gcagatcaaa tttagagcat tgacatatga agatctgtgg 27300
aatcagaaca gtttacaacc aaaatgagag attgctagca tgataaagac aggcacttca 27360
aaagagattc ctcgagatctc ttcacaatag tgacacaaaa gacaaagctg aagtgaagaa 27480
ttcccataat agagcatctc taattgtttc tgaatgcata cattttatta aatatatgat 27540
taaagactt tttataactt ttaatcttac ttttcaagat aataaccagt catttttatc 27600
actattacat ttagaatttt agatttgttt ctaagtagat taactgtatc gcctttcttc 27660
ttcattgcca attattacag taataacaaa gacttcttga gtatctctat ataataagggtg 27720
gcagcaggat ttagtgggaa aaatatgtcc caggcagttg gagagctggg caaattattg 27780
aaccttagtg tattaggtaa tagataggct agatcttttc acattctttt tgacctataa 27840
aattctaact tttgttacta taataaattt catttgccta ggagcataaa tctttataga 27900
gactcttaat attccaaaga atatacatat taagaatcta ggcttggcat ggtggctcat 27960
gcctgtaatc ccagcatttt gggaggccga ggcaagagga ccacttgagc tcaggagttc 28020
aagaccagct tgggcaagat agtgaaaccc catttgggcat ggtgggtgcat acctatcatc 28080
ccagctactt gggaggctaa cgcaggagga tcccttaagc ccaggagtgt gaggctcctg 28140
caagctatga ttgcaccact gcactccagc ctgagtgaac atgcaagacc ccatcttaaa 28200
aaaatagtaa tatattttta aaaataatct acataaattc ttaatgtttg aaagatgtga 28260
gagctcagta agctgatata ttagaaagcc agaaatccct tatgctgggtg tctgggtttt 28320
caaagtaatg ggaaacttac tttgccaag ttagccattt ttgtggtaga tagttctatt 28380
tttgcaata tctttatagc attgaacacc aaatctatac tctattaact tctaccatca 28440
atatttgttt tctttttaat ctggaacac aggaaccaat tttatttctt cattcatata 28500
acagctattc tttagtttct ctttttcaga ccaaacataa aatgagggag aatatccaaa 28560
ccataagtga aaataaatat cattactgtg agctttagtt tgctaaggat aatgacctcc 28620
agccctatcc atgtccctgc aaagggcatg attttgttct ttttatggct gcatagcatt 28680
cccatgggtg atgtatacca cattttcttt atccagtcta tcaactaatgg gcatttaggt 28740
tgattctatg tctttgctat accgaagagt gctagaggga gaggatcagg aaaaataact 28800
aatgggtact aggtttaata cctgggtgat gaaataatat gtacaacaaa accccatgac 28860
acaagtttac ctgtgtaaca aacctgcaca tgtaaccctg aactttgaaa aaagtatata 28920
tatgcacaca catatatatg catacatata tatgtgtgta tatatatgca tatatgtgtg 28980
tgtgtatata taaaaaaaaa tatatatata tatatatata tataattacc tcatttttcc 29040
agaaccaact tccagatgcc ctaccacatt ggttcttatt ctctgaacat tctgagacttt 29100
gtcagtgtct tccttaaaat atgcttccaa taactaaata caccaagaca gatgtgtgac 29160
tagtgtcaca cataacaaaa taaagcagga agtcttctga aaaatacaaa taatgtaaat 29220
tggtgggaga cagtgtttta taaagggag agcagagaga ggcaggcaga tatgtgatgt 29280
gaatcaata gttaaaccta tccaggcttt attttcctta agtataaaac acagtcttta 29340
ctagatgac tttcattgct actaaatgat ttttccgatt cctgtatgta ccataatcca 29400
cccattgccc aagcccacaa gctagaagtc aaccgcattt accacatttg atcatctctc 29460
aaaggactat gcagtcattc aatagacttt acccatcca ttcttgacct tcaagaatct 29520

```

actccccaga	aagaacaaac	atgtttttta	aaaatgtaaa	tgagactaca	ttattctctg	29580
gcttaattat	ccagtagatt	cccatatcac	ttcaataaaa	tttaagcact	ttatcatgac	29640
ctataaaaca	ctctaaaatc	tagtccctgc	ttacctctcc	aagctcacc	ccaaccattc	29700
tttcccttgt	gttctgactg	cagcccaccc	aacccaagac	cttgggattt	ttgcctggaa	29760
acttgtttcc	ctcatctcct	cacactgacc	ctcttttact	atgtcttagc	ccaaatgcgt	29820
tatcaaaata	atcataatga	cctgttagta	ctctattccg	ttaccctatt	ttattttgtt	29880
catagccttt	atcaatgttt	aagattattt	atctattttg	ttgcttgctt	tgatcctttt	29940
ccttctctgg	aatcttatac	tcctgtgagc	aggcacctta	ggctcctgtt	atcactttat	30000
ccccagcagt	tcagataagg	ctcagcacac	agatgctcag	taaatatttg	tggaagggat	30060
aaatgaatga	tattttatgt	gtattacagt	tctaaaattc	aatagttttg	tattaaatat	30120
cagttcta	atggcattta	tatgatttta	tctttcaaaa	cattagcaat	agattatatt	30180
taaatgataa	aagaaaacta	taactgcagc	caagtattct	caggattgta	tttctcttat	30240
attagcctaa	atgcaattaa	tctagctcat	atactttggg	cagcttatat	atattctgtt	30300
aatttcta	cttttccagg	tataaaaatc	cacatcaatg	gactgttagt	tttggaacaa	30360
aaatcaacc	tccttaaatg	aaaagaaatg	tcagaagatt	tattatccat	gagaagtacc	30420
gctctgcagc	aagagagtac	gacattgctg	ttgtgcaggt	ctcttccaga	gtcacctttt	30480
cggatgacat	acgccagatt	tgtttgccag	aagcctctgc	atccttccaa	ccaaatttga	30540
ctgtccacat	cacaggattt	ggagcacttt	actatggtgg	tggttatctc	aggatagcta	30600
acagagcgct	aagccctgtc	taaggcaatg	tgatttcac	tccatcaata	ttatcctgac	30660
agccatttcc	acacagtctg	gttggttagt	ttagggttct	tactttgtgt	gacagaaatt	30720
caattcacat	taaccagtgc	agaataaaaa	acaaagaaac	aaaaacttcc	acaaatttgg	30780
ctcatgta	ttggaagtca	aaaaagtgt	gtaagtcca	cttcagacac	aggggtttat	30840
atgatgtcat	ctggctctgt	gtctctgaat	ttgaattttt	tgccccttct	tttctctatg	30900
ttggcttcat	tcagagggat	gctagcttca	cctagtgtca	gaggtggcta	acaacacctc	30960
aacacatcat	cctcaacaaa	gaaaaaatac	atagaaagga	atatttattt	cttttctttg	31020
ccagaattca	cattaatttc	tattgttcca	gctgtgtcta	ggaggactca	gattgagtgg	31080
ctaactcaa	tattctttat	gcctatgtag	caaaatttgc	ttcagtactg	aagaagctaa	31140
tttaagtgtg	atggtgaata	agaatagtgt	agagataaat	tgtcaaaact	tttgtccctc	31200
ctaaaagtat	tcaacttgat	atactaaact	agtcttgtaa	gaaataatga	tgatttagtt	31260
actgaatgtt	ctaggcaatc	ttagttagac	acgctctgga	ttctaactg	tggtccaggt	31320
acatatgtat	aacaaagcta	gaaagtctct	ttaacactgg	gcttgagaaa	atgcaaaagg	31380
gctttctgag	aatgactaaa	tctatttgca	ggattctata	caatttattt	acatacaaga	31440
aattataaag	aataagcttt	tgattctcag	tctaccatta	aggaactagg	aataaccttt	31500
cactcacata	ggcaggaatc	ggttttaggg	tctctagatt	tttccagat	gtcccatgtg	31560
gttttgtttt	atcttataca	gagttagaca	tgcatgtctt	tctttaaggt	tgtattacca	31620
atcacagaaa	atattaccta	tggtttatta	attctagtag	atccagtgtc	gctgtaagcc	31680
tgacacctcc	ctaggctctg	actctcttgg	atggattttc	tctgaagata	gggcttgcat	31740
tctctgcttc	atagtgggtg	gaaagacatc	acaaatcccc	tttggcttgg	tggaagaaat	31800
cactttcagg	agtttgagac	tgccacagaa	acatacctgt	cataatgcgc	tgtgagtggc	31860
aacagaatct	gacacttata	gagcactcca	ccctacttga	acacggcctc	tcttggtgag	31920
tgaccacag	gtgcttttaa	tctattaaat	agattaaatt	aacctatcat	tcttaatctg	31980
ttaagtacat	taatagatta	aaagcagcca	ttcgttactc	accaagagag	gctatattca	32040
agtctgtaaa	gcaaacctta	agaagttttt	taaaattgaa	attgtacaaa	gtatattctc	32100
tgatcataat	ggaatcta	tagacatcag	taacagaaag	ataacataaa	aatccccaaa	32160
tgcttacc	ttaaaaaaca	tatgtaaata	aagagaatat	ctcgaagaaa	tttgtaaaaa	32220
caaatagaac	taaatgaaaa	caaaaatata	taaatatatg	ccagatgctg	ctaaaatagt	32280
gtagaaaggg	aaatttatag	aaaatgcata	ttataaggaa	agatatcaaa	tcaataatta	32340
agttctcact	tcaagaaact	agaaaaataa	aaaataaacc	taaaacaaac	ataaggaagg	32400
aaataataag	aataagaata	gaaatgaata	aaattaaaaa	taaactatag	aaaattgata	32460
aataaaaagc	tgattatttg	ataaaaatcaa	tattttgcta	gaaatgtcat	taagcatttt	32520
tacagaagat	gagatatagc	tcagggatgt	ccagaattta	tggttatgc	ttttcatgac	32580
ttggaataca	ttttaccaac	cagtttagtt	tgctgaagaa	gttgtggatt	tgcaactgtc	32640
cctacttaca	atacttagat	tgctcagttt	accttactct	tctcaccatt	attttatttt	32700
tatttttatt	tttattttta	ttttgaaaca	gagtctcgct	ctgtctccca	ggctggagtg	32760
cagtggcgtg	atctcggtc	actgcaaact	cgcctcccg	ggttcacgcc	attctcctgc	32820
ctcagcctcc	cgagttagctg	ggactgcagg	cgcaccacac	catgcccggc	taattgtttt	32880
gtagtttttag	taaagaaggg	gtttcacccg	gttagccagg	atggttttga	tctcctgacc	32940
tcgtgatcca	cctgcctcgg	cctcccaaag	tgctgggatt	acaggcgtga	gccaccgcgc	33000
gccaggccat	gaatgttttt	aattgatgat	atagtaggca	atataaatgt	gtgtgtgtgt	33060
gtgtgtgtgt	gtgtataata	tatataaacc	aattgtattc	aaataacaga	ataatttgaa	33120
aaatctctta	gcatatttct	gagttacaca	cttaaatctt	ccgagcactt	ttaaatatgt	33180

```

gtttacaaac atttcttcag aaataaatct tggaaatcgt cttctaaaga aactggtgta 33240
ttaggggttt ttcaaagtga cttaggtttt tttttaattg atgtataaaa ttgcatgtac 33300
ttaccatgtg caacataatg tgttgaagta tagtatatgt acactgtgag tgttaaactct 33360
agttaactaa gaagcgtctt attttacata attatcattt ttgtggcaag aacacttaat 33420
atctactctt gtagcgtttc tcaagaatac gatatatcaa cagtaggcaa ccagaagctg 33480
ggggtcttta caggggaagg agttaggag atgctggtca acaaattcat atttgcagtt 33540
aggaagaaaa agttcaagag atctctcatc catcatggtg actatagctg atgatataatc 33600
gtattcttgt attagttttt tataaatgtg taacaaataa tcacaaacag ttaaaacagc 33660
actcatttat ttttatctca ctgttttcat gagtcagacg ttcagacaca gcttagttga 33720
gtcctcttct cagggcttca ccaaactgta atcaagggtg cagctggggt tgtggccaca 33780
tctgtggctc ctttgaagggt ctcctcaagg tttgctggca gaattccttt actcgagct 33840
gtagaatgca tgccagcttg ctgctttaac tctttaggaa agtgtctcaa ctccagcaag 33900
gctcgccctt tttgaaatgg ctcagctgat taggtcaggc ccaccttga taatctcctt 33960
ttgatgaatt caaagtcaaa ctcattagag gtcttaatcg catctgtaaa attcctcat 34020
cttgccata taacataacc taatcatgag aatggcatcc ctcatttca cagatcctgc 34080
ccatatttgg gaggaggga atcacacagg aatcttgggg actatcctag aattctgcca 34140
accatgggggt catggtttcc caatcaatat atgggttgggt ataaagaatc cctgaatgct 34200
tgtgctattc ttagttttct acgtagcctg ccataataat ggtttctaaa actcagaacc 34260
tagcttacag tctgcagcca ccaacttgta atacattgga agtgaaatca ttgccgttta 34320
atgcatttat atatatatga tgtataatat atgtatatat cacatatatc ttatatatgt 34380
gaaagctcat cataaacttt aaataataaa ataaatgtac atagtattat aggcatttta 34440
tcaagccaat ggagaaaacc atctaggcat gcagagtttc tgggaacaat ctggaacca 34500
caaataaaaag ctttacaaaa gataaaaagg cttcctgaaa tatataagct gattattttt 34560
aagggttagat tttaccagga aaaagaatcc aaatggcttt cttgctttga gaagttttta 34620
taaaaatgtg attggacaat aattatcgtt agatgtgcca gatttaacca gaaattcttt 34680
tttctagaaa ctgcttatat taacttcatt ctgtattgac aattttacca tgaaaaaat 34740
attaggaaag tcttctcact tcactctagc caaagatgct gattgtaaat actagaataa 34800
ctctattttt ccttaagggg aatcccaaaa tgatctccga gaagccagag tgaaaatcat 34860
aagtgcagat gtctgcaagc aaccacaggt gtatggcaat gatataaac ctggaatgtt 34920
ctgtgccgga tatatggaag gaatttatga tgctgcagg gtaagttgga gggatttttt 34980
tatattacta actcaaaaat ttgtatctgg cttagaatat attatatgtt ctttacataa 35040
ggacaaaaca tagatatcat gtcagctcaa aaaagttaca aatgcaaatt tcacagcaca 35100
aaatactttt aaatgtttta ttaagataaa tgaagtaaga gtttctctga tgctatcaaa 35160
caaacaaaat tagaatttct taaccagaaa tccaaagatt aataaagcag tttattttct 35220
caagcggctc acattcaaga aagaaaataa tcataaacag agaagtataa agtgatgta 35280
tgaataatat aatgaaaagc aaatattttt cttgaaggaa acatttttgg aacaagtatc 35340
agagagatga gacgtaaata aggcctgaag aataaataac atccaatttc agaataagaa 35400
aataatgtta tagaaaagac aaaaagcata gccaaaatta tgaagggtgtg aaattacaat 35460
tcatatctga gggaactcca agtaattgggt tgggtctcag catgaggagg atgagaagag 35520
aaacaagtag ataaccatga gaagggtgat taggccatgt tgtgattcca tgggccctcc 35580
ccagtgccct catctgcctt ctaacatgga tgttttccag cgaaggtagg tttcttctctg 35640
gagacacttg ctttttaaca tgagatactt tagaactcta aggaggccac tctatgtgga 35700
aatgatggaa tggatttgat atcagggtggc agaaagtcct gtccagagtc ccacaaactg 35760
taccacatgt gcgacctcta tcagaaaagg agcagggacc tatgtgacat agaggctggg 35820
caaaagcagg atctggtcca cagccagcct cggttgctaa taatgtggag ggaggcaggc 35880
agaatttagg gattccaaca aaagggtccat accacgggga acagggtggaa ggtgcaggag 35940
tcttgagca gacaggaccg ggggaattcag gtgaaccatg acattactga aaagccttag 36000
gagggattgg tggcataga gatgcttcac tggattgggg agcagaggta aacttgctgc 36060
ctaactgtgc aaagtaagt ataaaaacaag gcttttagtca tagaaaaata cagtaagtta 36120
tcagggcagc gggtcaggta caaggatcca agacaggaat acagtgattg taattggggc 36180
acatgggtgag gggcctagtc tgatacaaca gaagtgaag caccaccaac acctcgtctt 36240
tctccataag tctttctctc cagagccctc atgacctaat cacctcttct taagtcccat 36300
ctctcaacac tattgtattg gagattaagt ttcccaacc tatgaactct tgggctcaca 36360
ttcaaaccat agcaccacc agcacaagaag cacagagctt ccaatctggt ttctagctcc 36420
ataccctaga accaaacagt aagaatcacc tctggaaatg tagcaataat ataatacata 36480
tttttaaaat ccagtggaag gattggaaga taaaatcaag gaaatctctc agaaagaaca 36540
acaacaacaa aaaagacaca gaggagaaaa ataatacaga aaattaagaa aactagagga 36600
taagctcagg agatccaaca ccaaatgaat aggagctctg aaaacataaa acgcgagtg 36660
acaatataaa aaaaaataaa gaatgctcct agttctgaag cttacatgca tcctattgaa 36720
gaaaagggtc aagtagtgct gggcacaata aatgaagtac ttctttccaa gacataccat 36780
cataaagggt cagaagccag ggataaggag aacaatctta aaactttgaa ggaagaacca 36840

```

```

tcagaactac atagaactcc tcaacagtaa ctctagaagg tagacgatgg tggaaaacac 36900
attcaaattt caaaggggaag attatttcaa cctagattcc taccatgct aactaaatat 36960
caactgtgag ggtggaatta agaagtttag acaagcaatg actgaaaaaa atgtacttct 37020
gataccctac ttcttaggaa actacttgag agggtagctc agcaaaatga gggaataaat 37080
caagaaagtg gaagacgtaa gacctgaaac tgtagtcca acactaaaga gtggtatcag 37140
ataatcccaa caccatagct ctgcaccagg cttaaagtaa ccagctcgaa ttgagcaga 37200
agtaagaaaa gattgtgtgt atgtgtatgt gtatgtgtgt atgtgtgtgt gtgtgtgtgt 37260
gtgtgttgat atggtggaac agcttcagag gaagtaaaag aactaacaag ctatctgatg 37320
tccttgaaca ttagtaaaaca ttattgtgag gtgttggtag atcttttgga gcattcagca 37380
tttaccaggt acatagaaaa ctatccacat gaaaaaaaga gttgtgttat taattctagg 37440
aaagcaaaaa aagatttctg taatccaaat atgttacttg actcttcaat taataaaatt 37500
tacacactgg tactaaatgt aggtctgttaa tttaaccaa aatagagatg ctataatgta 37560
aagatgtggt gtggaagaag tgcaagaag ttgtaaaaca actaaatccc taactacgta 37620
agagaaaaata aatatttact gtctaaacct agaagctgta atttgagcat attatctagt 37680
gataaggagt tagatactat aagaaatcat taaacaagca tgaagtggct acctcttgga 37740
gaacagcttg cgtgaggtaa catgggacat aactgctttt caagcctctt catgtttttt 37800
cgtttttgcc ttttttaact aagtgtgtgt tactctaaca aaataaattt ttttttttaa 37860
atgtgaaagt tgaaccttaa ggctctttgt aatattaaaa tccatgtctc aattaattat 37920
tctgtgttga tagtctatac atgtactgtc tagtaacaaa atatgtgatt catcaaaata 37980
tcttaaataa tgagctttat gtttagctaa ttttctttct tttttcttat gtttttattt 38040
ttaggggtgat tctgggggac ctttagtcac aagggatctg aaagatacgt ggtatctcat 38100
tggaattgta agctggggag ataactgtgg tcaaaaggac aagcctggag tctacacaca 38160
agtgacttat taccgaaact ggattgcttc aaaaacaggc atctaattca cgataaaaagt 38220
taaacaaga aagctgtatg caggtcatat atgcatgaga attcaactat ttagtgggtg 38280
tagtacaaca aagtgatatt aaattactgg atctagtaac atgaaacaca caacgtaagt 38340
tatttagaat cactttaatc aaccaataat ccttagccaa tttataaggg acttttattt 38400
gtaaagtaat ggatctggct tgaaaaatac ggtagagata cttagctctt taaatcacga 38460
atgttgaagt accagtgaga ctcaatacat atttttgaag atagtccatg ggatttttag 38520
aatgtcgttg tcaaggggtct ccttttaact gagaaacttt ttgaactcac aaagtgttca 38580
agaaaccctt gtataattcc ctacatttct ctcgagctca caaatacttt tttttctttt 38640
tccttattca atcagatttt ccaaagtacc tttccaccat aagaaatgaa ttttctactt 38700
ctacacccat ttgagagaca ccaataaaaag aaagtcatat gtaggaaaca aagtctgata 38760
gtaaaacaag ccagagatct tctaactttt tttagttata aaacctctaa tttttggtga 38820
cttttctaca cacacacaca cata 38844

```

<210> 4
 <211> 407
 <212> PRT
 <213> Human

```

<400> 4
Glu Pro Trp Val Ile Gly Leu Val Ile Phe Ile Ser Leu Ile Val Leu
1      5      10      15
Ala Val Cys Ile Gly Leu Thr Val His Tyr Val Arg Tyr Asn Gln Lys
20      25      30
Lys Thr Tyr Asn Tyr Tyr Ser Thr Leu Ser Phe Thr Thr Asp Lys Leu
35      40      45
Tyr Ala Glu Phe Gly Arg Glu Ala Ser Asn Asn Phe Thr Glu Met Ser
50      55      60
Gln Arg Leu Glu Ser Met Val Lys Asn Ala Phe Tyr Lys Ser Pro Leu
65      70      75      80
Arg Glu Glu Phe Val Lys Ser Gln Val Ile Lys Phe Ser Gln Gln Lys
85      90      95
His Gly Val Leu Ala His Met Leu Leu Ile Cys Arg Phe His Ser Thr
100     105     110
Glu Asp Pro Glu Thr Val Asp Lys Ile Val Gln Leu Val Leu His Glu
115     120     125
Lys Leu Gln Asp Ala Val Gly Pro Pro Lys Val Asp Pro His Ser Val
130     135     140

```

Lys	Ile	Lys	Lys	Ile	Asn	Lys	Thr	Glu	Thr	Asp	Ser	Tyr	Leu	Asn	His
145					150					155					160
Cys	Cys	Gly	Thr	Arg	Arg	Ser	Lys	Thr	Leu	Gly	Gln	Ser	Leu	Arg	Ile
				165						170					175
Val	Gly	Gly	Thr	Glu	Val	Glu	Glu	Gly	Glu	Trp	Pro	Trp	Gln	Ala	Ser
			180						185						190
Leu	Gln	Trp	Asp	Gly	Ser	His	Arg	Cys	Gly	Ala	Thr	Leu	Ile	Asn	Ala
		195					200								205
Thr	Trp	Leu	Val	Ser	Ala	Ala	His	Cys	Phe	Thr	Thr	Tyr	Lys	Asn	Pro
	210						215								220
Ala	Arg	Trp	Thr	Ala	Ser	Phe	Gly	Val	Thr	Ile	Lys	Pro	Ser	Lys	Met
225					230										240
Lys	Arg	Gly	Leu	Arg	Arg	Ile	Ile	Val	His	Glu	Lys	Tyr	Lys	His	Pro
				245					250						255
Ser	His	Asp	Tyr	Asp	Ile	Ser	Leu	Ala	Glu	Leu	Ser	Ser	Pro	Val	Pro
		260							265						270
Tyr	Thr	Asn	Ala	Val	His	Arg	Val	Cys	Leu	Pro	Asp	Ala	Ser	Tyr	Glu
		275					280								285
Phe	Gln	Pro	Gly	Asp	Val	Met	Phe	Val	Thr	Gly	Phe	Gly	Ala	Leu	Lys
	290					295					300				
Asn	Asp	Gly	Tyr	Ser	Gln	Asn	His	Leu	Arg	Gln	Ala	Gln	Val	Thr	Leu
305					310					315					320
Ile	Asp	Ala	Thr	Thr	Cys	Asn	Glu	Pro	Gln	Ala	Tyr	Asn	Asp	Ala	Ile
				325					330						335
Thr	Pro	Arg	Met	Leu	Cys	Ala	Gly	Ser	Leu	Glu	Gly	Lys	Thr	Asp	Ala
			340					345							350
Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Val	Ser	Ser	Asp	Ala	Arg	Asp
		355					360								365
Ile	Trp	Tyr	Leu	Ala	Gly	Ile	Val	Ser	Trp	Gly	Asp	Glu	Cys	Ala	Lys
	370					375					380				
Pro	Asn	Lys	Pro	Gly	Val	Tyr	Thr	Arg	Val	Thr	Ala	Leu	Arg	Asp	Trp
385					390					395					400
Ile	Thr	Ser	Lys	Thr	Gly	Ile									
				405											